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Day 1: Friday 21st November 2014 
 
09:00-09:45       Welcome & Introduction - Principles of GCP 
  Nicky Dodsworth 
09:45-10:15       From ICH-GCP Standard to Slovenian clinical trial legislation 
   Nicky Dodsworth & Maja Schara 
10:15-10:45       Ethics committees and ethical review 
  Ingrid Klingmann & Janez Primožič 
10:45-11:15  Coffee Break 
11:15-11:45       Optimising the Informed Consent process 
  Ingrid Klingmann 
11:45-13:00      Set-up of a clinical trial at the investigator site  
 Ingrid Klingmann 
13:00-14:30     Lunch Break & Satellite lecture (Takeda)  
14:30-15:30      Principles of document management 
      Nicky Dodsworth 
15:30-16:00       Quality management at a clinical trial site  
                          Nicky Dodsworth 
16:00-16:30       Coffee Break 
16:30-17:30       Reliable safety management at the site 
 Ingrid Klingmann 
 Exercise: Assessment of AEs and an SAE 
17:30                 End of Day 1 
 
Day 2: Saturday 22nd November 2014 
 
08:00-09:00  Skupščina Sekcije za internistično onkologijo 
09:00-10:30       Principles of clinical trial management 
  Ingrid Klingmann 
                          Exercise: Planning your resources for study execution 
10:30-10:50       Coffee Break 
10:50-12:00    Critically important aspects in clinical trial management 
  Nicky Dodsworth 
12:00-12:30       Final test and joined review of correct answers 






































Nicky Dodsworth, Premier Research, is currently Vice President, Global Quality Assurance 
for Premier Research with responsibility for pharmaceutical and medical device studies.  
Nicky is an active member of European Forum for Good Clinical Practice (EFGCP), in 2011 
she was appointed Chair of the Education Working Party and is a member of the Audit 
Working Party. Nicky has conducted widespread training for various groups and has 
presented in 14 different countries.  During 2010, she started to run the recently accredited 
EMWA Workshop on Quality Awareness in CSR Development. She is a Senior Associate 
Member of the Royal Society of Medicine. In 2009 Nicky became a Chartered Scientist, an 
award from the Science Council in the UK which is awarded to individuals who are 
professional scientists practicing and/or advancing science and for whom this is an integral 
part of their daily work. Nicky has worked closely with the Institute of Clinical Research 
since 1996, she is currently Co-Chair of the GCP Forum and she also works closely with the 
Ethics Forum. In July 2011, Nicky became a member of the Research Quality Assurance, 
West & Wales Organising Group which promotes information exchange at a regional level. 
Nicky has written many publications, including addressing risk mitigation in clinical research, 
quality by design and risk management, risk based approaches, training and education, 
auditing and inspections, fraud and misconduct, ISO 14155, implementing quality in times of 
change, improving quality through metrics, standards for Ethics Committees in Europe, 
Standard Operating Procedures and running trials in Eastern Europe and Russia. Nicky has 
assisted in preparation of the 4th Edition of Fraud and Misconduct, Royal Society of 
Medicine Press, by writing the chapter on enhanced audits. She has given over 60 lectures 
and presentations with various audiences across 13 different countries, many from 
academia and the NHS on clinical trials, good clinical practice, quality, risk assessment, 
informed consent, audits and audit findings, fraud and misconduct as well as on Ethics 
Committees. 
 
Ingrid Klingmann, MD, PhD, FFPM, FBCPM, PHARMAPLEX bvba, European Forum for 
Good Clinical Practice, Brussels (Belgium). Dr. med. Ingrid Klingmann is specialized in 
General Medicine, Clinical Pharmacology and Pharmaceutical Medicine. 
After having joined pharmaceutical industry as medical advisor, she held senior 
management positions in different international contract research organisations and was 
responsible for operational, scientific, regulatory and business aspects of international 
clinical research projects from Phase I to Phase IV. 
Since January 2003 she has her own pharmaceutical development and site management 
support consulting company. For 4 years she was also CEO of two investigative sites in 
London, UK, performing clinical trials in acute and chronic pain as well as musculo-skeletal 
diseases. 
Dr. Klingmann is Chairman of the Board of the European Forum for Good Clinical Practice 
(EFGCP). On behalf of EFGCP she was Work Package Leader of the PatientPartner 
Project and is currently Coordinator of the IMI project PharmaTrain and she is Work 
Package Leader of EUPATI, responsible for developing the EUPATI Network, the EUPATI 
National Platforms and the Ethics Panel.  
Dr. Klingmann chairs the clinical research module of the post-graduate Master in Regulatory 
Affairs course at the University of Bonn, Germany, and co-chairs the Diploma Course in 






Janez Primožič, MD, phD, Associate professor of paediatrics was heading Division for 
pediatric surgery and intensive care of the Department of surgery at the University Medical 
Center in Ljubljana from 1987 until 2010 when he retired. He completed his training in 
pediatric intensive care in UK (Great Ormond Street Hospital and Liverpool Childrens' 
Hospital) and in USA (Oakland Childrens' Hospital, Childrens' Hospital in Detroit, Childrens' 
Hospital in Albuquerque).  
In 1989 he was hired by the Ministry of Public Health in Kuwait to establish pediatric 
intensive care unit at Al Sabah Hospital and was its first head. His main professional interest 
was postoperative care of children undergoing heart surgery. In the year 1994 he developed 
the project of extracorporeal membranous oxygenation (ECMO) and implemented it for 
children in Slovenia. Due to his work with critically sick children he was soon envolved in 
resolving ethical problems and dilemmas. In 1994 he became the member of the Slovenian 
National Committee for Medical Ethics. He published several articles in domestic and 
international (SCI rated) medical journals. 
Regarding professional societies he was the president of the Slovenian Paediatric Society 
and as delegate founder of the European Society for Pediatric and Neonatal Intensive Care 
(ESPNIC). He is a member of honour of the Slovenian Society of Intensive Medicine. 
 
Maja Schara 
Curriculum vitae   
    
Full first and surname Maja Schara 
DOB 28.7.1964 
Nationality Slovenian 
Professional address JAZMP-Agency for Medicinal Products and Medical Devices 
Einspielerjeva 6 
1000 Ljubljana, Slovenia 
tel: + 386 8 2000 500 
e-mail: maja.schara@jazmp.si 




1997-2009: JAZMP- department for Import of medicinal products and 
medical devices 
1992-1997: Dental trade d.o.o.-Regulatory Affairs adviser 
1990-1991: Internships: Pharmacy of Ljubljana 
Education 
  
1979-1983: Classical Grammar School, Ljubljana 










The European Forum for Good Clinical Practice (EFGCP) is a not-for-profit organisation established by, and 
for, those with a professional involvement in clinical research. It is dedicated to promoting the interests of 
patients in clinical research through the development of European ethical and scientific standards. The 
EFGCP provides a common meeting ground for the many disciplines and organisations affected by GCP. 
 MEMBERSHIP  
EFGCP VISION:  
 
A Europe that leads the development of new treatments through research integrity in partnership with 
patients and researchers. 
 
EFGCP is the leading multi-stakeholder forum in Europe where science & ethics meet to promote Good 




• To promote open discussion on critical issues in biomedical research and health, 
• To promote education and awareness leading to the application of ethical and scientific requirements  
              in clinical research. 
• To facilitate the transfer of knowledge and skills across disciplines and sectors including training and  
             advice. 
• To promote a renewed emphasis on human values in research involving human participants.  
 
The EFGCP is a European organisation with a global vision. This is reflected in the many collaborative 
partnerships it has developed with European, North American and International Research patient, research, 




The basic source of funds for the EFGCP is membership fees. Additional funding for specific EFGCP 
activities is developed according to the objectives and scope of the activity concerned. In order to maintain its 
independence and high ethical standards, the EFGCP actively seeks funding across a wide range of funding 
organisations, including public (i.e. EU funded-projects) and private institutions. All EFGCP financial 






Membership in the EFGCP is open to professionals and individuals, representing patient groups, ethics 
committees, academic & industry research enterprises, regulatory officials, and those concerned to develop 




The EFGCP is governed by a Board of Directors. The Board has responsibility for providing leadership, 
policy-making, and financial decision-making in accordance with the Charter of Incorporation. Board 
members are elected by the EFGCP General Assembly. The members are elected for a term of 3 years, 
which is renewable. The Board is responsible to ensure that the EFGCP is managed to continually comply 
with the ethical and scientific standards required for providing European leadership in Good Clinical Practice. 
 
SCIENCE & ETHICS COUNCIL 
 
The EFGCP Science & Ethics Council is composed of leading European and international experts 
representing major institutions affecting the regulation and practices of Good Clinical Practice. It pools the 
efforts of the Board including the Working Parties chairpersons and the previous Advisory Council under one 
same roof.  
Although the executive power of the EFGCP continues to rest with the Board, the Council takes the lead in 
matters of Science and Ethics. The Working Parties which would like to broaden their activities, issue more 
position papers and propose topics for conference receive recommendations and approval from the new 
Council. 
The Science & Ethics Council contributes to the development of the EFGCP by  
• increasing input into EFGCP planning and projects,  
• extending the EFGCP basis of expertise and competence, and  
• increasing the awareness and recognition of the contributions to GCP made by the EFGCP.  
The Science and Ethics Council sees to optimally reflect the various components of the clinical research 
community: the patient associations, the sponsors, the CROs, the investigators and their networks, the ethics 
committees and the authorities. By itself, the new Council with 2 meetings a year will provide a unique 
opportunity for Forum discussions.  The members of the Science & Ethics Council are regularly invited to 




The EFGCP Working Parties serve as the central reference point for EFGCP research and the development 
of European guidances, reports, and publications in the area of Good Clinical Practice. The Working Parties 
are composed of EFGCP members with expertise and interest in contemporary areas such as the ethics, 
science, and regulation of clinical research in Europe and globally.  
 
The following six Working Parties are active:  
 
• Ethics Working Party  
• Audit Working Party  
• Education Working Party  
• Children's Medicines Working Party  
• Geriatric Medicines Working Party 
• Patients’ Roadmap to Treatment Working Party (in collaboration with the European Genetic Alliance 




The EFGCP Secretariat is the organisational arm of the EFGCP responsible for all the operations of the 
association and its membership services. The EFGCP events are also managed internally.  
 
ACTIVITIES                                                                     
 
To fulfill its mission it is necessary for the EFGCP to organise relevant activities. Activities include 





EFGCP is dedicated to bringing leading publications on GCP in Europe and abroad. The EFGCP publishes 
its own newsletter, The EFGCP News, quarterly as well as a number of European guidelines and key reports 
(Annual update of the EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical 
Research Projects in Europe, freely available on the website) 
 
CONFERENCES & WORKSHOPS 
 
Since its creation, EFGCP has been organising a significant number of conferences and workshops which 
consist in high level forum discussions characterised by interactive debates on a specific topic with the major 
stakeholders in the selected area. Among the organisations that have participated in projects led by the 
EFGCP are the European Commission, the European Parliament, EMA, EORTC, ESF, EAP, EPPOSI, 
EuropaBio, EFPIA, ICH, BARQA, WMA, CIOMS, the Faculty of Pharmaceutical Medicine, etc. Please consult 
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Ingrid Klingmann, MD, PhD, FFPM, FBCPM
EFGCP, Pharmaplex bvba, Brussels
Nicky Dodsworth, DCRR, CSci, MRQA
EFGCP, Premier Research, UK
Interactive Training in Applied GCP for Investigators & Site Personnel
GCP Compliance in Conducting 
Clinical Research
21 & 22 November 2014 
2 / 2121/11/2014
PRINCIPLES OF GOOD 
CLINICAL PRACTICE (GCP)
Nicky Dodsworth
Material developed in collaboration with  
Prof. Dr. JanHasker G. Jonkman
University of Groningen, The Netherlands &
Dr. Petra Knupfer




Development of GCP/ Legal aspects
Declaration of Helsinki
13 Principles of ICH GCP
Questions: True/False
4 / 2121/11/2014
GCP - GOOD CLINICAL PRACTICE 
International ethical and scientific quality standard
Compliance with this standard provides public 
assurance 
for designing, conducting, recording and reporting trials with 
human subjects. 
that the rights, safety, well-being of participants are protected 
that the safety of society is protected 
(reliable clinical data for market authorization)
5 / 2121/11/2014
ICH GCP
• International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuticals for 
Human Use 
(first meeting 1991 in Brussels, Belgium)
• World standard
finalized July 17, 1996
effective January 17, 1997
• Representatives of 
regulatory agencies 
and pharmaceutical 
industries of EU, 
USA, Japan
• Observers of WHO, 
Canada, EFTA
6 / 2121/11/2014
How was ICH GCP developed?
1977 USA started with formal GCP rules, FDA GCP 
1989 EU-GCP Note for Guidance
1996 ICH GCP Guideline:
to harmonize GCP in order to accept   
clinical data for market authorisation
7 / 2121/11/2014
GCP is based on:
World Medical Association’s “Declaration of Helsinki”
Ethical Principles for Medical Research Involving Human Subjects
Adopted by the 18th WMA General  Assembly, Helsinki, Finland, June 1964, 
and amended by the WMA General Assemblies in 
1975 (Tokyo, Japan), 1983 (Venice, Italy), 1989 (Hong Kong, China), 
1996 (Somerset West, South Africa), 2000 (Edinburgh, UK), 2002 (Washington, USA), 
2004 (Tokyo, Japan), 2008 (Seoul, South Korea) 
2013 (Fortaleza, Brazil)
Best-known declaration of the World Medical Association
Recommendations for medical researchers 
8 / 2121/11/2014
ICH GCP DIVIDED INTO…
1. Glossary
2. The Principles of ICH GCP




6. Clinical Trial Protocol and Protocol Amendment(s)
7. Investigator’s Brochure
8. Essential documents for the conduct of a clinical trial
9 / 2121/11/2014
ICH GCP - 13 PRINCIPLES  (1)
COMMON SENSE !
1. Clinical trials should be conducted in accordance with the 
ethical principles in the Declaration of Helsinki, consistent with 
GCP and the applicable regulatory requirements.
2. A trial should be initiated and continued only if the anticipated 
benefits – for individual and society - justify the risks.
3. The rights, safety and well-being of the trial subjects are the 
most important considerations and should prevail over 
interests of science and society.
10 / 2121/11/2014
ICH GCP - 13 PRINCIPLES  (2)
4. Non-clinical and clinical information on the investigational 
product (IMP) should be adequate to support the proposed 
trial.
5. Trials should be scientifically sound and described in a  
clear, detailed protocol. 
6. The trial should be conducted in compliance with the 
protocol that has received prior Independent Ethics 
Committee approval / favourable opinion.
7. The medical care and medical decisions should always be 
the responsibility of a qualified physician.
8. Each team member involved in conducting the trial should 
be qualified by education, training and experience to perform 
his/her respective tasks. 
11 / 2121/11/2014
ICH GCP - 13 PRINCIPLES  (3)
9. Freely given informed consent should be obtained from every 
subject prior to clinical trial participation.
10. All clinical trial information should be recorded, handled, stored 
in a way that allows accurate reporting, interpretation,  
verification.
11. Confidentiality of records should be protected respecting 
confidentiality rules in accordance with regulatory requirements.
12. IMP should be manufactured, handled and stored in accordance 
with good manufacturing practice (GMP) and used in 
accordance with the protocol. 
13. Systems, procedures that assure the quality of every aspect of 
the trial (e.g. SOPs, GLP) should be implemented.
12 / 2121/11/2014
TO WHOM  DOES THIS APPLY?
• SPONSOR / SPONSOR INVESTIGATOR  (Sections 5, 6, 7, 
and 8)
• CRO / MONITOR  (Sections 5, 6, 7, and 8) 
INVESTIGATOR (PRINCIPAL, SUB-INVESTIGATOR, SITE 
STAFF, PHARMACIST) (Sections 4 and 8)
• INSTITUTIONAL REVIEW BOARD (IRB) /  ETHICS 
COMMITTEE (EC)/ COMPETENT AUTHORITY (CA)  





The skills of an investigator for the performance of a clinical 




Related To The Respective Delegated Task
Education: 




Documented History Working With The Particular Trial 




ICH GCP provides assurance, consistent with the Declaration 




• Prior to the 1947 Nuremberg Code there 
was no generally accepted code of 
conduct governing the ethical aspects of 
human research
• The Declaration developed the ten 
principles first stated in the Nuremberg 
Code, and tied them to the Declaration 
of Geneva (1948), a statement of 
physician's ethical duties. 
18 / 2121/11/2014
Risk-Benefit
The rights, safety, and well-being of the trial subjects are the 
most important considerations but need not prevail over 




Principle 3: The rights, safety, and well-being 
of the trial subjects are the most important 
considerations and should prevail over 
interests of science and society. 
The advancement of medicine is never the 
most important factor in research; therefore 
investigators must never sacrifice the 
interests and rights of study subjects to 
ensure completion of a trial.
20 / 2121/11/2014
ICH-GCP is based on the Declaration of Helsinki
There are differences in clinical trial performance in 
different countries but global harmonisation is 
supported by the ICH-GCP standard
GCP defines the roles and responsibilities of 
sponsor, investigator, competent authorities and 
ethics committees
Trial performance according to GCP principles is 
protecting the study participants 
CONCLUSIONS (1)
21 / 2121/11/2014
GCP contributes to better reproducible and more 
reliable data (less misconduct and/or fraud) through
Strict compliance with Study Protocol
Full documentation of all stages of the study (not 
documented = not done)










FROM ICH-GCP STANDARD TO 
SLOVENIAN CLINICAL TRIAL 
LEGISLATION
Nicky Dodsworth
Material developed in collaboration with  
Prof. Dr. JanHasker G. Jonkman
University of Groningen, The Netherlands &
Dr. Petra Knupfer
Ethics Committee Baden-Württemberg, Germany 
2 / 12
GCP Implementation into Law 
21/11/2014
Medicines for Human Use (Clinical Trials) 
Legislation 2004 (Directive 2001/20/EC)
EU Directive on Good Clinical Practice
(Directive 2005/20/EC)
National Laws
Compliance with GCP is now a legal obligation
in Europe for all trials with investigational 
medicinal products
3 / 12
1965: Council Directive 65/65/EEC required “the 
submission of a dossier containing the results of 
tests and clinical trials.”
1975: Council Directive 75/318/EEC “laid down 
uniform rules on the presentation of such dossiers.”
THE EUROPEAN UNION (1)
21/11/2014
4 / 12
2001: Directive 2001/20/EC of the European 
Commission relates to “the implementation of good 
clinical practice (GCP) in the conduct of clinical trials 
on medicinal products for human use.”  [The Clinical 
Trials Directive]
2005: Directive 2005/28/EC of the European 
Commission “lays down principles and detailed 
guidelines for good clinical practice (GCP) as 
regards investigational medicinal products for 
human use.” [The GCP Directive]
THE EUROPEAN UNION (2)
21/11/2014
5 / 12
The legislations released by the European
Commission have different “legal weight”:
• “Regulation”: text has to be implemented in national 
legislation as it stands
• “Directive”: the principles have to be implemented in 
national legislation but leave the member states flexibility 
of interpretation and adaptation to national legislation
• “Guidance”: define in detail execution aspects and 
requirements generally lined out in the Directives





Chapter I: Application and application forms
Chapter II: Monitoring and pharmacovigilance 
Chapter III: Quality of the IMP
Chapter IV: Inspections
Chapter V: Additional information
Chapter VI: Legislation
THE EUROPEAN UNION (4)
21/11/2014
7 / 12
EudraLex, Volume 10: 
Chapter I: Application and application forms
CT-1: Detailed guidance for authorisation of a     
clinical trial and substantial amendment
CT-2: Detailed guidance on the application format 
and documentation to be submitted to ethics 
committees 
CT-5: Detailed guidance on the EudraCT Database
THE EUROPEAN UNION (5)
21/11/2014
8 / 12
EudraLex, Volume 10: 
Chapter I: Monitoring and pharmacovigilance
CT-3: Detailed guidance on adverse reaction 
reporting (SUSARs)
CT-4: Detailed guidance on the EudraVigilance
Database
Q&A specific to AR reporting
ICH-E2F: Note for guidance on the development of 
safety update reports
Note: there is NO guidance on monitoring of clinical trials!!
THE EUROPEAN UNION (6)
21/11/2014
9 / 12
EudraLex, Volume 10: 
Chapter V: Additional Information
ICH-E6: GCP guideline
GCP guideline for advanced therapy medicinal 
products
Recommendations on the content of the Trial Master 
File 
Ethical considerations for paediatric clinical trials
Guideline on information to be made public from 
EudraCT
THE EUROPEAN UNION (7)
21/11/2014
10 / 12
EudraLex, Volume 10: 
Chapter V: Legislation
Directive 2001/20/EC: Clinical Trials Directive
Commission Directive 2005/28/EC: GCP Directive
Commission Directive 2003/94/EC: GMP Directive
THE EUROPEAN UNION (8)
21/11/2014
11 / 12
EU Directive 2001/20/EC (“Clinical Trials Directive”) 
and Directive 2005/28/EC (“GCP Directive”) had to be 
implemented in national legislation in 2004
In addition, there is a whole European legal 
framework including European databases, 
guidelines, processes and forms that had to be 
integrated in the national legal frameworks to 
reliably enable ICH-GCP-conform performance of 




GCP contributes to better protection of study 
participants through
Evaluation / approval of protocol by Medical Ethics 
Committee
Only participation after written consent of subject
Surveillance of adverse events
































































































































































ETHICS COMMITTEES AND 
ETHICAL REVIEW
Ingrid Klingmann, MD, PhD
EFGCP, Pharmaplex bvba, Brussels
21/11/2014
2 / 12
Guiding Principles for ECs
Independence - in constitution and decision  making 
Competence  - in evaluating ethical issues
Interdisciplinarity - in composition




Spontaneous formation of ECs in hospitals, pharmaceutical 
companies, external groups
Different development in different countries concerning 
constitution, requirements, timelines, procedures, outcome, 
interaction with investigator and sponsor 
In more and more countries implementation of ECs in 
national legislation on different levels - or physicians 





Mostly helpful for investigators
Difficult for sponsors to cope with differences, changes, 
unpredictabilities, and partly inexperience of the ECs




Achievements Through Directive 2001/20/EC
EC systems have been implemented in all national legislations
ECs get “authority” status because in all EU countries their 
positive opinion is required before a study can be started 
Single opinion per Member State 




Achievements Through Directive 2001/20/EC
Theoretically: Defined list of content of review 
Ongoing involvement of EC during course of the trial






Directive: not a Regulation 
Establishment and operation of ECs under national 
responsibility:  different national systems remain 
Different systems to reach single opinion: need to contact all 
involved ECs will remain in most MSs






EU Guidance only on format and accompanying 
documentation of the application: not on criteria for review
List of required documentation differs from MS to MS: different 
application package for each MS in multinational trials




The EC Application Process
Principles in the EU
Favourable opinion required
One opinion / country, but acceptance of need for local review
Max. 60 days for review after receipt of complete submission
Application to EC parallel/sequentially to authority application
21/11/2014
10 / 12
The EC Application Process
Principles in the EU
Applicant submits the required information
EC gives feed-back whether submission is complete
Once submission is complete, the clock starts
One opportunity to request additional information. Clock stops 
until information is provided
21/11/2014
11 / 12
The EC Application Process
Time Frames in the EU 
60 days after receipt of a complete submission
90 days for gene therapy and somatic cell therapy or 
genetically modified organisms
180 days for these products if external consultation is required
No time limits for xenogenic cell therapy
21/11/2014
12 / 12
Ethics committees are helpful for investigators and 
sponsors in ensuring optimal protection of study 
participants
The Clinical Trial Directive has set the frame for 
ethical review in Europe
Performance of the ethical review is a national 













Scope of work presented by the NMEC members:
Assoc. Prof. of paediatrics, Janez Primožič, PhD
Tone Žakelj, professional coordinator of NMEC
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
2
I. HISTORY OF MEDICAL ETHICS
IN SLOVENIA
The Committee for medical ethics (CME) 
was established at the University of 
Ljubljana Medical Faculty in the early 
sixties of the last century to evaluate 
ethical acceptability of the proposed 
medical studies to acquire PhD or MSc 
degree in medicine at the Medical faculty. 
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
3
II. HISTORY OF MEDICAL ETHICS
IN SLOVENIA
1977
CME was authorized by the Medical 
Faculty (MF) of the University of Ljubljana 
to evaluate ethical acceptability of all the 
medical studies in the Republic of 
Slovenia. 
In the same year, regular teaching of 
medical ethics was introduced in MF.
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
4
JURIDICAL BASIS OF THE NMEC
FUNCTIONING IN THE REPUBLIC OF 
SLOVENIA
Ministerial Decree on the composition, 
tasks, competence and mode of working 
of the NMEC (1995 and amended in 
2009).
CME is obliged to respect the Slovenian & 
international legally binding documents, 
national and international guidelines and 
recommendations being issued by the 
European Commission for Bioethics of the 
Council of Europe, and European 
Commission.
Statutary notes of the NMEC.
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
5
PROPOSER AND APPOINTER OF THE 
NMEC OF SLOVENIA
The NMEC is an advisory board to the Ministry of 
Health of the Republic of Slovenia.
APPOINTED BY:
Minister of Health of the Republic of Slovenia
PROPOSED BY:
Medical faculties in Ljubljana and Maribor
Council for Health of the Republic of Slovenia
Slovenian Medical Chamber
Slovenian Medical Society
The NMEC members’ mandate lasts for 4 years and 
can be repeated. The members are volunteers.
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
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1 Specialist in forensic medicine and deontology
2 Surgeon, traumatologist
3 Psychiatrist
4 Specialist in internal medicine, angiologist









14 Lay person – professional coordinator
COMPOSITION OF NMEC BY PROFESSION –
15 members (14 at present)
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
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LEVELS IN THE ORGANIZATION OF THE 
FORUMS FOR BIOETHICS IN THE WORLD
National Ethics Councils (NEC)
Nuffield Council of Bioethics (UK)
Nationaler Ethikrat (Germany)
Comité Consultatif National d'Ethique (France) …
National committees for biomedical ethics 
/ Research ethics committees (REC)
Regional and hospital committees for 
biomedical ethics
At present, the NMEC is covering all the functions of the first two 
listed above.
BASIC DOCUMENTS FOR ETHICAL 
EVALUATION IN NMEC
Declaration of Helsinki 2013
Oviedo Convention 1997 and its protocols
Slovenian Code of Medical Deontology 1997
Regulation (EU) No 536/2014 on clinical trials on 
medicinal products for human use 2014
ICH-GCP guidelines
Slovenian law on medicines, on Patients’ rights
…
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
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Regulation (EU) No 536/2014 on clinical 
trials on medicinal products for human 
use, replacing Directive 2001/20/ES of the 
European Parliament and the Council.
Coordination of legislature among the EU member states 
in the field of good clinical practice regarding 
pharmaceutical trials in humans. 
Every EU member state has to issue a single final opinion 
by the central or principal Research Ethics Committee at 
least in 60 days for the international clinical trials.
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
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WORKLOAD OF THE NMEC
Regular sessions once per month, extraordinary when 
necessary.
Per session 40-70 proposals of new studies are presented & 
discussed; there are additional 70-100 items on the agenda 
(amendments, reports, comments, etc.). Under 
“miscellaneous” actual (pressing) ethical problems are dealt 
with – draft laws, ethical problems (e.g. usage of the 
human corps/limbs for artistic purposes, circumcision of 
boys for religious reasons) …
There is a 3-4% rise in the number of topics on the agenda 
per year.
About one percent of the proposals are not approved, for 
about 20% amendments are demanded. 
Follow-up of the approved works is requested from 
researchers and ev. problems (e.g. adverse events) have to 
be reported.
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
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METHODOLOGY OF THE NMEC
RESEARCH PROPOSALS EVALUATION
(SOP)
Aim of the study – clear hypothesis.
Informed consent – composition and clearness.
Direct or indirect benefit for the patient.
Inclusion/exclusion criteria.
Randomization of participants. 
Aim of every procedure in the study.
Benefits and risks for the participants. 
Discontinuation of the study.
Extra insurance of participants (in case of 
damage).
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
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treatment of infertility and the use of methods of 




homeopathy and non-academic healing practices




cloning and embryonic stem-cells …
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
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INTERNATIONAL COOPERATION OF THE 
NMEC
Participation in regular meetings of the DH-BIO of 
the Council of Europe.
Participation in the forums of the National Ethics 
Councils (NEC).
In the framework of the Conférence européenne 
des comités nationaux d'ethique (RECs -
COMETH).
On the occasion of the Slovenian presidency of 
EU in 2008 the NMEC organized the 11th Forum of 
NEC. 
Renewal of registration within the „Food and drug 
administration, US Department of Health and 
Human Services.
Primožič, Žakelj, Ljubljana 2014, 
Onkološki inštitut
14
FUTURE OF THE NMEC
Separation of the two duties: National Ethics 
Council and Research Ethics Committee.
Professionalization of the administrative services 
to the NMEC.




OPTIMISING THE INFORMED 
CONSENT PROCESS
Ingrid Klingmann, MD, PhD
EFGCP, Pharmaplex bvba
2 / 13
The Informed Consent Process




A process by which a subject voluntarily confirms 
his or her willingness to participate in a particular 
trial, after having been informed of all aspects of the 
trial that are relevant to the subject’s decision to 
participate. Informed consent is documented by 
means of a written, signed and dated informed 
consent form.
Freely given informed consent should be obtained 
from every subject prior to clinical trial participation
(ICH-GCP)
Informed Consent Process (1)
21/11/2014
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Informed Consent Process (2) 
The IC process consists of 
o Patient Information Sheet (PIS)
o Oral explanations provided by the investigator and/or 
experienced study nurse
o Sufficient time for the participant to make an informed 
decision about his/her participation
o Signing the Informed Consent Form (IC)
o Copy of PIS and signed IC to participant
o Re-consenting if new information becomes available 





ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL
Consumer goods
Pharmaceuticals
Detailed guidance on the application format and
documentation to be submitted in an application
for an Ethics Committee opinion on the clinical
trial on medicinal products for human use
ENTR/CT-2, Revision 1, February 2006
Informed Consent Process (3) 
21/11/2014
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Give it top priority
Ensure an atmosphere that encourages questions
Go slowly and with easy words together with the 
subject(s) through the subject information sheet
Have a proper form for the subject to sign
Ensure that patient information is provided by a 
properly trained person 
Ensuring an optimal patient information and consent 
process is one of the key responsibilities of the 
investigator
Informed Consent Process (4)
21/11/2014
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Ensure that the subject is re-consented if there is 
new information relating to the risk-benefit ratio
In paediatric studies the parents need to be informed 
and give written “consent”, the child must receive 
age-adapted information and should give an 
“assent”, if ever possible in writing. Refusal of a 
child must be respected  
Keep the proper paperwork
Informed Consent Process (5) 
21/11/2014
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Ethical considerations for clinical trials on 
medicinal products conducted with the paediatric
population
Recommendations of the ad hoc group for the development of implementing 
guidelines for Directive 2001/20/EC….
ftp://ftp.cordis.europa.eu/pub/fp7/docs/ethical-considerations-
paediatrics_en.pdf
Informed Consent Process (6) 
21/11/2014
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Informed Consent Process (7)
Language used should be as clear, non-technical  
and easily understandable as possible 
The participant’s understanding of the provided 
information should be assessed
ICH-GCP provides a list of topics to be addressed in 
the Patient Information Sheet
21/11/2014
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What needs to be included in a subject information 
sheet?
What is the objective of the trial?
How long will the trial last?
What will I have to do, which tests to undergo, how long to stay 
in house, and what will be the follow-up procedures in this 
trial?
Is there anything that I am not allowed to do when I’m on the 
trial?
Has the trial been officially approved?
Which medication will I get?
Information to Clinical Trial Subjects (1)
21/11/2014
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Which side-effects may occur to me?
What happens if I feel un-well?
Can I withdraw my consent at any time and under which 
conditions?
Who is funding the trial and is there a financial tie 
between investigator and sponsor?
Will I be properly compensated and all my travel 
expenses be met?
Will I be properly insured against any trial-related 
damage and what are the conditions? 
Who can I talk to if I have any more questions?
Information to Clinical Trial Subjects (2)
21/11/2014
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Information to Clinical Trial Subjects (3)
Patients need to be explained and understand that 
they participate in an experiment/alternative 
treatments
their participation has advantages but also 
negatives: 
they may not get the optimal dose or even receive placebo
they may face additional risks
the treatment may be too short
there may be no follow-on treatment
they may never learn which treatment they had
the physician has a personal interest in enrolling          
the patient into the trial
he/she can withdraw the consent at any time
21/11/2014
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“Informed consent” is an ongoing PROCESS from 
advertisement to signature on the consent form until 
end of the trial 
The patient information should be adapted to the 
subject’s needs, level and capacity of understanding 
The informed consent process is the basis for a 
good compliance of the subject during the trial and 





SET-UP OF A CLINICAL TRIAL 
AT THE INVESTIGATIVE SITE
Ingrid Klingmann, MD, PhD
EFGCP, Pharmaplex bvba, Brussels
21/11/2014
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Today’s Responsibilities of a PI











Today, the overall responsibility for a clinical trial 
has been moved away from the PI to the sponsor.
But the PI has the responsibility
for subject care, information to subjects and safety, 
including reporting to ECs
for the reliability of trial performance
for the quality of the data / results
TODAY’S RESPONSIBILITIES OF THE PI
21/11/2014
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A doctor or a person following a profession agreed 
in the MS for investigations because of the scientific 
background and the experience in patient care it 
requires.   
The investigator is responsible for the conduct of a 
clinical trial at a trial site. If a trial is conducted by a 
team of individuals at a trial site, the investigator is 
the leader responsible for the team and may be 





The PI needs to ensure a comprehensive 
understanding of
the current state of the respective area of research 
the IMP  
the protocol
alternative treatments
the subject’s risks when joining the trial 
GCP requirements
FAMILIARISATION 
WITH PROTOCOL AND IB
21/11/2014
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The PI needs to ensure reliably available qualified, 
well-informed and trained resources during 
preparation, performance and follow-up of the trial
his own time and physical presence
investigators and study nurses  
in pharmacy and other required departments
to perform ALL tasks of the trial within time and 




The PI needs to ensure reliably available suitable 
facilities during preparation, performance and 
follow-up of the trial
to screen, inform and treat subjects
to manage the trial
to perform all trial activities incl. data entry
to store the trial documentation  
to store and handle the trial medication




The PI needs to ensure reliably available medical 
care during preparation, performance and follow-up 
of the trial
to diagnose the subjects
to decide on subjects’ suitability concerning in- and 
exclusion criteria
to make all required medical decisions  
to ensure complete identification of AEs, their 
assessment and reporting




The PI needs to ensure reliably available 
communication tools and resources during 
preparation, performance and follow-up of the trial
with the sponsor (incl. monitor and auditor) 
with the ethics committee
with the subject and his family (incl. IC)
with the study team




The PI needs to ensure reliably available 
administration throughout the trial 
signed contract with the sponsor and sub-contractors
signed, approved protocol and all other documents 
required before study start
SOPs, job description, CV, training record of all staff 





The PI needs to ensure reliably available processes
throughout the trial 
delegation and signature process
subject identification, screening and enrolment 
processes, IMP distribution and accountability 
process
randomisation process
CRF completion and query process
AE assessment and reporting process




What can a PI delegate?
communication with the sponsor, monitor, auditor, 
inspector?
familiarity with IB and protocol?
information to subjects?
decision on inclusion and exclusion criteria? 
administration of study medication?
measurements and assessments?
data entry and CRF review?




The set-up of a clinical trial needs to be 
methodologically planned
Adequate resources and facilities need to be 
provided
Optimal medical care for the subject must be 
ensured at all times
Delegation of responsibilities is possible if the 
processes and communication lines are well defined








Material developed in collaboration with 
Genevieve Decoster




Original and Amended Versions









▪ ICH E6 – CMPM/ICH/135/95 – Note for Guidance on GCP
Europe
▪ Volume 10, Chapter V – Recommendation on the Content of the Trial Master File 
and Archiving – July 2006
▪ Directive 2005/28/EC, Chapter 4
▪ Directive 2001/20/EC – Article 15(5) and Article 21(2) 
▪ Reflection paper on expectations for electronic source data and data transcribed to 
electronic data collection tools in clinical trials, 01 August 2010
US
▪ CFR Title 21, Part 312
21/11/2014
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Essential documents are generated and filed 
throughout the entire clinical trial process.
Some must be available:
before the trial starts
during the conduct of the trial








Any or all of the trial documents 
may be subject to and should 
be available for:
On-site monitoring
Audit by the sponsor
Inspection by the regulatory 








Country-specific for regulatory documents; in EU, 
there are EU documents and domestic documents
Identical at each investigational site (multi-centre
trials)
Filed and archived at the investigational sites 
according to local regulations and site procedure
Unambiguous, signed and dated as appropriate.
Essential documents -
demonstrate 







‘Essential documents are those 
documents which individually and 
collectively permit evaluation of the 





In the EU, the investigators must retain the trial 
documents for at least 5 years after its completion 
(longer if locally required by competent authorities).
Medical files are retained in accordance with local 
legislation and hospital practice.
The investigator should take measures to prevent 
accidental or premature destruction of these 
documents.




The investigator should ensure the accuracy, 
completeness, legibility and timeliness of the data 
reported to the sponsor in the CRFs and in all 
required reports*.
Data reported on the CRF should be consistent with 
the source documents or the discrepancies should 
be explained*. CRF should be completed as soon as 
the data are available.
The investigator should maintain the trial documents 
as specified in Essential Documents** and as 
required by domestic regulatory requirement(s)*.




Ref: Annual report of the Good Clinical 
Practice Inspectors Working Group 2012 
Adopted by the GCP IWG on 21 May 2013 
21/11/2014
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Ref: Annual report of the Good Clinical 
Practice Inspectors Working Group 2012 
Adopted by the GCP IWG on 21 May 2013 
21/11/2014
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What do we look for at Audit/ Inspection?
▪ Files are present/available for audit
▪ Filing up to date, depending on status of 
study
▪ Chronology of events/able to recreate study
▪ Filing in date order
▪ Follow ICH GCP/ Vol 10
▪ Review against SOPs/templates
▪ Free of sticky labels







COMMON AUDIT FINDINGS - GENERAL
Absent files/sections/stored ‘elsewhere’ e.g. EC compliance 
statement, key correspondence, laboratory certification, CVs for new 
staff missing, validation of equipment
Documents are not signed or dated or documents may have pages 
with different dates/versions (e.g. CRF)
Poor version control, latest version missing
Subject identifiable information in files
Incomplete documents e.g. pages missing, CVs with no evidence of 
GCP training, current position not listed, key site personnel not listed 




Ensure ‘key’ correspondence is filed – make 
sure important decisions are documented
Audit trial maintained for issues
Avoid duplications
Header of e-mail correct?
E-mail etiquette!!!
These may not always be findings but they 
can be very frustrating
21/11/2014
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Lack of evidence of GCP training amongst Principal 
Investigator (PI) and research staff involved in the 
clinical trial
Inadequate arrangements for cover in absence of the PI
Delegation logs incomplete. Delegated responsibilities 
not clear
Lack of documentary evidence of the PI involvement in 




A training form should be maintained at the 
investigational site
When a monitor or a PI or any other person provides 
training on procedures or in the use of equipment, the 
completion of the training should also be recorded on the 
form
A training certificate and training agenda should be 
provided to the attendee and should be filed
The certificate should bear the training topics, the 




INVESTIGATIONAL MEDICINAL PRODUCTS 
(IMP)
Missing or unsigned documentation (e.g. shipping 
records, temperature log, duration of transportation, drug 
accountability)
Inadequate provisions for storage of IMPs (i.e. not kept 
separate from IMPs for other studies, not temperature 
controlled)




ELECTRONIC RECORDS AND SOURCE 
DOCUMENTS
Monitors had no access to e-records and/or e-source 
documents
The computer programmes were not validated
The computer screens were not user-protected
Both the investigator and the monitor argued that the 
programmes used were provided by Microsoft (e.g.





Omissions, errors and discrepancies in contracts
Responsibilities of collaborating parties not 
clearly defined (external lab, pharmacy, caterer, 
courier, etc.)
Lack of consistency between protocol and 
contract
(Many activities performed by hospital 
personnel, not directly involved in the study)
21/11/2014
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You can be a very experienced investigator and not fully 
comply with GCP document requirements
Before embarking on a clinical trial, make sure that
you have the time, the resources and the facilities
you and your team are trained on the project and on 
GCP requirements
you understand the local legal requirements
Only proper documentation can protect the subjects,





QUALITY MANAGEMENT AT A 
CLINICAL TRIAL SITE
Nicky Dodsworth






Definition and elements of a Quality 
Management System
Definition of SOP
How to write an SOP
Areas to cover by SOPs
21/11/2014
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According to the Clinical Trials 
Directive a sponsor of a clinical 
trial must have a quality 
management system in place. 
But does an investigative site 




it this is the best way to protect the patient 
and to ensure patient safety
it is the best way to ensure ethical and 
scientific good practice
it is the best way to ensure reliability of the 
results









A set of co-ordinated activities to direct and 
control an organisation in order to continually 




ELEMENTS OF A QMS
Standard Operating Procedures
Training of personnel






QA VS. QC (1)
All those planned and systematic actions 
that are established to ensure that the trial 
is performed and the data are generated, 
documented and reported in compliance 
with GCP and the applicable regulatory 
requirements. 
(ICH GCP Guideline Section 1.46)
21/11/2014
9 / 28
QA VS. QC (2)
The operational techniques and activities 
undertaken within the quality assurance 
system to verify that the requirements for 
quality of the trial-related activities have 
been fulfilled. 




While QC is continuously performed by 
staff members involved in the “production 
process”, the person(s) responsible for QA 
must be as independent as possible: 







Evaluation to show trial 
related activities and data 
were recorded, analysed 
and accurately reported to 




GRADING OF INSPECTION/ AUDIT FINDINGS (1)
“Critical” finding:
Definition:
Condition, practices or processes that adversely affect the rights,
safety or well-being of subjects and/or quality and integrity of data
21/11/2014
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GRADING OF INSPECTION/ AUDIT FINDINGS (2)
“Critical” finding:
Possible consequences:
rejection of data and/or legal action required 
drug “non approvable” by competent authority
Observation classified as “critical” may include:
pattern of deviations classified as “major”
bad quality of the data




GRADING OF INSPECTION/ AUDIT FINDINGS (3)
“Major” finding:
Definition:
Condition, practices or processes that might adversely affect 
the rights, safety or well being of subjects and/or 
quality and integrity of data 
Major observations are serious 




GRADING OF INSPECTION/ AUDIT FINDINGS (4)
“Major” finding:
Possible consequences:
data may be rejected and/or legal action are required
Observations classified as “major” may include 





Observation classified as “minor”, indicate the need for 
improvement of conditions, practices and processes
Many “minor” observations may indicate: 
bad quality 
Several minor findings may lead to a ‘MAJOR FINDING’  
with its consequences
GRADING OF INSPECTION/ AUDIT FINDINGS (5)
21/11/2014
17 / 28
STANDARD OPERATING PROCEDURES 
(SOPs)
Exercise:
Please spend three minutes to 
write down how you prepare a 
cup of coffee.





Detailed, written instructions to achieve 
uniformity of the performance of a 
specific function. 
(ICH GCP Guideline Section 1.55)
21/11/2014
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… of a process
Must be a true reflection of what is really done – if not: 
either change 
the procedure or the SOP!
21/11/2014
20 / 28
HOW TO WRITE AN SOP (2)
An SOP should:
be concise
be user-friendly and helpful
provide step-by-step instructions (in logical order)
cover every specific task that is repeated
identify responsibilities (avoid sharing!)
promote consistency across organisations
aid training of staff21/11/2014
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HOW TO WRITE AN SOP (3)
General principles:
Consistent within an organisation
Completed by related Work Instructions and 
Forms
Reviewed and officially approved
Current
Reviewed regularly (every 1-2 years) in line with a 
renewal plan for the SOP system
21/11/2014
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HOW TO WRITE AN SOP (4)
General principles:
available to all staff / team members
maintained centrally
distributed in a controlled, documented 
manner
storage of historical SOPs in the archive
21/11/2014
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HOW TO WRITE AN SOP (5)
Administrative SOPs:
SOP on SOPs
Responsibilities and management of the site 







HOW TO WRITE AN SOP (6)
Clinical SOPs:
preparation/review/approval of protocol + amendments
data handling
interaction with sponsor
interaction with ethics committee





























ICH GCP 1.47…operational techniques 
and activities….to verify that the 





SAFETY MANAGEMENT AT THE 
SITE
Ingrid Klingmann, MD, PhD
Material developed in collaboration with 
Genevieve Decoster
IT & GCP Consulting, Crupet, Belgium
2 / 18
No such thing as absolute safety, every life activity is 
associated with a risk
Need to know the risks & the benefits to evaluate if a 
course of action or a course of medicine is worth taking!
Risk/benefit profile: Need to understand these for every 
drug
“what is acceptable will differ between products & 
patients”
By the time drugs reach the market the risks are usually 
low, but for an accurate assessment, post-marketing 
clinical studies are critical as spontaneous reporting is 
very unreliable
THE CONCEPT OF SAFETY
21/11/2014
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Thalidomide, one of the first drugs recognized to 
cause birth defect in humans (1961).
The thalidomide tragedy led to much stricter testing 








Clinical Trials Directive 2001/20/EC:
Any untoward medical occurrence in a patient or 
clinical trial subject administered a medicinal 
product and which does not necessarily have a 




Clinical Trials Directive 2001/20/EC:
All untoward and unintended responses to an 





SEVERITY / SERIOUSNESS 
Severity of adverse events in clinical trials is 
reported according to ICH E2a guideline as
Grade 1 = mild
Grade 2 = moderate
Grade 3 = severe
This is not the same as SERIOUS which is based on 
patient outcome, seriousness serves as a guide for 
defining regulatory reporting obligations
21/11/2014
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Adverse Events: Defining Relatedness
Definitely related: There is a certainty that the event is related 
to the investigational product. 
Probably related: There is high likelihood that the event is 
related to the investigational product. 
Possibly related: There is a likelihood that the investigational 
product is the cause of the event, but other causes cannot be 
ruled out. 
Unlikely to be related: It is not likely that the event is related to 
the investigational product, and other more likely causes are 
present. 
Unrelated: Evidence exists that the event is related to 
something other than the investigational product
21/11/2014
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Any untoward medical occurrence that at any dose:
results in death
is life-threatening
requires inpatient hospitalization or prolongation of existing 
hospitalization
results in persistent or significant disability/incapacity
congenital anomaly/birth defect
is medically significant
THIS SHOULD BE REPORTED BY THE INVESTIGATOR 
to THE SPONSOR, IMMEDIATELY
DEFINITION: SERIOUS ADVERSE EVENT
21/11/2014
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Suspected (causality at least possible)
Unexpected (not in Investigator Brochure or Summary of 




THIS IS EVALUATED AND REPORTED ONLY BY 
THE SPONSOR 
DEFINITION OF SUSPECTED UNEXPECTED 






Investigators are responsible for
Training all site staff on the relevance and process of reliable 
adverse event collection
Collecting all spontaneously mentioned complaints and related 
relevant information completely and
Collecting systematically questioned complaints (AE 
checklists) and questionnaires according to the requirements 
of the protocol








Investigators are responsible for
Reporting laboratory abnormalities identified in the protocol as 
critical to safety evaluations
Assessing the adverse events according to the definitions in 
the protocol
Reporting serious adverse events (SAEs) within  24 hours to 
the sponsor
Notifying ethics committee (health authorities) if requested in 
the national legislation
Regularly communicates with site staff and monitor about 







Sponsors (commercial and non-commercial clinical 
trials) is responsible for processing:
Serious Adverse Events (SAE) as reported by the 
investigators
When an SAE is qualified to become a Suspected 
Unexpected Serious Adverse Reactions (SUSAR), it 
should be reported expeditedly to authorities and 
quarterly to Ethics Committees. 
7 days for life-threatening/death 
15 days for all others
Annual Safety Reports
The assessment of expected/unexpected is the 




Adverse Reactions (usually only drug-related, in some 
countries also drug-unrelated)
Investigational Medicinal Product (IMP), and the comparator 
(active ingredient or placebo)
Expedited Reports
Suspected Unexpected Serious Adverse Reactions (SUSARs)
Annual Safety Reports (“DSUR”)








EudraVigilance (European Union Drug Regulating 
Authorities Pharmacovigilance) is the European data 
processing network and management system for 
reporting and evaluation of SUSARs during the 
development of new drugs and following the marketing 
authorization of medicinal products in the European 
Economic Area (EEA). 
Database should provide an overview of SUSARs in all 
clinical trials in the EU
It is the sponsor’s responsibilities to report a SUSAR to 
the national competent authorities (CA), the Ethics 
Committees and the investigators21/11/2014
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MedDRA terminology standardises AE original terms and 
must be applied prior to analyse clinical trial results 
(especially safety data e.g. AEs & SAEs)
MedDRA terminology applies to all phases of drug 
development including post-registration studies, but 
excluding data from animal studies. MedDRA is not a 
dictionary defining terms
MedDRA consists of 26 System Organ Classes (SOC) 
listing more than 60,000 terms. There are 5 hierarchical 
levels of coding from the lowest level term (LLT) up to the 
high level term (SOC)
CTCAE version 4.0 mapping MedDRA version 12.1
MedDRA = Medical Dictionary for Regulatory Activities 
MedDRA
21/11/2014    
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Handling drug safety, whether in clinical trial 
environment or routine medical practice using 
prescribed medicines, requires a lot of expertise
Drug safety monitoring is a worldwide concern, not 




Investigators, sponsors, ethics committees, DSMB 
(Data Safety Monitoring Board) and health authorities 
should work together to ensure an adequate protection 
of trial participants.
Systems to report safety whether it’s AE, SAE, or 
SUSAR should be simple, accurate, reliable, and 




Carefully read one of the Case Studies 
Identify all adverse events of this patient
Consider their causality with the study medication
Decide whether this is a Serious Adverse Event









































































































































Proper planning of the site staff requirements for a clinical trial is 
vital to its success.
Prerequisites: 
Clear understanding of the Project, the Sub-Projects, the Work 
Packages and Deliverables to be performed
Experience concerning time required per task
Realistic estimation of the required / available time frames for the 
trial with best case and worst case scenarios
Comprehensive understanding of available own resources and 




Factors affecting human resource requirements in 
clinical trial sites:
Type of tasks to be performed
Number of tasks within one trial distributed over time
Number of patients to be screened and enrolled per month
Duration of the different tasks and total study duration
Percent of staff availability
Likelihood of peaks and troughs
Likelihood of staff turn-over / downtime




How best to calculate the required staff?
1. List the tasks to be performed per patient per visit with the 
function(s) involved and the expected duration. 
2. Map the hours / minutes required for one patient per visit per job 
category. 
3. Calculate whether all trial activities can be performed by one person 
or whether there is a need to include two persons in parallel to be able 
to perform the tasks within the required time window.
4. Define whether a person needs to give support / input to somebody 




How best to calculate the required staff?
5. Decide on the number of patients that can realistically be 
expected to be enrolled per day. Make also a best case scenario 
and a worst case scenario.
6. Figure out how many patients one person could handle per day, 
taking into account a staggering of trial activities, respectively, 
how much staff you would need to handle this number of enrolled 




Calculation of staff availability: 
1 Fulltime Equivalent   1 FTE
A year has 365 days   
Minus  52 x 2 Weekend days =  261 days
Minus 12 bank holidays =249 days
Minus 30 days vacation =219 days
Minus 10 days sick leave / kid’s leave / etc. =209 days
Minus 9 days training / seminars / conferences =200 days
Divided by 12 months:   One person will be in the average                     




Calculation of staff availability: 
As the month has in the average 20 working days you need more 
than 1 FTE to cover a full-time job function.
Experience has shown that it is prude to assume 1.5 FTEs to reliably 





Calculation of staff availability: 




Number of direct reports
Frequency of travel
Etc.
Depending on the type of responsibility the main question is:   





It is of vital importance to the success of the trial performance that a 
detailed staffing plan is worked out, agreed and communicated to all 












Communication is the basis for living and working 
together, happens therefore constantly    
but
Miscommunication or lack of communication     
happen very frequently




A Communication Plan is helpful to
Minimise / avoid misunderstandings
Motivate internal and external team members
Clearly outline expectations, tasks and responsibilities of all 
parties
Document what was done




Define your “Stakeholders”: 
Who needs which information
When they will need it
How it will be given to them 
By whom
Informational needs and methods of distribution vary widely
22/11/2014
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All materials for trial-
related assessments , e.g. 






Drinks + food for patients
„Resource Planning“ also means planning and maintenance of  all 




Reception and waiting area
Quiet room for IC













When planning space required for a trial the flow of study activities 





Space should be planned in such a way that it can easily 
be adapted to the needs of the respective trial
For all areas there needs to be a reliable procedure in 
place that supervises the stock of the respective 
material/utilities and ensures early replacement.
There is nothing more frustrating than having patients ready 
for inclusion but no study medication inhouse
22/11/2014
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Carefully read the study synopsis  
Define the study activities foreseen for the Screening Visit
Rank the activities according to your department practice and 
work flow
Decide on the person performing the activity
Decide on the time this activity will take












Prospective, Randomized, Double-blind, Dose-finding 
Study to Evaluate the Efficacy and Safety of  
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A Prospective Randomised, Double-blind, Dose-finding Study to Evaluate the 
Efficacy and Safety of R-Megaprofen in Comparison to Placebo and Paracetamol. 
 
1.2  Objectives 
 
1.2.1 Primary Objective 
 
To investigate the analgesic efficacy of different doses of R-Megaprofen within 3 
hours after drug administration in comparison to placebo and paracetamol in 
patients with acute moderate to severe pain after impacted or partly impacted  
lower third molar withdrawal. 
 
1.2.2 Secondary Objectives 
 
To identify the optimal analgesic dose of R-Megaprofen in comparison to placebo 
and paracetamol. 
 
To identify the non-effect dose of R-Megaprofen. 
 
To investigate the onset of action of the optimal dose of R-Megaprofen in 
comparison to placebo and paracetamol. 
 
To investigate the duration of action of R-Megaprofen in comparison to placebo 
and paracetamol. 
 
To investigate the percentage of patients requiring rescue medication under the 
different treatments. 
 
To investigate the relationship between analgesic efficacy and plasma 
concentrations of R-Megaprofen and paracetamol. 
 
To investigate the safety of R-Megaprofen. 
 
1.2.3 Study Design 
  
This Phase II study will be two-centre, double-blind, randomised, single-dose and 
six-arm parallel in design. It will evaluate the analgesic efficacy and safety of R-
Megaprofen compared to placebo and evaluate the dose response relationship 
of different doses of R-Megaprofen following third molar extraction under local 
anaesthetic. 
 
1.2.4 Study Population 
 
Approximately 430 patients, aged between 18 and 45 years inclusive, will be 
screened.  It is estimated that 10 – 25% of those screened will not satisfy all the 
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necessary inclusion/exclusion criteria. Approximately 360 patients who satisfy all 
the inclusion/exclusion criteria will be scheduled for dental surgery. It is estimated 
that only 85% of patients who undergo surgery will reach the necessary pain level 
within the designated time period post surgery (six hours). Hence, the first 306 
patients that meet the inclusion criteria with respect to pain level after surgery will 
be randomised to one of six treatment groups; 
 
1.2.5 Study Medication 
 
Group 1 50mg R-Megaprofen  
Group 2 100mg R-Megaprofen  
Group 3 200mg R-Megaprofen  
Group 4 400mg R-Megaprofen  
Group 5 1000mg paracetamol  
Group 6  placebo   
 
1.2.6 Study Plan 
Patients who meet all admission criteria after undergoing screening procedures 
will undergo surgical removal of one partial or complete bony impacted third 
mandibular molar.  A second ipsilateral maxillary third molar or adjacent 
supernumary tooth may be removed if warranted by the surgeon, and if its 
removal requires routine surgical procedures. Following surgery, when post-
surgical pain has reached the required intensity, patients will be randomised to 
receive one of six treatments. Patients must have moderate to severe pain to be 
randomised, which will be defined by a recording of at least 2 on a Verbal Rating 
Scale (VRS 0 - 3), and confirmed by recording at least 50mm on a Visual Analog 
Scale (VAS 100mm). Patients will record their pain level and pain relief at 10, 20, 
30, 40, 50, 60, 90, 120, 180, 240, 300 and 360 minutes after study drug 
administration. Patients will indicate time to first perceptible pain relief and time to 
meaningful pain relief via two masked stop watches started at the time of dose 
intake. All patients will have blood samples drawn for PK assessments (within five 
minutes of pain relief assessments) pre-dose and no later than the following 
nominal time post-dose 15, 25, 35, 45, 65, 95, 125, 185 and 245, 305 and 365 
minutes. If a blood sample is delayed, the exact time of withdrawal and a 
comment should be entered in the CRF. 
 
Patients who meet the pain threshold for inclusion into the study (VRS of at least 
2, and VAS of at least 50mm) may request rescue medication at any time during 
the pain assessment period (six hours post-dosing). However, patients will be 
asked to refrain from using rescue medication until 60 minutes post-dose in order 
to give the study medication a reasonable opportunity to work. Randomised 
patients will be considered evaluable when at least the first pain assessment 10 
minutes post-dosing is completed. The rescue medication provided will be 400mg 
Ibuprofen. The time to administration of rescue medication will be recorded in the 
CRF. Patients will continue to have pain assessments and blood samples taken 
for PK analysis until six hours post surgery even if they take rescue medication. 
All patients (including non-dosers) will be required to remain in the clinic for the 
recovery period and assessment periods. 
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Patients who do not meet the pain threshold necessary for inclusion into the study 
within six hours after surgery are considered non-dosers and will remain under 
supervision in the clinic for up to another six hours. Non-dosers will be 
administered analgesia as deemed appropriate by the investigator. The time to 
administration of analgesia and details of the type and dose of medication used 
will be recorded in the CRF. 
 
Patients who request rescue analgesics prior to meeting the pain threshold 
necessary for inclusion into the study will remain in the clinic for six hours as well. 
Patients who request analgesia prior to meeting the inclusion criteria will be 
considered non-dosers.  
 
1.2.7 Study Duration and Timings 
 
The length of the study for each patient will be three study visits within 38 days: a 
screening visit, which may take place up to 28 days prior to the oral surgery day, 
a visit at the oral surgery day and finally a follow up visit which will take place 7 





2.1 Primary Objective 
 
To investigate the analgesic efficacy of different doses of R-Megaprofen within 3 
hours after drug administration in comparison to placebo and paracetamol in 
patients with moderate to severe pain after impacted or partly impacted third 
molar withdrawal.  
 
2.2   Secondary Objectives 
 
To identify the optimal analgesic dose of R-Megaprofen in comparison to placebo 
and paracetamol. 
 
To identify the non-effect dose of R-Megaprofen. 
 
To investigate the onset of action of the optimal dose of R-Megaprofen in 
comparison to placebo and paracetamol. 
 
To investigate the duration of action of R-Megaprofen in comparison to placebo 
and paracetamol. 
 
To investigate the percentage of patients requiring rescue medication under the 
different treatments. 
 
To investigate the relationship between analgesic efficacy and plasma 
concentrations of R-Megaprofen and paracetamol. 
 
To investigate the safety of R-Megaprofen. 
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3.   Study Plan 
 
3.1  Study Design 
 
This Phase II study will be a two-centre, double-blind, randomised, single-dose 
and six-arm parallel in design. It will evaluate the acute analgesic efficacy and 
safety of R-Megaprofen compared to placebo and paracetamol and evaluate the 
dose response relationship of different doses of R-Megaprofen following third 
molar extraction under local anaesthetic. 
 
3.2     Study Population 
 
3.2.1   Source and Number of Patients 
 
Approximately 306 patients who will satisfy all the admission criteria including a 
VRS of at least 2 and a VAS of at least 50mm following the surgical extraction of 
at least one impacted or partly impacted lower third molar, will be randomised to 
one of six treatment groups. 
 
Fifty patients will be randomised to receive 50mg, 100mg, 200mg, 400mg of R-
Megaprofen or 1000mg paracetamol or placebo. 
 
 
3.2.2  Patient Restrictions and Concomitant Medications 
 
Patients may be resident in the unit for up to 12 hours post-surgery on oral 
surgery day. 
 
Patients will be asked not to eat anything after 5:00 a.m. prior to attending the 
clinic on the day of surgery. 
 
Before and after surgery, water and apple juice will be permitted ad libitum. 
 
Patients may have soup 90 minutes post-dose, food will be allowed 3 hours post-
dose. 
 
Patients who have taken medication of the types and within the timeframes 
indicated in the exclusion criteria will not be permitted into the study.  Additionally, 
patients will be asked to refrain from drinking alcohol within 12 hours prior to 
attending the clinic on the oral surgery day. 
 
Patients may need to take medication e.g. oral contraceptives during the study 
period (from screening until follow up).  It is accepted that analgesics will be 
required and antibiotic treatment may be required following discharge from the 
clinic.  Details of all medications (including chlorhexidine mouthwash) taken 
between clinic discharge and follow up visit must be reported to the investigator 
and the details will be recorded on the CRF. 
 
In order to participate in the study, patients must have their surgery completed 
before 12 noon.  
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3.3   Clinical Supplies 
 
3.3.1   Study Medications 
 
The study medication is produced by Manufac AG, Cologne. In order to provide 
several dosages while using one tablet size, each verum tablet will contain the 
same amount of 50mg R-Megaprofen. 
 
Further drug information on the placebo to match R-Megaprofen and paracetamol 
is provided in Appendix B. 
 
Patients will be randomised to one of the following six treatments  
 
Group 1  R-Megaprofen 50mg:   
Group 2  R-Megaprofen 100mg:   
Group 3  R-Megaprofen 200mg    
Group 4  R-Megaprofen 400mg   
Group 5  paracetamol 1000mg  
Group 6  placebo  
 
In order to ensure complete blinding for research personnel and patients the 
double dummy technique is used:  each patient will receive 8 small tablets 
(containing R-Megaprofen or placebo) and 2 big tablets (containing paracetamol 
or placebo) 
  
 Group 1: 50 mg 
R-Megaprofen 
Group 2: 100 
mg R-
Megaprofen 
Group 3: 200 
mg R-
Megaprofen 
Group 4: 400 
mg R-
Megaprofen 
Group 5: no 
active 
ingredient 









7 6 4 0 8 8 
# of 
paracetamol 
500 mg tablets 




2 2 2 2 2 0 
 
Rescue medication in the form of ibuprofen 400 mg will be available to patients at 
any time during the pain assessment period (six hours post dosing).  Secondary 
rescue medication will be administered to patients at the investigator’s discretion. 
 
 
3.3.2 Accountability of Study Supplies 
 
All material supplied is for use only in this clinical study and should not be used 
for any other purpose. 
 
The investigator or designee will maintain a full record of drug accountability.  A 
Drug Dispensing Log must be kept current and will contain the following 
information: 
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♦ the identification of the patient to whom the drug was dispensed; 
 
♦ the date(s) and quantity of the drug dispensed to the patient. 
 
The inventory must be available for inspection by the study monitor during the 
study.  At the end of the study, drug supplies will be verified by the monitor.  Drug 
supplies will then be either collected by the study monitor or returned by the 
investigator or designee to Minipharm GmbH. 
 
3.3.3   Storage of Clinical Supplies 
 
Clinical supplies must be stored in compliance with the label requirements at 




3.4  Study Schedule 
 
The study schedule is summarised in Table 1. 
 
3.4.1 Selection and Screening Phase 
 
Potential patients will contact the site to enquire about the study (in response to 
advertisements, word of mouth, etc).  The medium through which patients 
became aware of the site and the study will be detailed on the telephone screen 
report.   
 
A Research Ethics Committee approved telephone screen will be used to obtain 
information to assess a patient’s eligibility into and availability to participate in the 
study. 
 
Patients who satisfy the eligibility and availability requirements of the telephone 
screen will be scheduled to attend a pre-screening examination at the study site. 
 
The investigator or designee will discuss the details of the study with suitable 
patients, who will subsequently be provided with written information about the 
study and be given adequate time to read and consider the information provided.  
If the patient wishes to participate in the study, they will be required to give written 
informed consent before any screening procedures are performed.  All patients 
who provide signed informed consent will be assigned an enrolment number. 
 
Patients undergo panoramic dental x-ray to determine whether the patient has at 
least one partial or complete bony impacted lower third molar. The oral surgeon 
performs an oral examination of the patient and decides on the suitability of the 
patient from a dental point of view. 
 
Patients who fail oral screening will not proceed any further.  A single page CRF 
detailing the outcome of oral screening will be completed also for these patients.  
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Those patients considered to be eligible following oral screening will proceed to 
have a medical assessment with the investigator or designee and details will be 
recorded on the CRF.  The medical assessment will include demographics (age, 
sex, race, height and weight), relevant medical history and relevant allergies, in 
particular hypersensitivity to paracetamol or ibuprofen (rescue medication), and 
any agents used for local anaesthesia.  A history of oral health and details of any 
medications currently being taken by the patient will be recorded.  Measurement 
of vital signs (heart rate and blood pressure) will be conducted to confirm that 
they are within clinically acceptable limits.  Blood will be drawn for analysis of 
biochemistry, urine for urinanalysis. 
 
A urine drug screen will be performed to test for illegal drug use (excluding 
cannabis).  Patients who test positive for illegal drug use maybe re-tested if in the 
investigator’s opinion the result is likely to be false.  However, patients who retest 
positive for illegal drug use will be discontinued from the study. 
 
A urine pregnancy test will be performed on all female patients of child bearing 
potential at screening, these test must prove negative for a patient to be eligible 
to participate in the study. 
 
Breath alcohol tests will be performed and must prove negative before a patient 
can proceed in the study. 
 
Patients will then be scheduled to return to the site within 28 days for oral 
surgery, and they will be instructed to fast from 5:00 a.m. prior to attending the 




3.4.2 Baseline Phase 
 
Patients will arrive at the clinic at a pre-appointed time on the morning of oral 
surgery for the following assessments and procedures prior to surgery: 
 
• Review of haematology and blood biochemistry results from screening visit 
 
• Urine drug screen (excluding cannabis), result must be available prior to 
dosing  
 
• Alcohol breath test, result must be available prior to dosing 
 
• Urine pregnancy tests (females of child bearing potential only), result must 
be available prior to dosing 
 
• Vital signs (heart rate and blood pressure) 
 
• Insert indwelling cannula into an appropriate vein in the arm 
 
• Training in stopwatch procedures  
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• Training in pain assessment scales and clinical definitions of what is meant 
by perceptible and meaningful pain relief will be provided. 
 





3.4.3  Treatment Phase 
 
After successful completion of all baseline assessments and procedures the 
patients will undergo oral surgery: 
♦ Local anaesthetic administered 
 
♦ Oral surgery performed employing standard techniques 
 
♦ Post surgical pain assessments will be performed when patients complain of 
pain  
 
♦ Randomisation to treatment group, if moderate to severe pain (recorded as a 
2 for moderate and 3 for severe on the VRS, and at least 50 mm on the VAS) 
is experienced.   
 
♦ Pre-dose blood sample taken 
 
♦ Administration of study medication according to the randomisation schedule 
 
♦ Two stopwatches started, to be stopped at ‘perceptible’ and at ‘meaningful’ 
pain relief 
 
♦ Pain assessment using the 4 point VRS and 100mm VAS as well as pain relief 
assessments using the 5-point (VRS) categorical scale will be made at 10, 20, 
30, 40, 50, 60, 90, 120, 180, 240, 300 and 360  minutes post-dose prompted 
by the clinic staff 
 
♦ Blood samples will be drawn for PK analysis via an indwelling cannula in the 
crook of the arm, near the wrist or the back of the hand within five minutes of 
completing their pain assessments made at 15, 25,  35, 45, 65, 95, 125, 185, 
245, 305 and 365 minutes post-dose.  There is no associated PK sample for 
the 50 minute pain assessments. After each blood sample is taken the iv 
cannula should be flushed with 3 ml isotonic sodium chloride solution 
 
♦ The blood samples have to be centrifuged for 5 minutes within 3 minutes after 
blood withdrawal. After centrifuging plasma has to be drawn and stored in 
tubes labelled with the same patient number and the blood withdrawal time 
point. These samples need to be stored at – 70°C until analysis. The plasma 
levels of R-Megaprofen will be determined using a validated HPLC method in 
the Minipharm GmbH laboratory.  R-Megaprofen will be determined in a first 
batch of 72 patients. This will result in approximately 12 measurements per 
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time point and medication group. Knowing about the inter-subject variability of 
R-Megaprofen plasma levels and the relatively weak co-relation of NSAIDs 
plasma level and levels of pain relief (reference) the first batch shall be used 
to test if a relationship exists. As patients will not gain important medical 
information by learning the results of their PK analysis it is acceptable for the 
sponsor to decide if and how many more PK samples should be analysed. 
The exact number of samples analysed will be documented in the final report.  
The analysis of further patient plasma levels may be undertaken after closure 
of the study database and thus be viewed as being a non-integral part of the 
study. Relevant results of an extended analysis will be distributed to all parties 
having received the study report. 
 
As very late time-points are missing the half life of the drug cannot be determined 
from this PK analysis. 
Patients may request rescue medication at any time following the administration 
of study drug. However they will be asked to abstain until 60 minutes after 
administration of study drug, if possible.  The exact time of administration will be 
recorded on the CRF. All randomised patients will continue with pain 
assessments and blood sampling to 6 hours even if they take the rescue 
medication.  
 
If pain of at least moderate intensity is not experienced within six hours following 
surgery, randomisation will not take place, and study medication will not be 
dispensed.  The patient will be considered a non-doser, and the investigator will 
ensure that proper and appropriate care is administered. 
 
Discharge from the clinic and schedule to return in seven (±3) days for follow-up 
procedures. 
 
3.4.4  Follow up  
 
Patients will return to the clinic seven (±3) days after surgery and will undergo the 
following procedures: 
 
♦ Urine pregnancy test (females of child bearing potential only) 
 
♦ Vital signs (heart rate and blood pressure) 
 
♦ Follow up oral examination 
 
♦ Blood and urine collection for safety laboratory parameters 
 
♦ Physical examination 
 
The investigator or designee will question the patient regarding any adverse 
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4.        Study Procedures and Assessments 
 
4.1 Dental Procedures 
 
4.1.1   Pre- Screen Oral Examination 
 
An oral examination will take place at the screening examination to establish 
whether a patient has at least one partial or complete bony impacted lower third 
molar.  This will consist of a visual inspection of teeth, gums/tissue for signs of 
oedema, erythema or infection. 
 
4.1.2 Panoramic Dental X-ray 
 
Panoramic dental X-rays will be taken at the oral screening examination to 
confirm the appropriate bony impacted mandibular third molar is present.   
 
Possible levels of impaction are: 
 
1. Fully erupted or partially covered by soft tissue = erupted. 
2. Submerged, covered only by soft tissue = soft tissue.  
3. Partial bony impaction = partially imbedded in bone. 
4. Full bony impaction = fully imbedded and covered by alveolar bone.  
 
4.1.3 Standardised Local Anaesthesia 
 
Patients will be asked to rinse for 1 minute with chlorhexidine 0.1% solution.  A 
mixture of prilocaine 3% and felypressin 0.54 µg/ml will be used for local 
anaesthesia.  In the lower jaw an inferior alveolar nerve block as well as a lingual 
nerve block (local anaesthesia) will be performed as well as local buccal 
infiltration to the operation side.  The usual dose is between 3.6 and 5.4 ml (the 
maximum dose allowed is 10 ml).  In case an ipsilateral third molar is to be 
removed in the upper jaw, local anaesthesia at the tuberosity palatine foramen 
and buccal palatal infiltration in this area will be performed.  The usual dosage for 
this is between 1.8 and 3.6 ml (the maximum dose allowed is 6 ml). 
 
The doses of local anaesthesia used for lower and upper third molar removal will 
be recorded separately for each of these in the CRF.  Any deviation from 
anaesthesia protocol will be thoroughly documented in the CRF. 
 
4.1.4 Third Molar Extraction Surgery  
 
Third molar extractions surgery will be performed under local anaesthesia by a 
suitably qualified dental surgeon.  The surgical procedure will consist of an 
incision from the anterior border of the mandibular ramus continued as a marginal 
incision as necessary.  Thereafter, the buccal mucoperiosteal flap is elevated and 
bone is removed using a bur irrigated with sterile physiological saline solution. If 
necessary, splitting of the tooth will be performed.  Finally, the wound is cleaned, 
irrigated and closed with 3-0 sutures.  Patients may have additional teeth 
removed if warranted by the dental surgeon.  Oral surgery must be completed by 
noon. 
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The details of any local anaesthetic or other medications including chlorhexidine 
mouthwash used during surgery will be detailed on the concomitant medications 
page of the CRF. 
 
4.1.5 Follow up Oral Examination 
 
At the follow up visit an oral examination will be performed which will consist of: 
 
1. absorption of sutures (if not absorbed, they will be removed) and healing at 
surgical site 
 





4.2 Pain Assessments 
 
4.2.1  Pain Assessment Plan 
 
All pain assessments will be conducted by the patient.  Pain assessments taken 
up to and including six hours will be recorded in the CRFs. 
 
Soon after oral surgery, the patients will recover from the local anaesthesia.  This 
will be prior to administration of study medication and will be known as the 
recovery period.  During the recovery period, patients will record the level of post-
surgical pain on a 4 (0, 1, 2, 3) point VRS.  When the patient indicates the level of 
pain to be 2 or above on the VRS, this is considered to equate to pain of 
moderate/severe intensity.  To confirm the appropriate level of pain intensity for 
entry into the study, patients will also record the level of post-surgical pain 
intensity on a VAS.  When the patient indicates a level of at least 50 mm on the 
VAS, this is considered to equate to pain of at least moderate intensity. 
 
Patients will not be informed of the pain intensity levels which they need to 
achieve in order to be randomised.  Patients will be instructed to alert site staff 
when they perceive any change in their level of pain.  Staff will instruct patients to 
complete the pain intensity assessments.  If the patient indicates the level of pain 
to be 2 or above on the VRS then site staff will measure the VAS pain intensity 
assessment.  If the VAS does not reflect at least moderate (50 mm) pain, patients 
will be advised that they do not qualify to be randomised into the study and to 
remain in the recovery area.  They will be asked to alert site staff again when they 
perceive any change in their level of pain.  When a patient reports a change in 
pain to study staff they will be asked to complete the VRS and VAS scales again 
until such time as they meet the inclusion criteria. Patients who do not experience 
moderate to severe pain within 6 hours will not be randomised. 
 
Patients who experience moderate to severe pain as indicated by a score of 2 or 
more on a VRS and confirmed by VAS score of at least 50 mm on a 100 mm 
scale within 6 hours will be randomised to one of the six treatment groups.  The 
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qualifying VRS and VAS pain intensity scores for entry into the study will be 
recorded on the case report form as the baseline level of pain.  The patient may 
then be randomised according to the randomisation schedule and baseline pain 
level and study medication will be administered. Patients will receive 2 masked 
stop watches and will be instructed to stop the first stop watch when they first 
notice perceptible pain relief, and to stop the second stop watch when meaningful 
pain relief is noticed.  Patients will subsequently complete evaluations of pain 
intensity and pain relief at 10, 20, 30, 40 50, 60, 90, 120, 180, 240, 300 and 360 
minutes post-dose.  A running digital timer and the patient’s source document will 
prompt the site staff to alert the patient to conduct pain assessments at these 
intervals. 
 
All VAS and VRS assessments completed during the recovery period, before the 
baseline assessment of pain reaches moderate/severe in intensity will be 
available to monitor source documents. 
 
4.2.2   Pain Assessment Instruments 
 
Pain intensity will be evaluated using a 4-point categorical scale (VRS) and a 100 
mm VAS. 
 
4.2.2.1 Verbal Rating Score (VRS) 
 
0 = No pain or none 
1 = Mild 
2= Moderate 
3 = Severe 
 
Where No pain or none, Mild, Moderate and Severe are defined to the patient as: 
 
No pain or none  = that is that you are having absolutely no pain at the    
    surgical site. 
 
Mild  =        is pain you can’t ignore, but not something you would    
 normally treat. 
 
Moderate                  = is pain that interferes with your concentration. You     
would have difficulty reading or watching TV. You 
would definitely feel that you need to treat the pain. 
 
Severe                     = is pain that not only interferes with your concentration 
but also causes you to change what you are doing in 
some way. You would definitely feel that you need to 
treat the pain. 
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4.2.2.2 Visual Analogue Score (VAS) 
 
Patients will indicate their pain intensity on a pre-drawn 100 mm scale by drawing 
a line, approximately perpendicular to the scale and that bisects the scale.  One 
end of the scale will be marked “No pain”, and the opposite end will be marked 
“Worst possible pain”.  The VAS used in the recovery period and in the pain 
assessment period will be the same. 
  
Site staff must ensure the patient completes this assessment properly i.e. that the 
vertical line drawn by the patient crosses the scale. The VAS score (mm) will be 
measured by the site staff. The measurement must be taken from the left side of 
the scale (“No pain”) to the right side of the scale (“Worst possible Pain”).  
 
4.2.2.3 Pain Relief Verbal Rating Score 
 
Patients will rate the amount of pain relief from starting pain using a 5-point 
categorical scale as either:  
 
♦ No relief or exacerbation = 0 
♦ A little relief   = 1 
♦ Some relief    = 2 
♦ A lot of relief    = 3 
♦ Complete relief   = 4 
 
Defined as: 
♦ No relief: means the same amount of pain you started with or worse. 
♦ A little relief: means the pain is less than half gone 
♦ Some relief: means the pain is about half gone 
♦ A lot of relief: means the pain is more than half gone 
♦ Complete relief: means there is no pain 
 
The statement “My relief from starting pain is” will be used for this assessment 
on the CRF’s. 
 
4.2.2.4 Stopwatch Method/Time to Pain Relief 
 
After patients have been administered study medication, the site staff will 
simultaneously conduct the following stopwatch procedure: 
 
1.  Start both masked stop watches and instruct the patient to stop the first 
stopwatch upon feeling the first perceptible pain relief. The site staff will give the 
patient specific directions regarding this i.e. “I want you to stop this watch, 
marked ‘Perceptible’, when you first feel any pain relief whatsoever. This 
doesn’t mean when you feel completely better, although you might, but 
when you first feel any difference in the pain you have now.” 
 
2.  Instruct the patient to stop the second stopwatch upon feeling meaningful pain 
relief. The site staff will give the patient specific directions regarding this i.e. “I 
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want you to stop this watch, marked ‘Meaningful’, when the pain relief is 
meaningful to you.”  
 
3.  A digital timer will be started and will be placed with the CRF. The CRF will 
reflect the time of dose and all subsequent scheduled pain assessment and PK 




4.3  Pharmacokinetics 
 
4.3.1 Blood Samples for Pharmacokinetic Analyses 
 
Blood samples (5ml) will be drawn from an indwelling cannula situated in a 
suitable vein into lithium heparinised tubes The cannula will be flushed after 
sampling with approximately 2 ml saline. Blood samples will be drawn pre-dose 
(within 15 minutes of dosing) and no later than the following nominal times post 
dose 15, 25, 35, 45, 65, 95, 125, 185, 245, 305 and 365 minutes.  
 
The target sample times will be recorded on the CRF’s. The nominal times (the 
times the blood samples will be taken relative to the actual dosing time) should be 
entered on the CRF prior to dosing. The actual sample times (sample times 
actually taken) should be recorded alongside the nominal times on the CRF and 
should be entered at the time of or soon as possible after sampling. All times 
must be recorded in the 24 hour format. 
 
Where a cannula is used, and where a blockage occurs during the study it may 
be necessary to obtain subsequent samples by venepuncture. This must be 
recorded with an explanation on the CRF. 
 
Blood samples will be centrifuged at 3000rpm/ 4ْ C for 15 minutes. Approximately 
2ml plasma will be separated from each sample, split into two equal aliquots and 
each placed into 3.6ml polypropylene screw top tube labelled with the study 
number, subject number, and time point of the blood sample and will be frozen at 
-20ْ C within 1 hour of sampling. 
 
Approximately 70/130 ml of blood will be collected from each subject throughout 




4.4  Safety Variables 
 
4.4.1 Vital Signs (heart rate and blood pressure measurements) 
Systolic and diastolic blood pressure as well as heart rate at rest after 5 minutes 
in sitting position will be measured during the screening-visit, at baseline 
immediately before study medication administration and during the follow up-visit. 
The blood pressure will be measured using non-invasive equipment.  
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The following normal ranges for blood pressure and heart rate are provided as a 
guide only.   
 
• Blood Pressure: 
• Systolic   90 -150 mm Hg 
• Diastolic  60 – 90 mm Hg 
 
• Heart rate:  50 – 100 beats per minute 
 
The investigator can interpret individual findings based on the patient’s age, 
physical state and level of fitness.  Patients with readings marginally outside the 
normal range may be included in the study if in the investigator’s opinion these 
are not clinically significant. 
 
4.4.2 Urine Drug Screen 
 
Urine samples will be collected at screening and baseline and tested for 
benzodiazepines, opiates, amphetamines and barbiturates.  The results of these 
tests must be available prior to dosing.  Patients with positive results will be re-
tested (at the discretion of the investigator) or withdrawn.  One re-test only will be 
allowed per patient. 
 
4.4.3 Laboratory Parameters 
 
Blood and urine samples will be obtained during the screening visit and during the 
follow-up visit for determination of laboratory parameters. The following 
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4.4.4 Urine Pregnancy Test 
 
Female patients of child bearing potential will provide urine samples at screening, 
baseline and follow up for pregnancy testing. 
 
4.4.5      Alcohol Breath Test 
 




4.5  Adverse Events 
 
All adverse events (adverse experiences / adverse drug experiences) 
encountered during the clinical study, whether spontaneously reported by the 
patient at any time during the study or elicited by the investigator in a standard 
manner at the study visits, will be reported in the CRF. 
 
The investigator or designee must ask the patient the following question during 
each visit including any follow-visits: “Have you felt unwell, experienced any 
symptoms or taken any medication (since your last visit) (today) (since your 
last dose) (since your last session)”. 
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Study Schedule 
 
  Study Period 
Procedure         Pain Assessment Period   
























































Inclusion/exclusion criteria X     X*                           
Demographics and medical history X                                 
Current / concomitant medications X X             X               X 
Vital signs ( heart rate and blood pressure) X X                             X 
Blood biochemistry (ALT, AST) & Haematology X                                
Urine drug screen X X                               
Pregnancy test (if applicable) X X                             X 
Dental X-rays X                                 
Oral examination X X                             X 
Patient training using stopwatches & assessment scales X X                               
Alcohol breath test  X                               
Tooth extraction(s)     X                             
Pain intensity assessment on VRS       X*                           
Pain intensity assessment on VAS       X*                           
Pain relief assessment on VRS         X X X X X X X X X X X X   
Randomisation / dispense study medication       X*                           
PK samples taken within 5 min completion of pain 
assessments       X* X X X X  X X X X X X X   
Adverse events                                 X 
Medical sign off                                 X 
 
 
*Patients will be randomised following qualifying post-surgical pain assessments of moderate to severe intensity. Pain Intensity assessment on VRS must be 2 or 3 
indicating moderate to severe pain, and Pain intensity assessment on VAS must be at least 50 mm confirming moderate pain. 
α Blood biochemistry results reviewed. 





ASPECTS IN CLINICAL TRIAL 
MANAGEMENT
Nicky Dodsworth

















The Principal Investigator (PI) is the sponsor’s 
partner in planning the most time-critical element of 
a clinical trial: the patient recruitment period 
It is the PI’s responsibility to provide realistic and 
reliable information on the number of subjects he 
can contribute to ensure the GCP and to confirm 
availability of adequate resources throughout the 





number of suitable subjects available
number of suitable subjects willing to participate in  
the trial




DIFFICULTIES OF FEASIBILITY IN PRACTICE (1)
Time point of feasibility request in the preparation 
phase of a protocol: PI should have the possibility to 
impact the protocol details
Serial letter to many sites requesting information 
with limited chance of ultimately getting involved
Limited or no resources to generate data instead of 
“wild guesses” of recruitment numbers
Questions impossible to answer correctly (e.g. 
“Which percentage of your suitable subjects would 
be prepared to participate in this trial?”)
22/11/2014
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DIFFICULTIES OF FEASIBILITY IN PRACTICE (2)
Proposed solutions: 
Appoint a dedicated team member to generate/collect 
information on your key population, their typical in-
and exclusion parameters, and history of former trial 
experience
When a new IT system gets implemented in the 
hospital, ensure that searching for diagnosis, in- and 
exclusion criteria is possible
Clarify generally - potentially also with the EC - the 
confidentiality issues involved in reviewing subject 
files from other departments / hospitals
22/11/2014
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TRIAL ORGANISATION AND MANAGEMENT (1)
Today a clinical trial is a “PROJECT” and – like in 
any other organisation – needs properly planned and 
implemented processes, resources, facilities, budget 
and defined responsibilities:
define the team
ensure team members have appropriate
skills (incl. GCP!!!), experience and time
assign roles and responsibilities
agree on and implement processes and
procedures for all study activities – ensure
SOPs, work instructions, forms, logs, 
lists are in place
22/11/2014
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TRIAL ORGANISATION AND MANAGEMENT (2)
ensure awareness, commitment, resources and 
budget for involved other functions/departments
ensure all contractual agreements with sponsor, 
hospital, sub-contractors, etc. are signed, in place
ensure medical liability insurance covers clinical 
trials
ensure adequate facilities for all study activities and 
patient visits
ensure that investigator fee and subject 




TRIAL ORGANISATION AND MANAGEMENT (3)
ensure all technical elements like eCRF, IVRS, 
central lab/ECG/scan reading, etc. are in place
ensure that randomisation, blinding and un-
blinding procedures are in place and understood
ensure appropriate IMP storage, handling, 
accountability process
ensure appropriate sample handling, storage, 
shipment (special attention and conditions for 
biological samples!!!)
ensure that source documents are defined, 
accessible, and properly stored
22/11/2014
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TRIAL ORGANISATION AND MANAGEMENT (4)
ensure that AE assessment and reporting procedures are in 
place and understood
ensure training of all staff members in all trial-related 
activities, tasks and technologies
agree on communication process amongst all stakeholders 
including the sponsor
Last but not least:
ensure that the ethical review of the project has not only 
been performed by the EC but that every staff member
applies ethical considerations in their interaction with 




Typical areas of protocol violations:
wrong diagnosis
in- and exclusion criteria ignored
forbidden pre- or concomitant medication
expired IMP administered, titration mistakes
informed consent process not correct and/or conducted in 
time
mandatory assessments not performed or not at the right 
time
visit windows not respected




How much flexibility is there concerning






Sponsor and investigators need to agree UP FRONT in




How much flexibility is there concerning
visit windows? 
agree UP FRONT with sponsor in the protocol on number 
and time points of visits, on breadth of the windows in 
relation to time point and relevance of the visit 
avoid violations as much as possible but 
subject needs come first!






most critical for judgment on PK, efficacy and safety of the 
IMP – but most difficult to ensure (if IMP is not administered 
by study staff) 
Possible solutions:
compliance measurement tool provided by sponsor
compliance reminder tool provided by sponsor
information of subject about relevance of compliance
follow-up by study staff
22/11/2014
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DRUG HANDLING AND ACCOUNTABILITY (1)
Definition of IMP:
Active substance or placebo being tested or used as 
a reference in a clinical trial, including products 
already with a marketing authorisation but:  
used / assembled (formulated or packaged) in a way 
different from the authorised form, or
when used for an unauthorised indication, or




DRUG HANDLING AND ACCOUNTABILITY (2)
Definition of non-IMP:
rescue medication





DRUG HANDLING AND ACCOUNTABILITY (3)
Good Manufacturing Practice (GMP):
is an established quality standard for IMP production 
and control
is regulated by Directives 2003/94/EC, Directive 
2004/27/EC, Directive 2001/20/EC and Annex 13 of the 
Notice to Applicants “Rules Governing Medicinal 
Products in the EU”, Volume 4 
requires specially authorised facilities
requires a “Qualified Person”
(Annex 16 of the “Rules Governing Medicinal Products in the EU”, Volume 4)
22/11/2014
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additional label information, e.g. subject 
initials, date of preparation, expiry date
can be performed by site staff
22/11/2014
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DRUG HANDLING AND ACCOUNTABILITY (5)
IMP storage
site must have the required storing 
facilities (e.g. temperature controlled) 
site must have system to monitor and 
document the storage conditions
access to IMP storage must be controlled 
and documented





DRUG HANDLING AND ACCOUNTABILITY (6)
“Accountability” versus “Reconciliation”
Accountability:
The collection of information and 
documentation that is associated with 
the disposition of IMP related to the 
site, i.e. the quantity received from the 
sponsor, dispensed and returned 
versus protocol requirements and 
subjects usage
Reconciliation: 





not only possible but highly likely
has to be foreseen from the beginning




documentation compilation (CV, signature log, training 
record, etc.)









the act of intentionally falsifying research results, e.g. "Fudging", 
"massaging", or outright manufacture of experimental data. 
Falsification
the act of producing something that lacks authenticity with the intent
to commit fraud or deception, e.g. changing inclusion/exclusion 






the use or close imitation of the language and thoughts of 
another author and the representation of them as one's 
own original work.
Theft












FRAUD/ MISCONDUCT (4) – Warning Signs
Accessibility of Investigator and his staff
Faster recruitment/fewer withdrawals
Differences from other sites
Odd working days/hours
Quality of ‘essential’ documents – documents missing, cannot be found, 
may ‘find’ them later, separate notes made, only one pen used through out, 
very clean notes (no coffee marks!), identical data for different subjects
Return of IMP in immaculate condition, IMP irregularities
No medical licence
No PI expertise
High volume of work/other studies at site
22/11/2014
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FRAUD/ MISCONDUCT (5) – Warning Signs





Evidence that the randomisation code has been broken
Bad feedback from previous studies
CRF completion too good? 
Clean diary cards





Today, the basis for a successful clinical trial is not 
only
“Good Science” and “Good Ethical Standards” 
anymore but it requires an equal level of
“Good Project Management Standards” and  “Good 
Regulatory Practice” 
In other words:








1/ World Medical Association Declaration of Helsinki – 




2/ ICH E6 – Guideline for Good Clinical Practice – 
European Medicines Agency 
 
 
3/ Directive 2001/20/EC of the European Parliament and 
of the Council of 4 April 2001 on the approximation of the 
laws, regulations and administrative provisions of the 
Member States relating to the implementation of good 
clinical practice in the conduct of clinical trials on 
medicinal products for human use 
 
 
4/ News and updates on pharmaceuticals - EudraLex - 
Volume 10 Clinical trials guidelines | Public health, 
European Commission 
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48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996
52nd WMA General Assembly, Edinburgh, Scotland, October 2000 
53rd WMA General Assembly, Washington DC, USA, October 2002 (Note of
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Preamble
1.         The World Medical Association (WMA) has developed the Declaration of Helsinki
as a statement of ethical principles for medical research involving human subjects,
including research on identifiable human material and data.
            The Declaration is intended to be read as a whole and each of its constituent
paragraphs should be applied with consideration of all other relevant paragraphs.
2.         Consistent with the mandate of the WMA, the Declaration is addressed
primarily to physicians. The WMA encourages others who are involved in medical
research involving human subjects to adopt these principles. 
General Principles
3.         The Declaration of Geneva of the WMA binds the physician with the words,
“The health of my patient will be my first consideration,” and the International Code of
WMA Declaration of Helsinki - Ethical
Principles for Medical Research Involving
Human Subjects
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“The health of my patient will be my first consideration,” and the International Code of
Medical Ethics declares that, “A physician shall act in the patient's best interest when
providing medical care.”
4.         It is the duty of the physician to promote and safeguard the health, well-being
and rights of patients, including those who are involved in medical research. The
physician's knowledge and conscience are dedicated to the fulfilment of this duty.
5.         Medical progress is based on research that ultimately must include studies
involving human subjects.
6.         The primary purpose of medical research involving human subjects is to
understand the causes, development and effects of diseases and improve preventive,
diagnostic and therapeutic interventions (methods, procedures and treatments). Even
the best proven interventions must be evaluated continually through research for their
safety, effectiveness, efficiency, accessibility and quality.
7.         Medical research is subject to ethical standards that promote and ensure
respect for all human subjects and protect their health and rights.
8.         While the primary purpose of medical research is to generate new knowledge,
this goal can never take precedence over the rights and interests of individual
research subjects.
9.         It is the duty of physicians who are involved in medical research to protect the
life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of
personal information of research subjects. The responsibility for the protection of
research subjects must always rest with the physician or other health care
professionals and never with the research subjects, even though they have given
consent.
10.       Physicians must consider the ethical, legal and regulatory norms and
standards for research involving human subjects in their own countries as well as
applicable international norms and standards. No national or international ethical, legal
or regulatory requirement should reduce or eliminate any of the protections for
research subjects set forth in this Declaration.
11.       Medical research should be conducted in a manner that minimises possible
harm to the environment.
12.       Medical research involving human subjects must be conducted only by
individuals with the appropriate ethics and scientific education, training and 2/8
individuals with the appropriate ethics and scientific education, training and
qualifications. Research on patients or healthy volunteers requires the supervision of a
competent and appropriately qualified physician or other health care professional.
13.       Groups that are underrepresented in medical research should be provided
appropriate access to participation in research.
14.       Physicians who combine medical research with medical care should involve
their patients in research only to the extent that this is justified by its potential
preventive, diagnostic or therapeutic value and if the physician has good reason to
believe that participation in the research study will not adversely affect the health of
the patients who serve as research subjects.
15.       Appropriate compensation and treatment for subjects who are harmed as a
result of participating in research must be ensured.
Risks, Burdens and Benefits 
16.       In medical practice and in medical research, most interventions involve risks
and burdens.
           Medical research involving human subjects may only be conducted if the
importance of the objective outweighs the risks and burdens to the research subjects.
17.       All medical research involving human subjects must be preceded by careful
assessment of predictable risks and burdens to the individuals and groups involved in
the research in comparison with foreseeable benefits to them and to other individuals
or groups affected by the condition under investigation.
           Measures to minimise the risks must be implemented. The risks must be
continuously monitored, assessed and documented by the researcher. 
18.       Physicians may not be involved in a research study involving human subjects
unless they are confident that the risks have been adequately assessed and can be
satisfactorily managed.
           When the risks are found to outweigh the potential benefits or when there is
conclusive proof of definitive outcomes, physicians must assess whether to continue,
modify or immediately stop the study.           
Vulnerable Groups and Individuals
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19.       Some groups and individuals are particularly vulnerable and may have an
increased likelihood of being wronged or of incurring additional harm.
           All vulnerable groups and individuals should receive specifically considered
protection.
20.       Medical research with a vulnerable group is only justified if the research is
responsive to the health needs or priorities of this group and the research cannot be
carried out in a non-vulnerable group. In addition, this group should stand to benefit
from the knowledge, practices or interventions that result from the research.
Scientific Requirements and Research Protocols 
21.       Medical research involving human subjects must conform to generally
accepted scientific principles, be based on a thorough knowledge of the scientific
literature, other relevant sources of information, and adequate laboratory and, as
appropriate, animal experimentation. The welfare of animals used for research must
be respected.
22.       The design and performance of each research study involving human subjects
must be clearly described and justified in a research protocol.
           The protocol should contain a statement of the ethical considerations involved
and should indicate how the principles in this Declaration have been addressed. The
protocol should include information regarding funding, sponsors, institutional
affiliations, potential conflicts of interest, incentives for subjects and information
regarding provisions for treating and/or compensating subjects who are harmed as a
consequence of participation in the research study.
           In clinical trials, the protocol must also describe appropriate arrangements for
post-trial provisions.
Research Ethics Committees
23.       The research protocol must be submitted for consideration, comment,
guidance and approval to the concerned research ethics committee before the study
begins. This committee must be transparent in its functioning, must be independent of
the researcher, the sponsor and any other undue influence and must be duly qualified.
It must take into consideration the laws and regulations of the country or countries in
which the research is to be performed as well as applicable international norms and
standards but these must not be allowed to reduce or eliminate any of the protections4/8
standards but these must not be allowed to reduce or eliminate any of the protections
for research subjects set forth in this Declaration. 
           The committee must have the right to monitor ongoing studies. The researcher
must provide monitoring information to the committee, especially information about
any serious adverse events. No amendment to the protocol may be made without
consideration and approval by the committee. After the end of the study, the
researchers must submit a final report to the committee containing a summary of the
study’s findings and conclusions. 
Privacy and Confidentiality 
24.       Every precaution must be taken to protect the privacy of research subjects
and the confidentiality of their personal information.
Informed Consent 
25.       Participation by individuals capable of giving informed consent as subjects in
medical research must be voluntary. Although it may be appropriate to consult family
members or community leaders, no individual capable of giving informed consent may
be enrolled in a research study unless he or she freely agrees.
26.       In medical research involving human subjects capable of giving informed
consent, each potential subject must be adequately informed of the aims, methods,
sources of funding, any possible conflicts of interest, institutional affiliations of the
researcher, the anticipated benefits and potential risks of the study and the
discomfort it may entail, post-study provisions and any other relevant aspects of the
study. The potential subject must be informed of the right to refuse to participate in
the study or to withdraw consent to participate at any time without reprisal. Special
attention should be given to the specific information needs of individual potential
subjects as well as to the methods used to deliver the information.
           After ensuring that the potential subject has understood the information, the
physician or another appropriately qualified individual must then seek the potential
subject’s freely-given informed consent, preferably in writing. If the consent cannot be
expressed in writing, the non-written consent must be formally documented and
witnessed.      
           All medical research subjects should be given the option of being informed
about the general outcome and results of the study.
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27.       When seeking informed consent for participation in a research study the
physician must be particularly cautious if the potential subject is in a dependent
relationship with the physician or may consent under duress. In such situations the
informed consent must be sought by an appropriately qualified individual who is
completely independent of this relationship.
28.       For a potential research subject who is incapable of giving informed consent,
the physician must seek informed consent from the legally authorised representative.
These individuals must not be included in a research study that has no likelihood of
benefit for them unless it is intended to promote the health of the group represented
by the potential subject, the research cannot instead be performed with persons
capable of providing informed consent, and the research entails only minimal risk and
minimal burden.
29.       When a potential research subject who is deemed incapable of giving informed
consent is able to give assent to decisions about participation in research, the
physician must seek that assent in addition to the consent of the legally authorised
representative. The potential subject’s dissent should be respected.
30.       Research involving subjects who are physically or mentally incapable of giving
consent, for example, unconscious patients, may be done only if the physical or
mental condition that prevents giving informed consent is a necessary characteristic
of the research  group. In such circumstances the physician must seek informed
consent from the legally authorised representative. If no such representative is
available and if the research cannot be delayed, the study may proceed without
informed consent provided that the specific reasons for involving subjects with a
condition that renders them unable to give informed consent have been stated in the
research protocol and the study has been approved by a research ethics committee.
Consent to remain in the research must be obtained as soon as possible from the
subject or a legally authorised representative.
31.       The physician must fully inform the patient which aspects of their care are
related to the research. The refusal of a patient to participate in a study or the
patient’s decision to withdraw from the study must never adversely affect the patient-
physician relationship.
32.       For medical research using identifiable human material or data, such as
research on material or data contained in biobanks or similar repositories, physicians
must seek informed consent for its collection, storage and/or reuse. There may be
exceptional situations where consent would be impossible or impracticable to obtain
for such research. In such situations the research may be done only after 6/8
for such research. In such situations the research may be done only after
consideration and approval of a research ethics committee.
Use of Placebo
33.       The benefits, risks, burdens and effectiveness of a new intervention must be
tested against those of the best proven intervention(s), except in the following
circumstances:
           Where no proven intervention exists, the use of placebo, or no intervention, is
acceptable; or
           Where for compelling and scientifically sound methodological reasons the use
of any intervention less effective than the best proven one, the use of placebo, or no
intervention is necessary to determine the efficacy or safety of an intervention 
           and the patients who receive any intervention less effective than the best
proven one, placebo, or no intervention will not be subject to additional risks of serious
or irreversible harm as a result of not receiving the best proven intervention. 
           Extreme care must be taken to avoid abuse of this option.
Post-Trial Provisions
34.       In advance of a clinical trial, sponsors, researchers and host country
governments should make provisions for post-trial access for all participants who still
need an intervention identified as beneficial in the trial. This information must also be
disclosed to participants during the informed consent process.
Research Registration and Publication and Dissemination of
Results
35.       Every research study involving human subjects must be registered in a publicly
accessible database before recruitment of the first subject.
36.       Researchers, authors, sponsors, editors and publishers all have ethical
obligations with regard to the publication and dissemination of the results of research.
Researchers have a duty to make publicly available the results of their research on
human subjects and are accountable for the completeness and accuracy of their
reports. All parties should adhere to accepted guidelines for ethical reporting. Negative
and inconclusive as well as positive results must be published or otherwise made
publicly available. Sources of funding, institutional affiliations and conflicts of interest 7/8
publicly available. Sources of funding, institutional affiliations and conflicts of interest
must be declared in the publication. Reports of research not in accordance with the
principles of this Declaration should not be accepted for publication.
Unproven Interventions in Clinical Practice
37.       In the treatment of an individual patient, where proven interventions do not
exist or other known interventions have been ineffective, the physician, after seeking
expert advice, with informed consent from the patient or a legally authorised
representative, may use an unproven intervention if in the physician's judgement it
offers hope of saving life, re-establishing health or alleviating suffering. This
intervention should subsequently be made the object of research, designed to
evaluate its safety and efficacy. In all cases, new information must be recorded and,
where appropriate, made publicly available.
Disclaimer: © 2013 World Medical Association, Inc. All Rights Reserved. All intellectual
property rights in the Declaration of Helsinki are vested in the World Medical
Association.  Previous permissions granted to publish or reproduce otherwise WMA
policy don’t apply to this version of the Declaration of Helsinki until January 1st, 2014.
For further questions, please contact the WMA secretariat at secretariat@wma.net.
© World Medical Association, Inc. - All Rights reserved.
© Asociación médica mundial - Todos los derechos reservados.
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Good Clinical Practice (GCP) is an international ethical and scientific quality standard for 
designing, conducting, recording and reporting trials that involve the participation of human 
subjects. Compliance with this standard provides public assurance that the rights, safety and 
well-being of trial subjects are protected, consistent with the principles that have their origin in 
the Declaration of Helsinki, and that the clinical trial data are credible. 
The objective of this ICH GCP Guideline is to provide a unified standard for the European 
Union (EU), Japan and the United States to facilitate the mutual acceptance of clinical data by 
the regulatory authorities in these jurisdictions. 
The guideline was developed with consideration of the current good clinical practices of the 
European Union, Japan, and the United States, as well as those of Australia, Canada, the Nordic 
countries and the World Health Organization (WHO). 
This guideline should be followed when generating clinical trial data that are intended to be 
submitted to regulatory authorities. 
The principles established in this guideline may also be applied to other clinical investigations 




1.1 Adverse Drug Reaction (ADR) 
In the pre-approval clinical experience with a new medicinal product or its new usages, 
particularly as the therapeutic dose(s) may not be established: all noxious and unintended 
responses to a medicinal product related to any dose should be considered adverse drug 
reactions. The phrase responses to a medicinal product means that a causal relationship between 
a medicinal product and an adverse event is at least a reasonable possibility, i.e. the relationship 
cannot be ruled out. 
Regarding marketed medicinal products: a response to a drug which is noxious and unintended 
and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of 
diseases or for modification of physiological function (see the ICH Guideline for Clinical Safety 
Data Management: Definitions and Standards for Expedited Reporting). 
 
1.2 Adverse Event (AE) 
Any untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical product and which does not necessarily have a causal relationship with this 
treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product (see the ICH Guideline for Clinical Safety Data Management: 
Definitions and Standards for Expedited Reporting). 
 
1.3 Amendment (to the protocol) 
See Protocol Amendment. 
 
1.4 Applicable Regulatory Requirement(s) 
Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products. 
 
1.5 Approval (in relation to Institutional Review Boards) 
The affirmative decision of the IRB that the clinical trial has been reviewed and may be 
conducted at the institution site within the constraints set forth by the IRB, the institution, Good 
Clinical Practice (GCP), and the applicable regulatory requirements. 
 
1.6 Audit 
A systematic and independent examination of trial related activities and documents to determine 
whether the evaluated trial related activities were conducted, and the data were recorded, 
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analyzed and accurately reported according to the protocol, sponsor's standard operating 
procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s). 
 
1.7 Audit Certificate 
A declaration of confirmation by the auditor that an audit has taken place. 
 
1.8 Audit Report 
A written evaluation by the sponsor's auditor of the results of the audit. 
 
1.9 Audit Trail 
Documentation that allows reconstruction of the course of events. 
 
1.10 Blinding/Masking 
A procedure in which one or more parties to the trial are kept unaware of the treatment 
assignment(s). Single-blinding usually refers to the subject(s) being unaware, and double-
blinding usually refers to the subject(s), investigator(s), monitor, and, in some cases, data 
analyst(s) being unaware of the treatment assignment(s). 
 
1.11 Case Report Form (CRF) 
A printed, optical, or electronic document designed to record all of the protocol required 
information to be reported to the sponsor on each trial subject. 
 
1.12 Clinical Trial/Study 
Any investigation in human subjects intended to discover or verify the clinical, pharmacological 
and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any 
adverse reactions to an investigational product(s), and/or to study absorption, distribution, 
metabolism, and excretion of an investigational product(s) with the object of ascertaining its 
safety and/or efficacy. The terms clinical trial and clinical study are synonymous. 
 
1.13 Clinical Trial/Study Report 
A written description of a trial/study of any therapeutic, prophylactic, or diagnostic agent 
conducted in human subjects, in which the clinical and statistical description, presentations, and 
analyses are fully integrated into a single report (see the ICH Guideline for Structure and Content 
of Clinical Study Reports). 
 
1.14 Comparator (Product) 
An investigational or marketed product (i.e., active control), or placebo, used as a reference in a 
clinical trial. 
 
1.15 Compliance (in relation to trials) 
Adherence to all the trial-related requirements, Good Clinical Practice (GCP) requirements, and 
the applicable regulatory requirements. 
 
1.16 Confidentiality 
Prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary 
information or of a subject's identity. 
 
1.17 Contract 
A written, dated, and signed agreement between two or more involved parties that sets out any 
arrangements on delegation and distribution of tasks and obligations and, if appropriate, on 
financial matters. The protocol may serve as the basis of a contract. 
 
1.18 Coordinating Committee 
A committee that a sponsor may organize to coordinate the conduct of a multicentre trial. 
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1.19 Coordinating Investigator 
An investigator assigned the responsibility for the coordination of investigators at different 
centres participating in a multicentre trial. 
 
1.20 Contract Research Organization (CRO) 
A person or an organization (commercial, academic, or other) contracted by the sponsor to 
perform one or more of a sponsor's trial-related duties and functions. 
 
1.21 Direct Access 
Permission to examine, analyze, verify, and reproduce any records and reports that are important 
to evaluation of a clinical trial. Any party (e.g., domestic and foreign regulatory authorities, 
sponsor's monitors and auditors) with direct access should take all reasonable precautions within 
the constraints of the applicable regulatory requirement(s) to maintain the confidentiality of 
subjects' identities and sponsorís proprietary information. 
 
1.22 Documentation 
All records, in any form (including, but not limited to, written, electronic, magnetic, and optical 
records, and scans, x-rays, and electrocardiograms) that describe or record the methods, conduct, 
and/or results of a trial, the factors affecting a trial, and the actions taken. 
 
1.23 Essential Documents 
Documents which individually and collectively permit evaluation of the conduct of a study and 
the quality of the data produced (see 8. Essential Documents for the Conduct of a Clinical Trial).  
 
1.24 Good Clinical Practice (GCP) 
A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and 
reporting of clinical trials that provides assurance that the data and reported results are credible 
and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected. 
 
1.25 Independent Data-Monitoring Committee (IDMC) (Data and Safety Monitoring Board, 
Monitoring Committee, Data Monitoring Committee) 
An independent data-monitoring committee that may be established by the sponsor to assess at 
intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to 
recommend to the sponsor whether to continue, modify, or stop a trial. 
 
1.26 Impartial Witness 
A person, who is independent of the trial, who cannot be unfairly influenced by people involved 
with the trial, who attends the informed consent process if the subject or the subjectís legally 
acceptable representative cannot read, and who reads the informed consent form and any other 
written information supplied to the subject. 
 
1.27 Independent Ethics Committee (IEC) 
An independent body (a review board or a committee, institutional, regional, national, or 
supranational), constituted of medical professionals and non-medical members, whose 
responsibility it is to ensure the protection of the rights, safety and well-being of human subjects 
involved in a trial and to provide public assurance of that protection, by, among other things, 
reviewing and approving / providing favourable opinion on, the trial protocol, the suitability of 
the investigator(s), facilities, and the methods and material to be used in obtaining and 
documenting informed consent of the trial subjects. 
The legal status, composition, function, operations and regulatory requirements pertaining to 
Independent Ethics Committees may differ among countries, but should allow the Independent 
Ethics Committee to act in agreement with GCP as described in this guideline. 
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1.28 Informed Consent 
A process by which a subject voluntarily confirms his or her willingness to participate in a 
particular trial, after having been informed of all aspects of the trial that are relevant to the 
subject's decision to participate. Informed consent is documented by means of a written, signed 
and dated informed consent form. 
 
1.29 Inspection 
The act by a regulatory authority(ies) of conducting an official review of documents, facilities, 
records, and any other resources that are deemed by the authority(ies) to be related to the clinical 
trial and that may be located at the site of the trial, at the sponsor's and/or contract research 
organizationís (CROís) facilities, or at other establishments deemed appropriate by the 
regulatory authority(ies). 
 
1.30 Institution (medical)  
Any public or private entity or agency or medical or dental facility where clinical trials are 
conducted. 
 
1.31 Institutional Review Board (IRB) 
An independent body constituted of medical, scientific, and non-scientific members, whose 
responsibility is to ensure the protection of the rights, safety and well-being of human subjects 
involved in a trial by, among other things, reviewing, approving, and providing continuing 
review of trial protocol and amendments and of the methods and material to be used in obtaining 
and documenting informed consent of the trial subjects. 
 
1.32 Interim Clinical Trial/Study Report 
A report of intermediate results and their evaluation based on analyses performed during the 
course of a trial. 
 
1.33 Investigational Product 
A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a 
clinical trial, including a product with a marketing authorization when used or assembled 
(formulated or packaged) in a way different from the approved form, or when used for an 
unapproved indication, or when used to gain further information about an approved use. 
 
1.34 Investigator 
A person responsible for the conduct of the clinical trial at a trial site. If a trial is conducted by a 
team of individuals at a trial site, the investigator is the responsible leader of the team and may 
be called the principal investigator. See also Subinvestigator.  
 
1.35 Investigator / Institution 
An expression meaning "the investigator and/or institution, where required by the applicable 
regulatory requirements". 
 
1.36 Investigator's Brochure 
A compilation of the clinical and nonclinical data on the investigational product(s) which is 
relevant to the study of the investigational product(s) in human subjects (see 7. Investigatorís 
Brochure).  
 
1.37 Legally Acceptable Representative 
An individual or juridical or other body authorized under applicable law to consent, on behalf of 
a prospective subject, to the subject's participation in the clinical trial. 
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1.38 Monitoring 
The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, 
recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), 
Good Clinical Practice (GCP), and the applicable regulatory requirement(s).  
 
1.39 Monitoring Report 
A written report from the monitor to the sponsor after each site visit and/or other trial-related 
communication according to the sponsorís SOPs. 
 
1.40 Multicentre Trial 
A clinical trial conducted according to a single protocol but at more than one site, and therefore, 
carried out by more than one investigator. 
 
1.41 Nonclinical Study 
Biomedical studies not performed on human subjects. 
 
1.42 Opinion (in relation to Independent Ethics Committee) 
The judgement and/or the advice provided by an Independent Ethics Committee (IEC).  
 
1.43 Original Medical Record 
See Source Documents. 
 
1.44 Protocol 
A document that describes the objective(s), design, methodology, statistical considerations, and 
organization of a trial. The protocol usually also gives the background and rationale for the trial, 
but these could be provided in other protocol referenced documents. Throughout the ICH GCP 
Guideline the term protocol refers to protocol and protocol amendments. 
 
1.45 Protocol Amendment 
A written description of a change(s) to or formal clarification of a protocol. 
 
1.46 Quality Assurance (QA) 
All those planned and systematic actions that are established to ensure that the trial is performed 
and the data are generated, documented (recorded), and reported in compliance with Good 
Clinical Practice (GCP) and the applicable regulatory requirement(s).  
 
1.47 Quality Control (QC) 
The operational techniques and activities undertaken within the quality assurance system to 
verify that the requirements for quality of the trial-related activities have been fulfilled. 
 
1.48 Randomization 
The process of assigning trial subjects to treatment or control groups using an element of chance 
to determine the assignments in order to reduce bias. 
 
1.49 Regulatory Authorities  
Bodies having the power to regulate. In the ICH GCP guideline the expression Regulatory 
Authorities includes the authorities that review submitted clinical data and those that conduct 
inspections (see 1.29). These bodies are sometimes referred to as competent authorities. 
 
1.50 Serious Adverse Event (SAE) or Serious Adverse Drug Reaction (Serious ADR) 
Any untoward medical occurrence that at any dose: 
• results in death, 
• is life-threatening, 
• requires inpatient hospitalization or prolongation of existing hospitalization, 
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• results in persistent or significant disability/incapacity,  
or 
• is a congenital anomaly/birth defect  
(see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for 
Expedited Reporting). 
 
1.51 Source Data 
All information in original records and certified copies of original records of clinical findings, 
observations, or other activities in a clinical trial necessary for the reconstruction and evaluation 
of the trial. Source data are contained in source documents (original records or certified copies). 
 
1.52 Source Documents 
Original documents, data, and records (e.g., hospital records, clinical and office charts, 
laboratory notes, memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing 
records, recorded data from automated instruments, copies or transcriptions certified after 
verification as being accurate copies, microfiches, photographic negatives, microfilm or 
magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories and at 
medico-technical departments involved in the clinical trial). 
 
1.53 Sponsor 
An individual, company, institution, or organization which takes responsibility for the initiation, 
management, and/or financing of a clinical trial. 
 
1.54 Sponsor-Investigator 
An individual who both initiates and conducts, alone or with others, a clinical trial, and under 
whose immediate direction the investigational product is administered to, dispensed to, or used 
by a subject. The term does not include any person other than an individual (e.g., it does not 
include a corporation or an agency). The obligations of a sponsor-investigator include both those 
of a sponsor and those of an investigator. 
 
1.55 Standard Operating Procedures (SOPs) 
Detailed, written instructions to achieve uniformity of the performance of a specific function. 
 
1.56 Subinvestigator 
Any individual member of the clinical trial team designated and supervised by the investigator at 
a trial site to perform critical trial-related procedures and/or to make important trial-related 
decisions (e.g., associates, residents, research fellows). See also Investigator. 
 
1.57 Subject/Trial Subject 
An individual who participates in a clinical trial, either as a recipient of the investigational 
product(s) or as a control. 
 
1.58 Subject Identification Code 
A unique identifier assigned by the investigator to each trial subject to protect the subject's 
identity and used in lieu of the subject's name when the investigator reports adverse events 
and/or other trial related data. 
 
1.59 Trial Site 
The location(s) where trial-related activities are actually conducted. 
 
1.60 Unexpected Adverse Drug Reaction 
An adverse reaction, the nature or severity of which is not consistent with the applicable product 
information (e.g., Investigator's Brochure for an unapproved investigational product or package 
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insert/summary of product characteristics for an approved product) (see the ICH Guideline for 
Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).  
 
1.61 Vulnerable Subjects 
Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by the 
expectation, whether justified or not, of benefits associated with participation, or of a retaliatory 
response from senior members of a hierarchy in case of refusal to participate. Examples are 
members of a group with a hierarchical structure, such as medical, pharmacy, dental, and nursing 
students, subordinate hospital and laboratory personnel, employees of the pharmaceutical 
industry, members of the armed forces, and persons kept in detention. Other vulnerable subjects 
include patients with incurable diseases, persons in nursing homes, unemployed or impoverished 
persons, patients in emergency situations, ethnic minority groups, homeless persons, nomads, 
refugees, minors, and those incapable of giving consent. 
 
1.62 Well-being (of the trial subjects) 
The physical and mental integrity of the subjects participating in a clinical trial. 
 
2. THE PRINCIPLES OF ICH GCP 
 
2.1 Clinical trials should be conducted in accordance with the ethical principles that have 
their origin in the Declaration of Helsinki, and that are consistent with GCP and the 
applicable regulatory requirement(s). 
 
2.2 Before a trial is initiated, foreseeable risks and inconveniences should be weighed against 
the anticipated benefit for the individual trial subject and society. A trial should be 
initiated and continued only if the anticipated benefits justify the risks. 
 
2.3 The rights, safety, and well-being of the trial subjects are the most important 
considerations and should prevail over interests of science and society. 
 
2.4 The available nonclinical and clinical information on an investigational product should be 
adequate to support the proposed clinical trial. 
 
2.5 Clinical trials should be scientifically sound, and described in a clear, detailed protocol. 
 
2.6 A trial should be conducted in compliance with the protocol that has received prior 
institutional review board (IRB)/independent ethics committee (IEC) approval/favourable 
opinion.  
 
2.7 The medical care given to, and medical decisions made on behalf of, subjects should 
always be the responsibility of a qualified physician or, when appropriate, of a qualified 
dentist. 
 
2.8 Each individual involved in conducting a trial should be qualified by education, training, 
and experience to perform his or her respective task(s). 
 
2.9 Freely given informed consent should be obtained from every subject prior to clinical trial 
participation. 
 
2.10 All clinical trial information should be recorded, handled, and stored in a way that allows 
its accurate reporting, interpretation and verification. 
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2.11 The confidentiality of records that could identify subjects should be protected, respecting 
the privacy and confidentiality rules in accordance with the applicable regulatory 
requirement(s). 
 
2.12 Investigational products should be manufactured, handled, and stored in accordance with 
applicable good manufacturing practice (GMP). They should be used in accordance with 
the approved protocol. 
 
2.13 Systems with procedures that assure the quality of every aspect of the trial should be 
implemented. 
 





3.1.1 An IRB/IEC should safeguard the rights, safety, and well-being of all trial subjects. 
Special attention should be paid to trials that may include vulnerable subjects. 
 
3.1.2 The IRB/IEC should obtain the following documents: 
 trial protocol(s)/amendment(s), written informed consent form(s) and consent form 
updates that the investigator proposes for use in the trial, subject recruitment procedures 
(e.g. advertisements), written information to be provided to subjects, Investigator's 
Brochure (IB), available safety information, information about payments and 
compensation available to subjects, the investigatorís current curriculum vitae and/or 
other documentation evidencing qualifications, and any other documents that the IRB/IEC 
may need to fulfil its responsibilities. 
 The IRB/IEC should review a proposed clinical trial within a reasonable time and 
document its views in writing, clearly identifying the trial, the documents reviewed and 
the dates for the following:  
• approval/favourable opinion; 
• modifications required prior to its approval/favourable opinion; 
• disapproval / negative opinion; and 
• termination/suspension of any prior approval/favourable opinion.  
 
3.1.3 The IRB/IEC should consider the qualifications of the investigator for the proposed trial, 
as documented by a current curriculum vitae and/or by any other relevant documentation 
the IRB/IEC requests. 
 
3.1.4 The IRB/IEC should conduct continuing review of each ongoing trial at intervals 
appropriate to the degree of risk to human subjects, but at least once per year. 
 
3.1.5 The IRB/IEC may request more information than is outlined in paragraph 4.8.10 be given 
to subjects when, in the judgement of the IRB/IEC, the additional information would add 
meaningfully to the protection of the rights, safety and/or well-being of the subjects.  
 
3.1.6 When a non-therapeutic trial is to be carried out with the consent of the subjectís legally 
acceptable representative (see 4.8.12, 4.8.14), the IRB/IEC should determine that the 
proposed protocol and/or other document(s) adequately addresses relevant ethical 
concerns and meets applicable regulatory requirements for such trials. 
 
3.1.7 Where the protocol indicates that prior consent of the trial subject or the subjectís legally 
acceptable representative is not possible (see 4.8.15), the IRB/IEC should determine that 
the proposed protocol and/or other document(s) adequately addresses relevant ethical 
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concerns and meets applicable regulatory requirements for such trials (i.e. in emergency 
situations). 
 
3.1.8 The IRB/IEC should review both the amount and method of payment to subjects to assure 
that neither presents problems of coercion or undue influence on the trial subjects. 
Payments to a subject should be prorated and not wholly contingent on completion of the 
trial by the subject. 
 
3.1.9 The IRB/IEC should ensure that information regarding payment to subjects, including the 
methods, amounts, and schedule of payment to trial subjects, is set forth in the written 
informed consent form and any other written information to be provided to subjects. The 
way payment will be prorated should be specified. 
 
3.2 Composition, Functions and Operations 
 
3.2.1 The IRB/IEC should consist of a reasonable number of members, who collectively have 
the qualifications and experience to review and evaluate the science, medical aspects, and 
ethics of the proposed trial. It is recommended that the IRB/IEC should include: 
a) At least five members. 
b) At least one member whose primary area of interest is in a nonscientific area. 
c) At least one member who is independent of the institution/trial site. 
Only those IRB/IEC members who are independent of the investigator and the sponsor of 
the trial should vote/provide opinion on a trial-related matter. 
A list of IRB/IEC members and their qualifications should be maintained. 
 
3.2.2 The IRB/IEC should perform its functions according to written operating procedures, 
should maintain written records of its activities and minutes of its meetings, and should 
comply with GCP and with the applicable regulatory requirement(s). 
 
3.2.3 An IRB/IEC should make its decisions at announced meetings at which at least a quorum, 
as stipulated in its written operating procedures, is present. 
 
3.2.4 Only members who participate in the IRB/IEC review and discussion should vote/provide 
their opinion and/or advise.  
 
3.2.5 The investigator may provide information on any aspect of the trial, but should not 
participate in the deliberations of the IRB/IEC or in the vote/opinion of the IRB/IEC.  
 
3.2.6 An IRB/IEC may invite nonmembers with expertise in special areas for assistance. 
 
3.3 Procedures 
The IRB/IEC should establish, document in writing, and follow its procedures, which should 
include: 
 
3.3.1  Determining its composition (names and qualifications of the members) and the authority 
under which it is established. 
 
3.3.2 Scheduling, notifying its members of, and conducting its meetings. 
 
3.3.3 Conducting initial and continuing review of trials. 
 
3.3.4 Determining the frequency of continuing review, as appropriate. 
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3.3.5 Providing, according to the applicable regulatory requirements, expedited review and 
approval/favourable opinion of minor change(s) in ongoing trials that have the 
approval/favourable opinion of the IRB/IEC. 
 
3.3.6 Specifying that no subject should be admitted to a trial before the IRB/IEC issues its 
written approval/favourable opinion of the trial. 
 
3.3.7 Specifying that no deviations from, or changes of, the protocol should be initiated without 
prior written IRB/IEC approval/favourable opinion of an appropriate amendment, except 
when necessary to eliminate immediate hazards to the subjects or when the change(s) 
involves only logistical or administrative aspects of the trial (e.g., change of monitor(s), 
telephone number(s)) (see 4.5.2). 
 
3.3.8 Specifying that the investigator should promptly report to the IRB/IEC: 
a) Deviations from, or changes of, the protocol to eliminate immediate hazards to the 
trial subjects (see 3.3.7, 4.5.2, 4.5.4). 
b) Changes increasing the risk to subjects and/or affecting significantly the conduct of 
the trial (see 4.10.2).  
c) All adverse drug reactions (ADRs) that are both serious and unexpected.  
d) New information that may affect adversely the safety of the subjects or the conduct 
of the trial. 
 
3.3.9 Ensuring that the IRB/IEC promptly notify in writing the investigator/institution 
concerning: 
a) Its trial-related decisions/opinions. 
b) The reasons for its decisions/opinions. 
c) Procedures for appeal of its decisions/opinions. 
 
3.4 Records 
The IRB/IEC should retain all relevant records (e.g., written procedures, membership lists, lists 
of occupations/affiliations of members, submitted documents, minutes of meetings, and 
correspondence) for a period of at least 3 years after completion of the trial and make them 
available upon request from the regulatory authority(ies). 
The IRB/IEC may be asked by investigators, sponsors or regulatory authorities to provide its 
written procedures and membership lists. 
 
4. INVESTIGATOR  
 
4.1 Investigator's Qualifications and Agreements 
 
4.1.1 The investigator(s) should be qualified by education, training, and experience to assume 
responsibility for the proper conduct of the trial, should meet all the qualifications 
specified by the applicable regulatory requirement(s), and should provide evidence of 
such qualifications through up-to-date curriculum vitae and/or other relevant 
documentation requested by the sponsor, the IRB/IEC, and/or the regulatory 
authority(ies). 
 
4.1.2 The investigator should be thoroughly familiar with the appropriate use of the 
investigational product(s), as described in the protocol, in the current Investigator's 
Brochure, in the product information and in other information sources provided by the 
sponsor. 
 
4.1.3 The investigator should be aware of, and should comply with, GCP and the applicable 
regulatory requirements. 
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4.1.4 The investigator/institution should permit monitoring and auditing by the sponsor, and 
inspection by the appropriate regulatory authority(ies). 
 
4.1.5 The investigator should maintain a list of appropriately qualified persons to whom the 
investigator has delegated significant trial-related duties. 
 
4.2 Adequate Resources 
 
4.2.1 The investigator should be able to demonstrate (e.g., based on retrospective data) a 
potential for recruiting the required number of suitable subjects within the agreed 
recruitment period. 
 
4.2.2 The investigator should have sufficient time to properly conduct and complete the trial 
within the agreed trial period. 
 
4.2.3 The investigator should have available an adequate number of qualified staff and 
adequate facilities for the foreseen duration of the trial to conduct the trial properly and 
safely. 
 
4.2.4 The investigator should ensure that all persons assisting with the trial are adequately 
informed about the protocol, the investigational product(s), and their trial-related duties 
and functions. 
 
4.3 Medical Care of Trial Subjects 
 
4.3.1 A qualified physician (or dentist, when appropriate), who is an investigator or a sub-
investigator for the trial, should be responsible for all trial-related medical (or dental) 
decisions.  
 
4.3.2 During and following a subject's participation in a trial, the investigator/institution should 
ensure that adequate medical care is provided to a subject for any adverse events, 
including clinically significant laboratory values, related to the trial. The 
investigator/institution should inform a subject when medical care is needed for 
intercurrent illness(es) of which the investigator becomes aware.  
 
4.3.3 It is recommended that the investigator inform the subject's primary physician about the 
subject's participation in the trial if the subject has a primary physician and if the subject 
agrees to the primary physician being informed. 
 
4.3.4 Although a subject is not obliged to give his/her reason(s) for withdrawing prematurely 
from a trial, the investigator should make a reasonable effort to ascertain the reason(s), 
while fully respecting the subject's rights. 
 
4.4 Communication with IRB/IEC 
 
4.4.1 Before initiating a trial, the investigator/institution should have written and dated 
approval/favourable opinion from the IRB/IEC for the trial protocol, written informed 
consent form, consent form updates, subject recruitment procedures (e.g., 
advertisements), and any other written information to be provided to subjects.  
 
4.4.2 As part of the investigator's/institutionís written application to the IRB/IEC, the 
investigator/institution should provide the IRB/IEC with a current copy of the 
Investigator's Brochure. If the Investigator's Brochure is updated during the trial, the 
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investigator/institution should supply a copy of the updated Investigatorís Brochure to the 
IRB/IEC. 
 
4.4.3 During the trial the investigator/institution should provide to the IRB/IEC all documents 
subject to review.  
 
4.5 Compliance with Protocol 
 
4.5.1 The investigator/institution should conduct the trial in compliance with the protocol 
agreed to by the sponsor and, if required, by the regulatory authority(ies) and which was 
given approval/favourable opinion by the IRB/IEC. The investigator/institution and the 
sponsor should sign the protocol, or an alternative contract, to confirm agreement. 
 
4.5.2 The investigator should not implement any deviation from, or changes of the protocol 
without agreement by the sponsor and prior review and documented approval/favourable 
opinion from the IRB/IEC of an amendment, except where necessary to eliminate an 
immediate hazard(s) to trial subjects, or when the change(s) involves only logistical or 
administrative aspects of the trial (e.g., change in monitor(s), change of telephone 
number(s)). 
 
4.5.3 The investigator, or person designated by the investigator, should document and explain 
any deviation from the approved protocol. 
 
4.5.4 The investigator may implement a deviation from, or a change of, the protocol to 
eliminate an immediate hazard(s) to trial subjects without prior IRB/IEC 
approval/favourable opinion. As soon as possible, the implemented deviation or change, 
the reasons for it, and, if appropriate, the proposed protocol amendment(s) should be 
submitted: 
a) to the IRB/IEC for review and approval/favourable opinion, 
b) to the sponsor for agreement and, if required,  
c) to the regulatory authority(ies). 
 
4.6 Investigational Product(s) 
 
4.6.1 Responsibility for investigational product(s) accountability at the trial site(s) rests with 
the investigator/institution. 
 
4.6.2 Where allowed/required, the investigator/institution may/should assign some or all of the 
investigator's/institutionís duties for investigational product(s) accountability at the trial 
site(s) to an appropriate pharmacist or another appropriate individual who is under the 
supervision of the investigator/institution.. 
 
4.6.3 The investigator/institution and/or a pharmacist or other appropriate individual, who is 
designated by the investigator/institution, should maintain records of the product's 
delivery to the trial site, the inventory at the site, the use by each subject, and the return to 
the sponsor or alternative disposition of unused product(s). These records should include 
dates, quantities, batch/serial numbers, expiration dates (if applicable), and the unique 
code numbers assigned to the investigational product(s) and trial subjects. Investigators 
should maintain records that document adequately that the subjects were provided the 
doses specified by the protocol and reconcile all investigational product(s) received from 
the sponsor. 
 
4.6.4 The investigational product(s) should be stored as specified by the sponsor (see 5.13.2 
and 5.14.3) and in accordance with applicable regulatory requirement(s). 
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4.6.5 The investigator should ensure that the investigational product(s) are used only in 
accordance with the approved protocol. 
 
4.6.6 The investigator, or a person designated by the investigator/institution, should explain the 
correct use of the investigational product(s) to each subject and should check, at intervals 
appropriate for the trial, that each subject is following the instructions properly. 
 
4.7 Randomization Procedures and Unblinding 
The investigator should follow the trial's randomization procedures, if any, and should ensure 
that the code is broken only in accordance with the protocol. If the trial is blinded, the 
investigator should promptly document and explain to the sponsor any premature unblinding 
(e.g., accidental unblinding, unblinding due to a serious adverse event) of the investigational 
product(s). 
 
4.8 Informed Consent of Trial Subjects 
 
4.8.1 In obtaining and documenting informed consent, the investigator should comply with the 
applicable regulatory requirement(s), and should adhere to GCP and to the ethical 
principles that have their origin in the Declaration of Helsinki. Prior to the beginning of 
the trial, the investigator should have the IRB/IEC's written approval/favourable opinion 
of the written informed consent form and any other written information to be provided to 
subjects. 
 
4.8.2 The written informed consent form and any other written information to be provided to 
subjects should be revised whenever important new information becomes available that 
may be relevant to the subjectís consent. Any revised written informed consent form, and 
written information should receive the IRB/IEC's approval/favourable opinion in advance 
of use. The subject or the subjectís legally acceptable representative should be informed 
in a timely manner if new information becomes available that may be relevant to the 
subjectís willingness to continue participation in the trial. The communication of this 
information should be documented. 
 
4.8.3 Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to 
participate or to continue to participate in a trial. 
 
4.8.4 None of the oral and written information concerning the trial, including the written 
informed consent form, should contain any language that causes the subject or the 
subject's legally acceptable representative to waive or to appear to waive any legal rights, 
or that releases or appears to release the investigator, the institution, the sponsor, or their 
agents from liability for negligence. 
 
4.8.5 The investigator, or a person designated by the investigator, should fully inform the 
subject or, if the subject is unable to provide informed consent, the subject's legally 
acceptable representative, of all pertinent aspects of the trial including the written 
information and the approval/ favourable opinion by the IRB/IEC. 
 
4.8.6 The language used in the oral and written information about the trial, including the 
written informed consent form, should be as non-technical as practical and should be 
understandable to the subject or the subject's legally acceptable representative and the 
impartial witness, where applicable.  
 
4.8.7 Before informed consent may be obtained, the investigator, or a person designated by the 
investigator, should provide the subject or the subject's legally acceptable representative 
ample time and opportunity to inquire about details of the trial and to decide whether or 
© EMEA 2006   17 
121
not to participate in the trial. All questions about the trial should be answered to the 
satisfaction of the subject or the subject's legally acceptable representative. 
 
4.8.8 Prior to a subjectís participation in the trial, the written informed consent form should be 
signed and personally dated by the subject or by the subject's legally acceptable 
representative, and by the person who conducted the informed consent discussion.  
 
4.8.9 If a subject is unable to read or if a legally acceptable representative is unable to read, an 
impartial witness should be present during the entire informed consent discussion. After 
the written informed consent form and any other written information to be provided to 
subjects, is read and explained to the subject or the subjectís legally acceptable 
representative, and after the subject or the subjectís legally acceptable representative has 
orally consented to the subjectís participation in the trial and, if capable of doing so, has 
signed and personally dated the informed consent form, the witness should sign and 
personally date the consent form. By signing the consent form, the witness attests that the 
information in the consent form and any other written information was accurately 
explained to, and apparently understood by, the subject or the subject's legally acceptable 
representative, and that informed consent was freely given by the subject or the subjectís 
legally acceptable representative. 
 
4.8.10 Both the informed consent discussion and the written informed consent form and any 
other written information to be provided to subjects should include explanations of the 
following: 
a) That the trial involves research. 
b) The purpose of the trial. 
c) The trial treatment(s) and the probability for random assignment to each treatment. 
d) The trial procedures to be followed, including all invasive procedures. 
e) The subject's responsibilities. 
f) Those aspects of the trial that are experimental. 
g) The reasonably foreseeable risks or inconveniences to the subject and, when 
applicable, to an embryo, fetus, or nursing infant. 
h) The reasonably expected benefits. When there is no intended clinical benefit to the 
subject, the subject should be made aware of this.  
i) The alternative procedure(s) or course(s) of treatment that may be available to the 
subject, and their important potential benefits and risks.  
j) The compensation and/or treatment available to the subject in the event of trial-
related injury.  
k) The anticipated prorated payment, if any, to the subject for participating in the trial. 
l) The anticipated expenses, if any, to the subject for participating in the trial. 
m) That the subject's participation in the trial is voluntary and that the subject may 
refuse to participate or withdraw from the trial, at any time, without penalty or loss of 
benefits to which the subject is otherwise entitled.  
n) That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) 
will be granted direct access to the subject's original medical records for verification 
of clinical trial procedures and/or data, without violating the confidentiality of the 
subject, to the extent permitted by the applicable laws and regulations and that, by 
signing a written informed consent form, the subject or the subject's legally 
acceptable representative is authorizing such access.  
o) That records identifying the subject will be kept confidential and, to the extent 
permitted by the applicable laws and/or regulations, will not be made publicly 
available. If the results of the trial are published, the subjectís identity will remain 
confidential.  
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p) That the subject or the subject's legally acceptable representative will be informed in 
a timely manner if information becomes available that may be relevant to the 
subject's willingness to continue participation in the trial.  
q) The person(s) to contact for further information regarding the trial and the rights of 
trial subjects, and whom to contact in the event of trial-related injury.  
r) The foreseeable circumstances and/or reasons under which the subject's participation 
in the trial may be terminated.  
s) The expected duration of the subject's participation in the trial. 
t) The approximate number of subjects involved in the trial.  
 
4.8.11 Prior to participation in the trial, the subject or the subject's legally acceptable 
representative should receive a copy of the signed and dated written informed consent 
form and any other written information provided to the subjects. During a subjectís 
participation in the trial, the subject or the subjectís legally acceptable representative 
should receive a copy of the signed and dated consent form updates and a copy of any 
amendments to the written information provided to subjects. 
 
4.8.12 When a clinical trial (therapeutic or non-therapeutic) includes subjects who can only be 
enrolled in the trial with the consent of the subjectís legally acceptable representative 
(e.g., minors, or patients with severe dementia), the subject should be informed about the 
trial to the extent compatible with the subjectís understanding and, if capable, the subject 
should sign and personally date the written informed consent. 
 
4.8.13 Except as described in 4.8.14, a non-therapeutic trial (i.e. a trial in which there is no 
anticipated direct clinical benefit to the subject), should be conducted in subjects who 
personally give consent and who sign and date the written informed consent form. 
 
4.8.14 Non-therapeutic trials may be conducted in subjects with consent of a legally acceptable 
representative provided the following conditions are fulfilled: 
a) The objectives of the trial can not be met by means of a trial in subjects who can give 
informed consent personally. 
b) The foreseeable risks to the subjects are low. 
c) The negative impact on the subjectís well-being is minimized and low. 
d) The trial is not prohibited by law. 
e) The approval/favourable opinion of the IRB/IEC is expressly sought on the inclusion 
of such subjects, and the written approval/ favourable opinion covers this aspect.  
Such trials, unless an exception is justified, should be conducted in patients having a 
disease or condition for which the investigational product is intended. Subjects in these 
trials should be particularly closely monitored and should be withdrawn if they appear to 
be unduly distressed. 
 
4.8.15 In emergency situations, when prior consent of the subject is not possible, the consent of 
the subject's legally acceptable representative, if present, should be requested. When prior 
consent of the subject is not possible, and the subjectís legally acceptable representative is 
not available, enrolment of the subject should require measures described in the protocol 
and/or elsewhere, with documented approval/favourable opinion by the IRB/IEC, to 
protect the rights, safety and well-being of the subject and to ensure compliance with 
applicable regulatory requirements. The subject or the subject's legally acceptable 
representative should be informed about the trial as soon as possible and consent to 
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4.9 Records and Reports 
 
4.9.1 The investigator should ensure the accuracy, completeness, legibility, and timeliness of 
the data reported to the sponsor in the CRFs and in all required reports. 
 
4.9.2 Data reported on the CRF, that are derived from source documents, should be consistent 
with the source documents or the discrepancies should be explained. 
 
4.9.3 Any change or correction to a CRF should be dated, initialed, and explained (if necessary) 
and should not obscure the original entry (i.e. an audit trail should be maintained); this 
applies to both written and electronic changes or corrections (see 5.18.4 (n)). Sponsors 
should provide guidance to investigators and/or the investigators' designated 
representatives on making such corrections. Sponsors should have written procedures to 
assure that changes or corrections in CRFs made by sponsor's designated representatives 
are documented, are necessary, and are endorsed by the investigator. The investigator 
should retain records of the changes and corrections. 
 
4.9.4 The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (see 8.) and as required by the applicable 
regulatory requirement(s). The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents. 
 
4.9.5 Essential documents should be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents 
should be retained for a longer period however if required by the applicable regulatory 
requirements or by an agreement with the sponsor. It is the responsibility of the sponsor 
to inform the investigator/institution as to when these documents no longer need to be 
retained (see 5.5.12). 
 
4.9.6 The financial aspects of the trial should be documented in an agreement between the 
sponsor and the investigator/institution. 
 
4.9.7 Upon request of the monitor, auditor, IRB/IEC, or regulatory authority, the 
investigator/institution should make available for direct access all requested trial-related 
records.  
 
4.10 Progress Reports 
 
4.10.1 The investigator should submit written summaries of the trial status to the IRB/IEC 
annually, or more frequently, if requested by the IRB/IEC. 
 
4.10.2 The investigator should promptly provide written reports to the sponsor, the IRB/IEC (see 
3.3.8) and, where applicable, the institution on any changes significantly affecting the 
conduct of the trial, and/or increasing the risk to subjects. 
 
4.11 Safety Reporting 
 
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except 
for those SAEs that the protocol or other document (e.g., Investigator's Brochure) 
identifies as not needing immediate reporting. The immediate reports should be followed 
promptly by detailed, written reports. The immediate and follow-up reports should 
identify subjects by unique code numbers assigned to the trial subjects rather than by the 
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subjects' names, personal identification numbers, and/or addresses. The investigator 
should also comply with the applicable regulatory requirement(s) related to the reporting 
of unexpected serious adverse drug reactions to the regulatory authority(ies) and the 
IRB/IEC. 
 
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to 
safety evaluations should be reported to the sponsor according to the reporting 
requirements and within the time periods specified by the sponsor in the protocol. 
 
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any 
additional requested information (e.g., autopsy reports and terminal medical reports). 
 
4.12 Premature Termination or Suspension of a Trial 
If the trial is prematurely terminated or suspended for any reason, the investigator/institution 
should promptly inform the trial subjects, should assure appropriate therapy and follow-up for 
the subjects, and, where required by the applicable regulatory requirement(s), should inform the 
regulatory authority(ies). In addition: 
 
4.12.1 If the investigator terminates or suspends a trial without prior agreement of the sponsor, 
the investigator should inform the institution where applicable, and the 
investigator/institution should promptly inform the sponsor and the IRB/IEC, and should 
provide the sponsor and the IRB/IEC a detailed written explanation of the termination or 
suspension. 
 
4.12.2 If the sponsor terminates or suspends a trial (see 5.21), the investigator should promptly 
inform the institution where applicable and the investigator/institution should promptly 
inform the IRB/IEC and provide the IRB/IEC a detailed written explanation of the 
termination or suspension. 
 
4.12.3 If the IRB/IEC terminates or suspends its approval/favourable opinion of a trial (see 3.1.2 
and 3.3.9), the investigator should inform the institution where applicable and the 
investigator/institution should promptly notify the sponsor and provide the sponsor with a 
detailed written explanation of the termination or suspension. 
 
4.13 Final Report(s) by Investigator 
Upon completion of the trial, the investigator, where applicable, should inform the institution; 
the investigator/institution should provide the IRB/IEC with a summary of the trialís outcome, 




5.1 Quality Assurance and Quality Control 
 
5.1.1 The sponsor is responsible for implementing and maintaining quality assurance and 
quality control systems with written SOPs to ensure that trials are conducted and data are 
generated, documented (recorded), and reported in compliance with the protocol, GCP, 
and the applicable regulatory requirement(s). 
 
5.1.2 The sponsor is responsible for securing agreement from all involved parties to ensure 
direct access (see 1.21) to all trial related sites, source data/documents , and reports for 
the purpose of monitoring and auditing by the sponsor, and inspection by domestic and 
foreign regulatory authorities. 
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5.1.3 Quality control should be applied to each stage of data handling to ensure that all data are 
reliable and have been processed correctly. 
 
5.1.4 Agreements, made by the sponsor with the investigator/institution and any other parties 
involved with the clinical trial, should be in writing, as part of the protocol or in a 
separate agreement. 
 
5.2 Contract Research Organization (CRO) 
 
5.2.1 A sponsor may transfer any or all of the sponsor's trial-related duties and functions to a 
CRO, but the ultimate responsibility for the quality and integrity of the trial data always 
resides with the sponsor. The CRO should implement quality assurance and quality 
control. 
 
5.2.2 Any trial-related duty and function that is transferred to and assumed by a CRO should be 
specified in writing. 
 
5.2.3 Any trial-related duties and functions not specifically transferred to and assumed by a 
CRO are retained by the sponsor. 
 
5.2.4 All references to a sponsor in this guideline also apply to a CRO to the extent that a CRO 
has assumed the trial related duties and functions of a sponsor. 
 
5.3 Medical Expertise 
The sponsor should designate appropriately qualified medical personnel who will be readily 
available to advise on trial related medical questions or problems. If necessary, outside 
consultant(s) may be appointed for this purpose.  
 
5.4 Trial Design 
 
5.4.1 The sponsor should utilize qualified individuals (e.g. biostatisticians, clinical 
pharmacologists, and physicians) as appropriate, throughout all stages of the trial process, 
from designing the protocol and CRFs and planning the analyses to analyzing and 
preparing interim and final clinical trial reports. 
 
5.4.2 For further guidance: Clinical Trial Protocol and Protocol Amendment(s) (see 6.), the 
ICH Guideline for Structure and Content of Clinical Study Reports, and other appropriate 
ICH guidance on trial design, protocol and conduct.  
 
5.5 Trial Management, Data Handling, and Record Keeping 
 
5.5.1 The sponsor should utilize appropriately qualified individuals to supervise the overall 
conduct of the trial, to handle the data, to verify the data, to conduct the statistical 
analyses, and to prepare the trial reports. 
 
5.5.2 The sponsor may consider establishing an independent data-monitoring committee 
(IDMC) to assess the progress of a clinical trial, including the safety data and the critical 
efficacy endpoints at intervals, and to recommend to the sponsor whether to continue, 
modify, or stop a trial. The IDMC should have written operating procedures and maintain 
written records of all its meetings. 
 
5.5.3 When using electronic trial data handling and/or remote electronic trial data systems, the 
sponsor should: 
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a) Ensure and document that the electronic data processing system(s) conforms to the 
sponsorís established requirements for completeness, accuracy, reliability, and 
consistent intended performance (i.e. validation). 
b) Maintains SOPs for using these systems. 
c) Ensure that the systems are designed to permit data changes in such a way that the 
data changes are documented and that there is no deletion of entered data (i.e. 
maintain an audit trail, data trail, edit trail). 
d) Maintain a security system that prevents unauthorized access to the data. 
e) Maintain a list of the individuals who are authorized to make data changes (see 4.1.5 
and 4.9.3). 
f) Maintain adequate backup of the data. 
g) Safeguard the blinding, if any (e.g. maintain the blinding during data entry and 
processing). 
 
5.5.4 If data are transformed during processing, it should always be possible to compare the 
original data and observations with the processed data. 
 
5.5.5 The sponsor should use an unambiguous subject identification code (see 1.58) that allows 
identification of all the data reported for each subject. 
 
5.5.6 The sponsor, or other owners of the data, should retain all of the sponsor-specific 
essential documents pertaining to the trial (see 8. Essential Documents for the Conduct of 
a Clinical Trial).  
 
5.5.7 The sponsor should retain all sponsor-specific essential documents in conformance with 
the applicable regulatory requirement(s) of the country(ies) where the product is 
approved, and/or where the sponsor intends to apply for approval(s). 
 
5.5.8 If the sponsor discontinues the clinical development of an investigational product (i.e. for 
any or all indications, routes of administration, or dosage forms), the sponsor should 
maintain all sponsor-specific essential documents for at least 2 years after formal 
discontinuation or in conformance with the applicable regulatory requirement(s).  
 
5.5.9 If the sponsor discontinues the clinical development of an investigational product, the 
sponsor should notify all the trial investigators/institutions and all the regulatory 
authorities. 
 
5.5.10 Any transfer of ownership of the data should be reported to the appropriate authority(ies), 
as required by the applicable regulatory requirement(s). 
 
5.5.11 The sponsor specific essential documents should be retained until at least 2 years after the 
last approval of a marketing application in an ICH region and until there are no pending 
or contemplated marketing applications in an ICH region or at least 2 years have elapsed 
since the formal discontinuation of clinical development of the investigational product. 
These documents should be retained for a longer period however if required by the 
applicable regulatory requirement(s) or if needed by the sponsor. 
 
5.5.12 The sponsor should inform the investigator(s)/institution(s) in writing of the need for 
record retention and should notify the investigator(s)/institution(s) in writing when the 
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5.6 Investigator Selection 
 
5.6.1 The sponsor is responsible for selecting the investigator(s)/institution(s). Each 
investigator should be qualified by training and experience and should have adequate 
resources (see 4.1, 4.2) to properly conduct the trial for which the investigator is selected. 
If organization of a coordinating committee and/or selection of coordinating 
investigator(s) are to be utilized in multicentre trials, their organization and/or selection 
are the sponsor's responsibility. 
 
5.6.2 Before entering an agreement with an investigator/institution to conduct a trial, the 
sponsor should provide the investigator(s)/institution(s) with the protocol and an up-to-
date Investigator's Brochure, and should provide sufficient time for the 
investigator/institution to review the protocol and the information provided. 
 
5.6.3 The sponsor should obtain the investigator's/institution's agreement: 
(a) to conduct the trial in compliance with GCP, with the applicable regulatory 
requirement(s) (see 4.1.3), and with the protocol agreed to by the sponsor and given 
approval/favourable opinion by the IRB/IEC (see 4.5.1);  
(b) to comply with procedures for data recording/reporting; 
(c) to permit monitoring, auditing and inspection (see 4.1.4) and  
(d) to retain the trial related essential documents until the sponsor informs the 
investigator/institution these documents are no longer needed (see 4.9.4 and 5.5.12). 
The sponsor and the investigator/institution should sign the protocol, or an alternative 
document, to confirm this agreement. 
 
5.7 Allocation of Responsibilities 
Prior to initiating a trial, the sponsor should define, establish, and allocate all trial-related duties 
and functions. 
 
5.8 Compensation to Subjects and Investigators 
 
5.8.1 If required by the applicable regulatory requirement(s), the sponsor should provide 
insurance or should indemnify (legal and financial coverage) the investigator/the 
institution against claims arising from the trial, except for claims that arise from 
malpractice and/or negligence. 
 
5.8.2 The sponsor's policies and procedures should address the costs of treatment of trial 
subjects in the event of trial-related injuries in accordance with the applicable regulatory 
requirement(s). 
 
5.8.3 When trial subjects receive compensation, the method and manner of compensation 
should comply with applicable regulatory requirement(s). 
 
5.9 Financing 
The financial aspects of the trial should be documented in an agreement between the sponsor and 
the investigator/institution. 
 
5.10 Notification/Submission to Regulatory Authority(ies) 
Before initiating the clinical trial(s), the sponsor (or the sponsor and the investigator, if required 
by the applicable regulatory requirement(s)) should submit any required application(s) to the 
appropriate authority(ies) for review, acceptance, and/or permission (as required by the 
applicable regulatory requirement(s)) to begin the trial(s). Any notification/submission should be 
dated and contain sufficient information to identify the protocol. 
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5.11 Confirmation of Review by IRB/IEC 
 
5.11.1 The sponsor should obtain from the investigator/institution: 
a) The name and address of the investigator's/institutionís IRB/IEC. 
b) A statement obtained from the IRB/IEC that it is organized and operates according to 
GCP and the applicable laws and regulations.  
c) Documented IRB/IEC approval/favourable opinion and, if requested by the sponsor, 
a current copy of protocol, written informed consent form(s) and any other written 
information to be provided to subjects, subject recruiting procedures, and documents 
related to payments and compensation available to the subjects, and any other 
documents that the IRB/IEC may have requested.  
 
5.11.2 If the IRB/IEC conditions its approval/favourable opinion upon change(s) in any aspect of 
the trial, such as modification(s) of the protocol, written informed consent form and any 
other written information to be provided to subjects, and/or other procedures, the sponsor 
should obtain from the investigator/institution a copy of the modification(s) made and the 
date approval/favourable opinion was given by the IRB/IEC. 
 
5.11.3 The sponsor should obtain from the investigator/institution documentation and dates of 
any IRB/IEC reapprovals/re-evaluations with favourable opinion, and of any withdrawals 
or suspensions of approval/favourable opinion.  
 
5.12 Information on Investigational Product(s) 
 
5.12.1 When planning trials, the sponsor should ensure that sufficient safety and efficacy data 
from nonclinical studies and/or clinical trials are available to support human exposure by 
the route, at the dosages, for the duration, and in the trial population to be studied. 
 
5.12.2 The sponsor should update the Investigator's Brochure as significant new information 
becomes available (see 7. Investigator's Brochure). 
 
5.13 Manufacturing, Packaging, Labelling, and Coding Investigational Product(s) 
 
5.13.1 The sponsor should ensure that the investigational product(s) (including active 
comparator(s) and placebo, if applicable) is characterized as appropriate to the stage of 
development of the product(s), is manufactured in accordance with any applicable GMP, 
and is coded and labelled in a manner that protects the blinding, if applicable. In addition, 
the labelling should comply with applicable regulatory requirement(s). 
 
5.13.2 The sponsor should determine, for the investigational product(s), acceptable storage 
temperatures, storage conditions (e.g. protection from light), storage times, reconstitution 
fluids and procedures, and devices for product infusion, if any. The sponsor should 
inform all involved parties (e.g. monitors, investigators, pharmacists, storage managers) 
of these determinations. 
 
5.13.3 The investigational product(s) should be packaged to prevent contamination and 
unacceptable deterioration during transport and storage. 
 
5.13.4 In blinded trials, the coding system for the investigational product(s) should include a 
mechanism that permits rapid identification of the product(s) in case of a medical 
emergency, but does not permit undetectable breaks of the blinding. 
 
5.13.5 If significant formulation changes are made in the investigational or comparator 
product(s) during the course of clinical development, the results of any additional studies 
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of the formulated product(s) (e.g. stability, dissolution rate, bioavailability) needed to 
assess whether these changes would significantly alter the pharmacokinetic profile of the 
product should be available prior to the use of the new formulation in clinical trials. 
 
5.14 Supplying and Handling Investigational Product(s) 
 
5.14.1 The sponsor is responsible for supplying the investigator(s)/institution(s) with the 
investigational product(s). 
 
5.14.2 The sponsor should not supply an investigator/institution with the investigational 
product(s) until the sponsor obtains all required documentation (e.g. approval/favourable 
opinion from IRB/IEC and regulatory authority(ies)). 
 
5.14.3 The sponsor should ensure that written procedures include instructions that the 
investigator/institution should follow for the handling and storage of investigational 
product(s) for the trial and documentation thereof. The procedures should address 
adequate and safe receipt, handling, storage, dispensing, retrieval of unused product from 
subjects, and return of unused investigational product(s) to the sponsor (or alternative 
disposition if authorized by the sponsor and in compliance with the applicable regulatory 
requirement(s)).  
 
5.14.4 The sponsor should: 
a) Ensure timely delivery of investigational product(s) to the investigator(s). 
b) Maintain records that document shipment, receipt, disposition, return, and 
destruction of the investigational product(s) (see 8. Essential Documents for the 
Conduct of a Clinical Trial). 
c) Maintain a system for retrieving investigational products and documenting this 
retrieval (e.g. for deficient product recall, reclaim after trial completion, expired 
product reclaim).  
d) Maintain a system for the disposition of unused investigational product(s) and for the 
documentation of this disposition.  
 
5.14.5 The sponsor should: 
a) Take steps to ensure that the investigational product(s) are stable over the period of 
use. 
b) Maintain sufficient quantities of the investigational product(s) used in the trials to 
reconfirm specifications, should this become necessary, and maintain records of 
batch sample analyses and characteristics. To the extent stability permits, samples 
should be retained either until the analyses of the trial data are complete or as 
required by the applicable regulatory requirement(s), whichever represents the longer 
retention period.  
 
5.15 Record Access 
 
5.15.1 The sponsor should ensure that it is specified in the protocol or other written agreement 
that the investigator(s)/institution(s) provide direct access to source data/documents for 
trial-related monitoring, audits, IRB/IEC review, and regulatory inspection. 
 
5.15.2 The sponsor should verify that each subject has consented, in writing, to direct access to 
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5.16 Safety Information 
 
5.16.1 The sponsor is responsible for the ongoing safety evaluation of the investigational 
product(s). 
 
5.16.2 The sponsor should promptly notify all concerned investigator(s)/institution(s) and the 
regulatory authority(ies) of findings that could affect adversely the safety of subjects, 
impact the conduct of the trial, or alter the IRB/IEC's approval/favourable opinion to 
continue the trial. 
 
5.17 Adverse Drug Reaction Reporting 
 
5.17.1 The sponsor should expedite the reporting to all concerned investigator(s)/institutions(s), 
to the IRB(s)/IEC(s), where required, and to the regulatory authority(ies) of all adverse 
drug reactions (ADRs) that are both serious and unexpected. 
 
5.17.2 Such expedited reports should comply with the applicable regulatory requirement(s) and 
with the ICH Guideline for Clinical Safety Data Management: Definitions and Standards 
for Expedited Reporting. 
 
5.17.3 The sponsor should submit to the regulatory authority(ies) all safety updates and periodic 





The purposes of trial monitoring are to verify that: 
a) The rights and well-being of human subjects are protected. 
b) The reported trial data are accurate, complete, and verifiable from source documents. 
c) The conduct of the trial is in compliance with the currently approved 
protocol/amendment(s), with GCP, and with the applicable regulatory 
requirement(s).  
 
5.18.2 Selection and Qualifications of Monitors 
a) Monitors should be appointed by the sponsor. 
b) Monitors should be appropriately trained, and should have the scientific and/or 
clinical knowledge needed to monitor the trial adequately. A monitorís qualifications 
should be documented.  
c) Monitors should be thoroughly familiar with the investigational product(s), the 
protocol, written informed consent form and any other written information to be 
provided to subjects, the sponsorís SOPs, GCP, and the applicable regulatory 
requirement(s).  
 
5.18.3 Extent and Nature of Monitoring 
The sponsor should ensure that the trials are adequately monitored. The sponsor should 
determine the appropriate extent and nature of monitoring. The determination of the 
extent and nature of monitoring should be based on considerations such as the objective, 
purpose, design, complexity, blinding, size, and endpoints of the trial. In general there is a 
need for on-site monitoring, before, during, and after the trial; however in exceptional 
circumstances the sponsor may determine that central monitoring in conjunction with 
procedures such as investigatorsí training and meetings, and extensive written guidance 
can assure appropriate conduct of the trial in accordance with GCP. Statistically 
controlled sampling may be an acceptable method for selecting the data to be verified. 
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5.18.4 Monitor's Responsibilities 
The monitor(s) in accordance with the sponsorís requirements should ensure that the trial 
is conducted and documented properly by carrying out the following activities when 
relevant and necessary to the trial and the trial site: 
a) Acting as the main line of communication between the sponsor and the investigator. 
b) Verifying that the investigator has adequate qualifications and resources (see 4.1, 4.2, 
5.6) and remain adequate throughout the trial period, that facilities, including 
laboratories, equipment, and staff, are adequate to safely and properly conduct the 
trial and remain adequate throughout the trial period.  
c) Verifying, for the investigational product(s): 
i) That storage times and conditions are acceptable, and that supplies are 
sufficient throughout the trial. 
ii) That the investigational product(s) are supplied only to subjects who are 
eligible to receive it and at the protocol specified dose(s). 
iii) That subjects are provided with necessary instruction on properly using, 
handling, storing, and returning the investigational product(s). 
iv) That the receipt, use, and return of the investigational product(s) at the trial 
sites are controlled and documented adequately. 
v) That the disposition of unused investigational product(s) at the trial sites 
complies with applicable regulatory requirement(s) and is in accordance with 
the sponsor. 
d) Verifying that the investigator follows the approved protocol and all approved 
amendment(s), if any.  
e) Verifying that written informed consent was obtained before each subject's 
participation in the trial.  
f) Ensuring that the investigator receives the current Investigator's Brochure, all 
documents, and all trial supplies needed to conduct the trial properly and to comply 
with the applicable regulatory requirement(s).  
g) Ensuring that the investigator and the investigator's trial staff are adequately 
informed about the trial.  
h) Verifying that the investigator and the investigator's trial staff are performing the 
specified trial functions, in accordance with the protocol and any other written 
agreement between the sponsor and the investigator/institution, and have not 
delegated these functions to unauthorized individuals.  
i) Verifying that the investigator is enroling only eligible subjects.  
j) Reporting the subject recruitment rate.  
k) Verifying that source documents and other trial records are accurate, complete, kept 
up-to-date and maintained.  
l)  Verifying that the investigator provides all the required reports, notifications, 
applications, and submissions, and that these documents are accurate, complete, 
timely, legible, dated, and identify the trial.  
m) Checking the accuracy and completeness of the CRF entries, source documents and 
other trial-related records against each other. The monitor specifically should verify 
that:  
i) The data required by the protocol are reported accurately on the CRFs and are 
consistent with the source documents. 
ii) Any dose and/or therapy modifications are well documented for each of the 
trial subjects.  
iii) Adverse events, concomitant medications and intercurrent illnesses are 
reported in accordance with the protocol on the CRFs.  
iv) Visits that the subjects fail to make, tests that are not conducted, and 
examinations that are not performed are clearly reported as such on the CRFs.  
v) All withdrawals and dropouts of enrolled subjects from the trial are reported 
and explained on the CRFs.  
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n) Informing the investigator of any CRF entry error, omission, or illegibility. The 
monitor should ensure that appropriate corrections, additions, or deletions are made, 
dated, explained (if necessary), and initialled by the investigator or by a member of 
the investigator's trial staff who is authorized to initial CRF changes for the 
investigator. This authorization should be documented.  
o) Determining whether all adverse events (AEs) are appropriately reported within the 
time periods required by GCP, the protocol, the IRB/IEC, the sponsor, and the 
applicable regulatory requirement(s).  
p) Determining whether the investigator is maintaining the essential documents (see 8. 
Essential Documents for the Conduct of a Clinical Trial).  
q) Communicating deviations from the protocol, SOPs, GCP, and the applicable 
regulatory requirements to the investigator and taking appropriate action designed to 
prevent recurrence of the detected deviations.  
 
5.18.5 Monitoring Procedures 
The monitor(s) should follow the sponsorís established written SOPs as well as those 
procedures that are specified by the sponsor for monitoring a specific trial. 
 
5.18.6 Monitoring Report 
a) The monitor should submit a written report to the sponsor after each trial-site visit or 
trial-related communication.  
b) Reports should include the date, site, name of the monitor, and name of the 
investigator or other individual(s) contacted.  
c) Reports should include a summary of what the monitor reviewed and the monitor's 
statements concerning the significant findings/facts, deviations and deficiencies, 
conclusions, actions taken or to be taken and/or actions recommended to secure 
compliance.  
d) The review and follow-up of the monitoring report with the sponsor should be 
documented by the sponsorís designated representative.  
 
5.19 Audit 




The purpose of a sponsor's audit, which is independent of and separate from routine 
monitoring or quality control functions, should be to evaluate trial conduct and 
compliance with the protocol, SOPs, GCP, and the applicable regulatory requirements. 
 
5.19.2 Selection and Qualification of Auditors 
a) The sponsor should appoint individuals, who are independent of the clinical 
trials/systems, to conduct audits.  
b) The sponsor should ensure that the auditors are qualified by training and experience 
to conduct audits properly. An auditorís qualifications should be documented.  
 
5.19.3 Auditing Procedures 
a) The sponsor should ensure that the auditing of clinical trials/systems is conducted in 
accordance with the sponsor's written procedures on what to audit, how to audit, the 
frequency of audits, and the form and content of audit reports.  
b) The sponsor's audit plan and procedures for a trial audit should be guided by the 
importance of the trial to submissions to regulatory authorities, the number of 
subjects in the trial, the type and complexity of the trial, the level of risks to the trial 
subjects, and any identified problem(s).  
c) The observations and findings of the auditor(s) should be documented.  
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d) To preserve the independence and value of the audit function, the regulatory 
authority(ies) should not routinely request the audit reports. Regulatory authority(ies) 
may seek access to an audit report on a case by case basis when evidence of serious 
GCP non-compliance exists, or in the course of legal proceedings.  





5.20.1 Noncompliance with the protocol, SOPs, GCP, and/or applicable regulatory 
requirement(s) by an investigator/institution, or by member(s) of the sponsor's staff 
should lead to prompt action by the sponsor to secure compliance. 
 
5.20.2 If the monitoring and/or auditing identifies serious and/or persistent noncompliance on 
the part of an investigator/institution, the sponsor should terminate the 
investigator's/institutionís participation in the trial. When an investigator's/institutionís 
participation is terminated because of noncompliance, the sponsor should notify promptly 
the regulatory authority(ies). 
 
5.21 Premature Termination or Suspension of a Trial 
If a trial is prematurely terminated or suspended, the sponsor should promptly inform the 
investigators/institutions, and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension. The IRB/IEC should also be informed promptly 
and provided the reason(s) for the termination or suspension by the sponsor or by the 
investigator/institution, as specified by the applicable regulatory requirement(s). 
 
5.22 Clinical Trial/Study Reports 
Whether the trial is completed or prematurely terminated, the sponsor should ensure that the 
clinical trial reports are prepared and provided to the regulatory agency(ies) as required by the 
applicable regulatory requirement(s). The sponsor should also ensure that the clinical trial reports 
in marketing applications meet the standards of the ICH Guideline for Structure and Content of 
Clinical Study Reports. (NOTE: The ICH Guideline for Structure and Content of Clinical Study 
Reports specifies that abbreviated study reports may be acceptable in certain cases.) 
 
5.23 Multicentre Trials 
For multicentre trials, the sponsor should ensure that: 
 
5.23.1 All investigators conduct the trial in strict compliance with the protocol agreed to by the 
sponsor and, if required, by the regulatory authority(ies), and given approval/favourable 
opinion by the IRB/IEC. 
 
5.23.2 The CRFs are designed to capture the required data at all multicentre trial sites. For those 
investigators who are collecting additional data, supplemental CRFs should also be 
provided that are designed to capture the additional data. 
 
5.23.3 The responsibilities of coordinating investigator(s) and the other participating 
investigators are documented prior to the start of the trial. 
 
5.23.4 All investigators are given instructions on following the protocol, on complying with a 
uniform set of standards for the assessment of clinical and laboratory findings, and on 
completing the CRFs. 
 
5.23.5 Communication between investigators is facilitated. 
© EMEA 2006   30 
134
6. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S) 
The contents of a trial protocol should generally include the following topics. However, site 
specific information may be provided on separate protocol page(s), or addressed in a separate 
agreement, and some of the information listed below may be contained in other protocol 
referenced documents, such as an Investigatorís Brochure. 
 
6.1 General Information 
 
6.1.1 Protocol title, protocol identifying number, and date. Any amendment(s) should also bear 
the amendment number(s) and date(s). 
 
6.1.2 Name and address of the sponsor and monitor (if other than the sponsor). 
 
6.1.3 Name and title of the person(s) authorized to sign the protocol and the protocol 
amendment(s) for the sponsor. 
 
6.1.4 Name, title, address, and telephone number(s) of the sponsor's medical expert (or dentist 
when appropriate) for the trial. 
 
6.1.5 Name and title of the investigator(s) who is (are) responsible for conducting the trial, and 
the address and telephone number(s) of the trial site(s). 
 
6.1.6 Name, title, address, and telephone number(s) of the qualified physician (or dentist, if 
applicable), who is responsible for all trial-site related medical (or dental) decisions (if 
other than investigator). 
 
6.1.7 Name(s) and address(es) of the clinical laboratory(ies) and other medical and/or technical 
department(s) and/or institutions involved in the trial. 
 
6.2 Background Information 
 
6.2.1 Name and description of the investigational product(s). 
 
6.2.2 A summary of findings from nonclinical studies that potentially have clinical significance 
and from clinical trials that are relevant to the trial. 
 
6.2.3 Summary of the known and potential risks and benefits, if any, to human subjects. 
 
6.2.4 Description of and justification for the route of administration, dosage, dosage regimen, 
and treatment period(s). 
 
6.2.5 A statement that the trial will be conducted in compliance with the protocol, GCP and the 
applicable regulatory requirement(s). 
 
6.2.6 Description of the population to be studied. 
 
6.2.7 References to literature and data that are relevant to the trial, and that provide background 
for the trial. 
 
6.3  Trial Objectives and Purpose 
A detailed description of the objectives and the purpose of the trial. 
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6.4 Trial Design 
The scientific integrity of the trial and the credibility of the data from the trial depend 
substantially on the trial design. A description of the trial design, should include: 
 
6.4.1 A specific statement of the primary endpoints and the secondary endpoints, if any, to be 
measured during the trial.  
 
6.4.2 A description of the type/design of trial to be conducted (e.g. double-blind, placebo-
controlled, parallel design) and a schematic diagram of trial design, procedures and 
stages. 
 




6.4.4 A description of the trial treatment(s) and the dosage and dosage regimen of the 
investigational product(s). Also include a description of the dosage form, packaging, and 
labelling of the investigational product(s). 
 
6.4.5 The expected duration of subject participation, and a description of the sequence and 
duration of all trial periods, including follow-up, if any. 
 
6.4.6 A description of the "stopping rules" or "discontinuation criteria" for individual subjects, 
parts of trial and entire trial. 
 
6.4.7 Accountability procedures for the investigational product(s), including the placebo(s) and 
comparator(s), if any. 
 
6.4.8 Maintenance of trial treatment randomization codes and procedures for breaking codes. 
 
6.4.9 The identification of any data to be recorded directly on the CRFs (i.e. no prior written or 
electronic record of data), and to be considered to be source data. 
 
6.5 Selection and Withdrawal of Subjects 
 
6.5.1 Subject inclusion criteria. 
 
6.5.2 Subject exclusion criteria. 
 
6.5.3 Subject withdrawal criteria (i.e. terminating investigational product treatment/trial 
treatment) and procedures specifying: 
a) When and how to withdraw subjects from the trial/ investigational product treatment. 
b) The type and timing of the data to be collected for withdrawn subjects. 
c) Whether and how subjects are to be replaced. 
d) The follow-up for subjects withdrawn from investigational product treatment/trial 
treatment. 
 
6.6 Treatment of Subjects 
 
6.6.1 The treatment(s) to be administered, including the name(s) of all the product(s), the 
dose(s), the dosing schedule(s), the route/mode(s) of administration, and the treatment 
period(s), including the follow-up period(s) for subjects for each investigational product 
treatment/trial treatment group/arm of the trial. 
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6.6.2 Medication(s)/treatment(s) permitted (including rescue medication) and not permitted 
before and/or during the trial. 
 
6.6.3 Procedures for monitoring subject compliance. 
 
6.7 Assessment of Efficacy 
 
6.7.1 Specification of the efficacy parameters. 
 
6.7.2 Methods and timing for assessing, recording, and analysing of efficacy parameters. 
 
6.8 Assessment of Safety 
 
6.8.1 Specification of safety parameters. 
 
6.8.2 The methods and timing for assessing, recording, and analysing safety parameters. 
 
6.8.3 Procedures for eliciting reports of and for recording and reporting adverse event and 
intercurrent illnesses. 
 




6.9.1 A description of the statistical methods to be employed, including timing of any planned 
interim analysis(ses). 
 
6.9.2 The number of subjects planned to be enrolled. In multicentre trials, the numbers of 
enrolled subjects projected for each trial site should be specified. Reason for choice of 
sample size, including reflections on (or calculations of) the power of the trial and clinical 
justification. 
 
6.9.3 The level of significance to be used. 
 
6.9.4 Criteria for the termination of the trial. 
 
6.9.5 Procedure for accounting for missing, unused, and spurious data. 
 
6.9.6 Procedures for reporting any deviation(s) from the original statistical plan (any 
deviation(s) from the original statistical plan should be described and justified in protocol 
and/or in the final report, as appropriate). 
 
6.9.7 The selection of subjects to be included in the analyses (e.g. all randomized subjects, all 
dosed subjects, all eligible subjects, evaluable subjects). 
 
6.10 Direct Access to Source Data/Documents 
The sponsor should ensure that it is specified in the protocol or other written agreement that the 
investigator(s)/institution(s) will permit trial-related monitoring, audits, IRB/IEC review, and 
regulatory inspection(s), providing direct access to source data/documents. 
 
6.11 Quality Control and Quality Assurance  
 
6.12 Ethics 
Description of ethical considerations relating to the trial. 
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6.13 Data Handling and Record Keeping 
 
6.14 Financing and Insurance 
Financing and insurance if not addressed in a separate agreement. 
 
6.15 Publication Policy 
Publication policy, if not addressed in a separate agreement. 
 
6.16 Supplements 
(NOTE: Since the protocol and the clinical trial/study report are closely related, further relevant 
information can be found in the ICH Guideline for Structure and Content of Clinical Study 
Reports.) 
 
7. INVESTIGATORíS BROCHURE 
 
7.1 Introduction 
The Investigator's Brochure (IB) is a compilation of the clinical and nonclinical data on the 
investigational product(s) that are relevant to the study of the product(s) in human subjects. Its 
purpose is to provide the investigators and others involved in the trial with the information to 
facilitate their understanding of the rationale for, and their compliance with, many key features 
of the protocol, such as the dose, dose frequency/interval, methods of administration: and safety 
monitoring procedures. The IB also provides insight to support the clinical management of the 
study subjects during the course of the clinical trial. The information should be presented in a 
concise, simple, objective, balanced, and non-promotional form that enables a clinician, or 
potential investigator, to understand it and make his/her own unbiased risk-benefit assessment of 
the appropriateness of the proposed trial. For this reason, a medically qualified person should 
generally participate in the editing of an IB, but the contents of the IB should be approved by the 
disciplines that generated the described data. 
This guideline delineates the minimum information that should be included in an IB and 
provides suggestions for its layout. It is expected that the type and extent of information 
available will vary with the stage of development of the investigational product. If the 
investigational product is marketed and its pharmacology is widely understood by medical 
practitioners, an extensive IB may not be necessary. Where permitted by regulatory authorities, a 
basic product information brochure, package leaflet, or labelling may be an appropriate 
alternative, provided that it includes current, comprehensive, and detailed information on all 
aspects of the investigational product that might be of importance to the investigator. If a 
marketed product is being studied for a new use (i.e., a new indication), an IB specific to that 
new use should be prepared. The IB should be reviewed at least annually and revised as 
necessary in compliance with a sponsor's written procedures. More frequent revision may be 
appropriate depending on the stage of development and the generation of relevant new 
information. However, in accordance with Good Clinical Practice, relevant new information may 
be so important that it should be communicated to the investigators, and possibly to the 
Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs) and/or regulatory 
authorities before it is included in a revised IB. 
Generally, the sponsor is responsible for ensuring that an up-to-date IB is made available to the 
investigator(s) and the investigators are responsible for providing the up-to-date IB to the 
responsible IRBs/IECs. In the case of an investigator sponsored trial, the sponsor-investigator 
should determine whether a brochure is available from the commercial manufacturer. If the 
investigational product is provided by the sponsor-investigator, then he or she should provide the 
necessary information to the trial personnel. In cases where preparation of a formal IB is 
impractical, the sponsor-investigator should provide, as a substitute, an expanded background 
information section in the trial protocol that contains the minimum current information described 
in this guideline. 
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7.2 General Considerations 
The IB should include: 
 
7.2.1 Title Page 
This should provide the sponsor's name, the identity of each investigational product (i.e., 
research number, chemical or approved generic name, and trade name(s) where legally 
permissible and desired by the sponsor), and the release date. It is also suggested that an 
edition number, and a reference to the number and date of the edition it supersedes, be 
provided. An example is given in Appendix 1. 
 
7.2.2 Confidentiality Statement 
The sponsor may wish to include a statement instructing the investigator/recipients to 
treat the IB as a confidential document for the sole information and use of the 
investigator's team and the IRB/IEC.  
 
7.3 Contents of the Investigatorís Brochure 
The IB should contain the following sections, each with literature references where appropriate: 
 
7.3.1 Table of Contents 
An example of the Table of Contents is given in Appendix 2 
 
7.3.2 Summary 
A brief summary (preferably not exceeding two pages) should be given, highlighting the 
significant physical, chemical, pharmaceutical, pharmacological, toxicological, 
pharmacokinetic, metabolic, and clinical information available that is relevant to the stage 
of clinical development of the investigational product. 
 
7.3.3 Introduction 
A brief introductory statement should be provided that contains the chemical name (and 
generic and trade name(s) when approved) of the investigational product(s), all active 
ingredients, the investigational product (s ) pharmacological class and its expected 
position within this class (e.g. advantages), the rationale for performing research with the 
investigational product(s), and the anticipated prophylactic, therapeutic, or diagnostic 
indication(s). Finally, the introductory statement should provide the general approach to 
be followed in evaluating the investigational product. 
 
7.3.4  Physical, Chemical, and Pharmaceutical Properties and Formulation  
A description should be provided of the investigational product substance(s) (including 
the chemical and/or structural formula(e)), and a brief summary should be given of the 
relevant physical, chemical, and pharmaceutical properties.  
To permit appropriate safety measures to be taken in the course of the trial, a description 
of the formulation(s) to be used, including excipients, should be provided and justified if 
clinically relevant. Instructions for the storage and handling of the dosage form(s) should 
also be given. 
Any structural similarities to other known compounds should be mentioned. 
 
7.3.5  Nonclinical Studies 
Introduction: 
The results of all relevant nonclinical pharmacology, toxicology, pharmacokinetic, and 
investigational product metabolism studies should be provided in summary form. This 
summary should address the methodology used, the results, and a discussion of the 
relevance of the findings to the investigated therapeutic and the possible unfavourable and 
unintended effects in humans. 
The information provided may include the following, as appropriate, if known/available: 
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• Species tested 
• Number and sex of animals in each group 
• Unit dose (e.g., milligram/kilogram (mg/kg)) 
• Dose interval 
• Route of administration 
• Duration of dosing 
• Information on systemic distribution 
• Duration of post-exposure follow-up 
• Results, including the following aspects: 
− Nature and frequency of pharmacological or toxic effects 
− Severity or intensity of pharmacological or toxic effects 
− Time to onset of effects 
− Reversibility of effects 
− Duration of effects 
− Dose response 
Tabular format/listings should be used whenever possible to enhance the clarity of the 
presentation.  
The following sections should discuss the most important findings from the studies, 
including the dose response of observed effects, the relevance to humans, and any aspects 
to be studied in humans. If applicable, the effective and nontoxic dose findings in the 
same animal species should be compared (i.e., the therapeutic index should be discussed). 
The relevance of this information to the proposed human dosing should be addressed. 
Whenever possible, comparisons should be made in terms of blood/tissue levels rather 
than on a mg/kg basis.  
a) Nonclinical Pharmacology 
A summary of the pharmacological aspects of the investigational product and, where 
appropriate, its significant metabolites studied in animals, should be included. Such a 
summary should incorporate studies that assess potential therapeutic activity (e.g. 
efficacy models, receptor binding, and specificity) as well as those that assess safety 
(e.g., special studies to assess pharmacological actions other than the intended 
therapeutic effect(s)). 
b) Pharmacokinetics and Product Metabolism in Animals 
A summary of the pharmacokinetics and biological transformation and disposition of 
the investigational product in all species studied should be given. The discussion of 
the findings should address the absorption and the local and systemic bioavailability 
of the investigational product and its metabolites, and their relationship to the 
pharmacological and toxicological findings in animal species.  
c) Toxicology 
A summary of the toxicological effects found in relevant studies conducted in 
different animal species should be described under the following headings where 
appropriate:  
− Single dose 
− Repeated dose 
− CarcinogenicitySpecial studies (e.g. irritancy and sensitisation)  
− Reproductive toxicity 
− Genotoxicity (mutagenicity)  
 
7.3.6  Effects in Humans 
Introduction:  
A thorough discussion of the known effects of the investigational product(s) in humans 
should be provided, including information on pharmacokinetics, metabolism, 
pharmacodynamics, dose response, safety, efficacy, and other pharmacological activities. 
© EMEA 2006   36 
140
Where possible, a summary of each completed clinical trial should be provided. 
Information should also be provided regarding results of any use of the investigational 
product(s) other than from in clinical trials, such as from experience during marketing.  
a) Pharmacokinetics and Product Metabolism in Humans 
− A summary of information on the pharmacokinetics of the investigational 
product(s) should be presented, including the following, if available:  
− Pharmacokinetics (including metabolism, as appropriate, and absorption, 
plasma protein binding, distribution, and elimination).  
− Bioavailability of the investigational product (absolute, where possible, 
and/or relative) using a reference dosage form.  
− Population subgroups (e.g., gender, age, and impaired organ function).  
− Interactions (e.g., product-product interactions and effects of food).  
− Other pharmacokinetic data (e.g., results of population studies performed 
within clinical trial(s).  
b) Safety and Efficacy 
A summary of information should be provided about the investigational 
product's/products' (including metabolites, where appropriate) safety, 
pharmacodynamics, efficacy, and dose response that were obtained from preceding 
trials in humans (healthy volunteers and/or patients). The implications of this 
information should be discussed. In cases where a number of clinical trials have been 
completed, the use of summaries of safety and efficacy across multiple trials by 
indications in subgroups may provide a clear presentation of the data. Tabular 
summaries of adverse drug reactions for all the clinical trials (including those for all 
the studied indications) would be useful. Important differences in adverse drug 
reaction patterns/incidences across indications or subgroups should be discussed. 
The IB should provide a description of the possible risks and adverse drug reactions 
to be anticipated on the basis of prior experiences with the product under 
investigation and with related products. A description should also be provided of the 
precautions or special monitoring to be done as part of the investigational use of the 
product(s). 
c) Marketing Experience 
The IB should identify countries where the investigational product has been 
marketed or approved. Any significant information arising from the marketed use 
should be summarised (e.g., formulations, dosages, routes of administration, and 
adverse product reactions). The IB should also identify all the countries where the 
investigational product did not receive approval/registration for marketing or was 
withdrawn from marketing/registration. 
 
7.3.7  Summary of Data and Guidance for the Investigator 
This section should provide an overall discussion of the nonclinical and clinical data, and 
should summarise the information from various sources on different aspects of the 
investigational product(s), wherever possible. In this way, the investigator can be 
provided with the most informative interpretation of the available data and with an 
assessment of the implications of the information for future clinical trials. 
Where appropriate, the published reports on related products should be discussed. This 
could help the investigator to anticipate adverse drug reactions or other problems in 
clinical trials. 
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The overall aim of this section is to provide the investigator with a clear understanding of 
the possible risks and adverse reactions, and of the specific tests, observations, and 
precautions that may be needed for a clinical trial. This understanding should be based on 
the available physical, chemical, pharmaceutical, pharmacological, toxicological, and 
clinical information on the investigational product(s). Guidance should also be provided to 
the clinical investigator on the recognition and treatment of possible overdose and adverse 
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drug reactions that is based on previous human experience and on the pharmacology of the 
investigational product. 
7.4 APPENDIX 1:  
 






Name(s): Chemical, Generic (if approved) 








Replaces Previous Edition Number: 
Date: 
 
7.5 APPENDIX 2:  
 
TABLE OF CONTENTS OF INVESTIGATOR'S BROCHURE (Example)  
 
- Confidentiality Statement (optional).................................................................................  
- Signature Page (optional)..................................................................................................  
1. Table of Contents .............................................................................................................  
2. Summary ..........................................................................................................................  
3. Introduction ......................................................................................................................  
4. Physical, Chemical, and Pharmaceutical Properties and Formulation ............................  
5. Nonclinical Studies ..........................................................................................................  
5.1 Nonclinical Pharmacology ...............................................................................................  
5.2 Pharmacokinetics and Product Metabolism in Animals ..................................................  
5.3 Toxicology .......................................................................................................................  
6. Effects in Humans ............................................................................................................  
6.1 Pharmacokinetics and Product Metabolism in Humans ..................................................  
6.2 Safety and Efficacy ..........................................................................................................  
6.3 Marketing Experience ......................................................................................................  
7. Summary of Data and Guidance for the Investigator ......................................................  
 
NB: References on 1. Publications 
  2. Reports 
These references should be found at the end of each chapter 
Appendices (if any) 
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8. ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 
 
8.1 Introduction 
Essential Documents are those documents which individually and collectively permit evaluation 
of the conduct of a trial and the quality of the data produced. These documents serve to 
demonstrate the compliance of the investigator, sponsor and monitor with the standards of Good 
Clinical Practice and with all applicable regulatory requirements. 
Essential Documents also serve a number of other important purposes. Filing essential 
documents at the investigator/institution and sponsor sites in a timely manner can greatly assist 
in the successful management of a trial by the investigator, sponsor and monitor. These 
documents are also the ones which are usually audited by the sponsor's independent audit 
function and inspected by the regulatory authority (ies) as part of the process to confirm the 
validity of the trial conduct and the integrity of data collected. 
The minimum list of essential documents which has been developed follows. The various 
documents are grouped in three sections according to the stage of the trial during which they will 
normally be generated: 1) before the clinical phase of the trial commences, 2) during the clinical 
conduct of the trial, and 3) after completion or termination of the trial. A description is given of 
the purpose of each document, and whether it should be filed in either the investigator/institution 
or sponsor files, or both. It is acceptable to combine some of the documents, provided the 
individual elements are readily identifiable. 
Trial master files should be established at the beginning of the trial, both at the 
investigator/institutionís site and at the sponsor's office. A final close-out of a trial can only be 
done when the monitor has reviewed both investigator/institution and sponsor files and 
confirmed that all necessary documents are in the appropriate files. 
Any or all of the documents addressed in this guideline may be subject to, and should be 
available for, audit by the sponsorís auditor and inspection by the regulatory authority(ies). 
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8.2 Before the Clinical Phase of the Trial Commences 
During this planning stage the following documents should be generated and should be on file before the trial formally starts 
 
 Title of Document Purpose Located in Files of 
   Investigator/ 
Institution 
Sponsor 
8.2.1 INVESTIGATORÍS BROCHURE To document that relevant and current scientific 
information about the investigational product has 
been provided to the investigator 
X X 
8.2.2 SIGNED PROTOCOL AND AMENDMENTS, 
IF ANY, AND SAMPLE CASE REPORT 
FORM (CRF) 
To document investigator and sponsor agreement 
to the protocol/amendment(s) and CRF 
X X 
8.2.3 INFORMATION GIVEN TO TRIAL 
SUBJECT 
- INFORMED CONSENT FORM 
(including all applicable translations) 
 
 
To document the informed consent 
X X 
 - ANY OTHER WRITTEN INFORMATION To document that subjects will be given 
appropriate written information (content and 
wording) to support their ability to give fully 
informed consent 
X X 
 - ADVERTISEMENT FOR SUBJECT 
RECRUITMENT (if used) 
To document that recruitment measures are 
appropriate and not coercive 
X  
8.2.4 FINANCIAL ASPECTS OF THE TRIAL To document the financial agreement between the 
investigator/institution and the sponsor for the trial 
 
X X 
8.2.5 INSURANCE STATEMENT 
(where required) 
To document that compensation to subject(s) for 
trial-related injury will be available 
X X 
8.2.6 SIGNED AGREEMENT BETWEEN 
INVOLVED PARTIES, e.g.: 
- investigator/institution and sponsor 
- investigator/institution and CRO 
 
- sponsor and CRO 
- investigator/institution and authority(ies) 
(where required) 













 Title of Document Purpose Located in Files of 
   Investigator/ 
Institution 
Sponsor 
8.2.7 DATED, DOCUMENTED 
APPROVAL/FAVOURABLE OPINION OF 
INSTITUTIONAL REVIEW BOARD (IRB) 
/INDEPENDENT ETHICS COMMITTEE 
(IEC) OF THE FOLLOWING: 
- protocol and any amendments 
- CRF (if applicable) 
- informed consent form(s) 
- any other written information to be provided 
to the subject(s) 
- advertisement for subject recruitment  
 (if used) 
- subject compensation (if any) 
- any other documents given approval/ 
favourable opinion 
To document that the trial has been subject to  
IRB/IEC review and given approval/favourable 
opinion. To identify the version number and date 
of the document(s) 
X X 
8.2.8 INSTITUTIONAL REVIEW 
BOARD/INDEPENDENT ETHICS 
COMMITTEE COMPOSITION 
To document that the IRB/IEC is constituted in 




8.2.9 REGULATORY AUTHORITY(IES) 
AUTHORISATION/APPROVAL/ 
NOTIFICATION OF PROTOCOL 
(where required) 
To document appropriate 
authorisation/approval/notification by the 
regulatory authority(ies) has been obtained prior to 
initiation of the trial in compliance with the 







8.2.10 CURRICULUM VITAE AND/OR OTHER 
RELEVANT DOCUMENTS EVIDENCING 
QUALIFICATIONS OF INVESTIGATOR(S) 
AND SUB-INVESTIGATOR(S) 
To document qualifications and eligibility to 
conduct trial and/or provide medical supervision of 
subjects 
X X 
8.2.11 NORMAL VALUE(S)/RANGE(S) FOR 
MEDICAL/ LABORATORY/TECHNICAL 
PROCEDURE(S) AND/OR TEST(S) 
INCLUDED IN THE PROTOCOL 
 




 Title of Document Purpose Located in Files of 





- certification or 
- accreditation or 
- established quality control and/or external 
quality assessment or 
- other validation (where required) 
To document competence of facility to perform 





8.2.13 SAMPLE OF LABEL(S) ATTACHED TO 
INVESTIGATIONAL PRODUCT 
CONTAINER(S) 
To document compliance with applicable labelling 
regulations and appropriateness of instructions 
provided to the subjects 
 X 
8.2.14 INSTRUCTIONS FOR HANDLING OF 
INVESTIGATIONAL PRODUCT(S) AND 
TRIAL-RELATED MATERIALS 
(if not included in protocol or Investigatorís 
Brochure) 
To document instructions needed to ensure proper 
storage, packaging, dispensing and disposition of 
investigational products and trial-related materials 
X X 
8.2.15 SHIPPING RECORDS FOR 
INVESTIGATIONAL PRODUCT(S) AND 
TRIAL-RELATED MATERIALS 
To document shipment dates, batch numbers and 
method of shipment of investigational product(s) 
and trial-related materials. Allows tracking of 
product batch, review of shipping conditions, and 
accountability 
X X 
8.2.16 CERTIFICATE(S) OF ANALYSIS OF 
INVESTIGATIONAL PRODUCT(S) SHIPPED
To document identity, purity, and strength of 
investigational product(s) to be used in the trial 
 
 X 
8.2.17 DECODING PROCEDURES FOR BLINDED 
TRIALS  
To document how, in case of an emergency, 
identity of blinded investigational product can be 
revealed without breaking the blind for the 




(third party if 
applicable) 






(third party if 
applicable) 
 
MASTER RANDOMISATION LIST 
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 Title of Document Purpose Located in Files of 
   Investigator/ 
Institution 
Sponsor 
8.2.19 PRE-TRIAL MONITORING REPORT To document that the site is suitable for the trial 
(may be combined with 8.2.20) 
 X 
8.2.20 TRIAL INITIATION MONITORING 
REPORT 
To document that trial procedures were reviewed 
with the investigator and the investigatorís trial 




8.3 During the Clinical Conduct of the Trial 
In addition to having on file the above documents, the following should be added to the files during the trial as evidence that all new relevant 
information is documented as it becomes available 
 
 Title of Document Purpose Located in Files of 
   Investigator/ 
Institution 
Sponsor 
8.3.1 INVESTIGATORÍS BROCHURE UPDATES To document that investigator is informed in a 
timely manner of relevant information as it 
becomes available 
X X 
     
8.3.2 ANY REVISION TO: 
- protocol/amendment(s) and CRF 
- informed consent form 
- any other written information provided to 
subjects 
- advertisement for subject recruitment  
  (if used) 
To document revisions of these trial related 
documents that take effect during trial 
X X 
8.3.3 DATED, DOCUMENTED 
APPROVAL/FAVOURABLE OPINION OF 
INSTITUTIONAL REVIEW BOARD (IRB) 
/INDEPENDENT ETHICS COMMITTEE 
(IEC) OF THE FOLLOWING: 
- protocol amendment(s) 
- revision(s) of: 
- informed consent form 
- any other written information to be 
provided to the subject 
- advertisement for subject recruitment  
 (if used)  
- any other documents given 
approval/favourable opinion 
- continuing review of trial (where required) 
To document that the amendment(s) and/or 
revision(s) have been subject to IRB/IEC review 
and were given approval/favourable opinion. To 





 Title of Document Purpose Located in Files of 
   Investigator/ 
Institution 
Sponsor 
8.3.4 REGULATORY AUTHORITY(IES) 
AUTHORISATIONS/APPROVALS/NOTIFIC
ATIONS WHERE REQUIRED FOR: 
- protocol amendment(s) and other documents 












8.3.6 UPDATES TO NORMAL 
VALUE(S)/RANGE(S) FOR MEDICAL/ 
LABORATORY/ TECHNICAL 
PROCEDURE(S)/TEST(S) INCLUDED IN 
THE PROTOCOL 
To document normal values and ranges that are 
revised during the trial (see 8.2.11) 
X X 
8.3.7 UPDATES OF MEDICAL/LABORATORY/ 
TECHNICAL PROCEDURES/TESTS 
- certification or 
- accreditation or 
- established quality control and/or external 
quality assessment or 
- other validation (where required) 
To document that tests remain adequate throughout 





8.3.8 DOCUMENTATION OF 
INVESTIGATIONAL PRODUCT(S) AND 
TRIAL-RELATED MATERIALS SHIPMENT 
(see 8.2.15.) X X 
8.3.9 CERTIFICATE(S) OF ANALYSIS FOR NEW 
BATCHES OF INVESTIGATIONAL 
PRODUCTS 
(see 8.2.16)  X 
8.3.10 MONITORING VISIT REPORTS To document site visits by, and findings of, the 
monitor 
 X 
8.3.11 RELEVANT COMMUNICATIONS OTHER 
THAN SITE VISITS 
- letters 
- meeting notes 
To document any agreements or significant 
discussions regarding trial administration, protocol 




- notes of telephone calls 
 
 Title of Document Purpose Located in Files of 
   Investigator/ 
Institution 
Sponsor 
8.3.12 SIGNED INFORMED CONSENT FORMS To document that consent is obtained in 
accordance with GCP and protocol and dated prior 
to participation of each subject in trial. Also to 
document direct access permission (see 8.2.3) 
X  
8.3.13 SOURCE DOCUMENTS To document the existence of the subject and 
substantiate integrity of trial data collected. To 
include original documents related to the trial, to 
medical treatment, and history of subject 
X  
 
 Title of Document Purpose Located in Files of 
   Investigator/ 
Institution 
Sponsor 
8.3.14 SIGNED, DATED AND COMPLETED 
CASE REPORT FORMS (CRF) 
To document that the investigator or authorised 






8.3.15 DOCUMENTATION OF CRF 
CORRECTIONS 
To document all changes/additions or corrections 





8.3.16 NOTIFICATION BY ORIGINATING 
INVESTIGATOR TO SPONSOR OF 
SERIOUS ADVERSE EVENTS AND 
RELATED REPORTS 
Notification by originating investigator to sponsor 
of serious adverse events and related reports in 
accordance with 4.11 
X X 
8.3.17 NOTIFICATION BY SPONSOR AND/OR 
INVESTIGATOR, WHERE APPLICABLE, 
TO REGULATORY AUTHORITY(IES) AND 
IRB(S)/IEC(S) OF UNEXPECTED SERIOUS 
ADVERSE DRUG REACTIONS AND OF 
OTHER SAFETY INFORMATION 
Notification by sponsor and/or investigator, where 
applicable, to regulatory authorities and 
IRB(s)/IEC(s) of unexpected serious adverse drug 
reactions in accordance with 5.17 and 4.11.1 and 






8.3.18 NOTIFICATION BY SPONSOR TO 
INVESTIGATORS OF SAFETY 
INFORMATION 
Notification by sponsor to investigators of safety 
information in accordance with 5.16.2 
X X 
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8.3.19 INTERIM OR ANNUAL REPORTS TO 
IRB/IEC AND AUTHORITY(IES) 
Interim or annual reports provided to IRB/IEC in 
accordance with 4.10 and to authority(ies) in 




8.3.20 SUBJECT SCREENING LOG To document identification of subjects who 




8.3.21 SUBJECT IDENTIFICATION CODE LIST To document that investigator/institution keeps a 
confidential list of names of all subjects allocated 
to trial numbers on enrolling in the trial. Allows 
investigator/institution to reveal identity of any 
subject 
X  
8.3.22 SUBJECT ENROLMENT LOG To document chronological enrolment of subjects 
by trial number 
 
X  
8.3.23 INVESTIGATIONAL PRODUCTS 
ACCOUNTABILITY AT THE SITE 
To document that investigational product(s) have 
been used according to the protocol 
X X 
8.3.24 SIGNATURE SHEET To document signatures and initials of all persons 
authorised to make entries and/or corrections on 
CRFs 
X X 
8.3.25 RECORD OF RETAINED BODY FLUIDS/ 
TISSUE SAMPLES (IF ANY) 
To document location and identification of 
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8.4 After Completion or Termination of the Trial 
After completion or termination of the trial, all of the documents identified in sections 8.2 and 8.3 should be in the file together with the following 
 
 Title of Document Purpose Located in Files of 
   Investigator/ 
Institution 
Sponsor 
8.4.1 INVESTIGATIONAL PRODUCT(S) 
ACCOUNTABILITY AT SITE 
To document that the investigational product(s) 
have been used according to the protocol. To 
documents the final accounting of investigational 
product(s) received at the site, dispensed to 
subjects, returned by the subjects, and returned to 
sponsor 
X X 
8.4.2 DOCUMENTATION OF 
INVESTIGATIONAL PRODUCT 
DESTRUCTION 
To document destruction of unused investigational 
products by sponsor or at site 
 
X 
(if destroyed at 
site) 
X 
8.4.3 COMPLETED SUBJECT IDENTIFICATION 
CODE LIST 
To permit identification of all subjects enrolled in 
the trial in case follow-up is required. List should 
be kept in a confidential manner and for agreed 
upon time 
X  
8.4.4 AUDIT CERTIFICATE (if available) To document that audit was performed  X 
8.4.5 FINAL TRIAL CLOSE-OUT MONITORING 
REPORT 
To document that all activities required for trial 
close-out are completed, and copies of essential 
documents are held in the appropriate files 
 X 
8.4.6 TREATMENT ALLOCATION AND 
DECODING DOCUMENTATION 
Returned to sponsor to document any decoding 
that may have occurred 
 X 
 
8.4.7 FINAL REPORT BY INVESTIGATOR TO 
IRB/IEC WHERE REQUIRED, AND WHERE 
APPLICABLE, TO THE REGULATORY 
AUTHORITY(IES) 
To document completion of the trial X  
8.4.8 CLINICAL STUDY REPORT 
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DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
of 4 April 2001
on the approximation of the laws, regulations and administrative provisions of the Member States
relating to the implementation of good clinical practice in the conduct of clinical trials on
medicinal products for human use
THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE
EUROPEAN UNION,
Having regard to the Treaty establishing the European
Community, and in particular Article 95 thereof,
Having regard to the proposal from the Commission (1),
Having regard to the opinion of the Economic and Social
Committee (2),
Acting in accordance with the procedure laid down in Article
251 of the Treaty (3),
Whereas:
(1) Council Directive 65/65/EEC of 26 January 1965 on the
approximation of provisions laid down by law, regula-
tion or administrative action relating to medicinal prod-
ucts (4) requires that applications for authorisation to
place a medicinal product on the market should be
accompanied by a dossier containing particulars and
documents relating to the results of tests and clinical
trials carried out on the product. Council Directive 75/
318/EEC of 20 May 1975 on the approximation of the
laws of Member States relating to analytical, pharmaco-
toxicological and clinical standards and protocols in
respect of the testing of medicinal products (5) lays down
uniform rules on the compilation of dossiers including
their presentation.
(2) The accepted basis for the conduct of clinical trials in
humans is founded in the protection of human rights
and the dignity of the human being with regard to the
application of biology and medicine, as for instance
reflected in the 1996 version of the Helsinki Declaration.
The clinical trial subject's protection is safeguarded
through risk assessment based on the results of toxico-
logical experiments prior to any clinical trial, screening
by ethics committees and Member States' competent
authorities, and rules on the protection of personal data.
(3) Persons who are incapable of giving legal consent to
clinical trials should be given special protection. It is
incumbent on the Member States to lay down rules to
this effect. Such persons may not be included in clinical
trials if the same results can be obtained using persons
capable of giving consent. Normally these persons
should be included in clinical trials only when there are
grounds for expecting that the administering of the
medicinal product would be of direct benefit to the
patient, thereby outweighing the risks. However, there is
a need for clinical trials involving children to improve
the treatment available to them. Children represent a
vulnerable population with developmental, physiological
and psychological differences from adults, which make
age- and development- related research important for
their benefit. Medicinal products, including vaccines, for
children need to be tested scientifically before wide-
spread use. This can only be achieved by ensuring that
medicinal products which are likely to be of significant
clinical value for children are fully studied. The clinical
trials required for this purpose should be carried out
under conditions affording the best possible protection
for the subjects. Criteria for the protection of children in
clinical trials therefore need to be laid down.
(4) In the case of other persons incapable of giving their
consent, such as persons with dementia, psychiatric
patients, etc., inclusion in clinical trials in such cases
should be on an even more restrictive basis. Medicinal
products for trial may be administered to all such indi-
viduals only when there are grounds for assuming that
the direct benefit to the patient outweighs the risks.
Moreover, in such cases the written consent of the
patient's legal representative, given in cooperation with
the treating doctor, is necessary before participation in
any such clinical trial.
(5) The notion of legal representative refers back to existing
national law and consequently may include natural or
legal persons, an authority and/or a body provided for
by national law.
(6) In order to achieve optimum protection of health, obso-
lete or repetitive tests will not be carried out, whether
within the Community or in third countries. The harmo-
nisation of technical requirements for the development
(1) OJ C 306, 8.10.1997, p. 9 and
OJ C 161, 8.6.1999, p. 5.
(2) OJ C 95, 30.3.1998, p. 1.
(3) Opinion of the European Parliament of 17 November 1998 (OJ C
379, 7. 12. 1998, p. 27). Council Common Position of 20 July
2000 (OJ C 300, 20.10.2000, p. 32) and Decision of the European
Parliament of 12 December 2000. Council Decision of 26 February
2001.
(4) OJ 22, 9.2.1965, p. 1/65. Directive as last amended by Council
Directive 93/39/EEC (OJ L 214, 24.8.1993, p. 22).
(5) OJ L 147, 9.6.1975, p. 1. Directive as last amended by Commission
Directive 1999/83/EC (OJ L 243, 15.9.1999, p. 9).
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of medicinal products should therefore be pursued
through the appropriate fora, in particular the Inter-
national Conference on Harmonisation.
(7) For medicinal products falling within the scope of Part A
of the Annex to Council Regulation (EEC) No 2309/93
of 22 July 1993 laying down Community procedures for
the authorisation and supervision of medicinal products
for human and veterinary use and establishing a Euro-
pean Agency for the Evaluation of Medicinal Prod-
ucts (1), which include products intended for gene
therapy or cell therapy, prior scientific evaluation by the
European Agency for the Evaluation of Medicinal Prod-
ucts (hereinafter referred to as the ‘Agency’), assisted by
the Committee for Proprietary Medicinal Products, is
mandatory before the Commission grants marketing
authorisation. In the course of this evaluation, the said
Committee may request full details of the results of the
clinical trials on which the application for marketing
authorisation is based and, consequently, on the manner
in which these trials were conducted and the same
Committee may go so far as to require the applicant for
such authorisation to conduct further clinical trials.
Provision must therefore be made to allow the Agency
to have full information on the conduct of any clinical
trial for such medicinal products.
(8) A single opinion for each Member State concerned
reduces delay in the commencement of a trial without
jeopardising the well-being of the people participating in
the trial or excluding the possibility of rejecting it in
specific sites.
(9) Information on the content, commencement and
termination of a clinical trial should be available to the
Member States where the trial takes place and all the
other Member States should have access to the same
information. A European database bringing together this
information should therefore be set up, with due regard
for the rules of confidentiality.
(10) Clinical trials are a complex operation, generally lasting
one or more years, usually involving numerous partici-
pants and several trial sites, often in different Member
States. Member States' current practices diverge consid-
erably on the rules on commencement and conduct of
the clinical trials and the requirements for carrying them
out vary widely. This therefore results in delays and
complications detrimental to effective conduct of such
trials in the Community. It is therefore necessary to
simplify and harmonise the administrative provisions
governing such trials by establishing a clear, transparent
procedure and creating conditions conducive to effective
coordination of such clinical trials in the Community by
the authorities concerned.
(11) As a rule, authorisation should be implicit, i.e. if there
has been a vote in favour by the Ethics Committee and
the competent authority has not objected within a given
period, it should be possible to begin the clinical trials.
In exceptional cases raising especially complex prob-
lems, explicit written authorisation should, however, be
required.
(12) The principles of good manufacturing practice should be
applied to investigational medicinal products.
(13) Special provisions should be laid down for the labelling
of these products.
(14) Non-commercial clinical trials conducted by researchers
without the participation of the pharmaceuticals
industry may be of great benefit to the patients
concerned. The Directive should therefore take account
of the special position of trials whose planning does not
require particular manufacturing or packaging processes,
if these trials are carried out with medicinal products
with a marketing authorisation within the meaning of
Directive 65/65/EEC, manufactured or imported in
accordance with the provisions of Directives 75/
319/EEC and 91/356/EEC, and on patients with the
same characteristics as those covered by the indication
specified in this marketing authorisation. Labelling of the
investigational medicinal products intended for trials of
this nature should be subject to simplified provisions
laid down in the good manufacturing practice guidelines
on investigational products and in Directive 91/
356/EEC.
(15) The verification of compliance with the standards of
good clinical practice and the need to subject data,
information and documents to inspection in order to
confirm that they have been properly generated,
recorded and reported are essential in order to justify the
involvement of human subjects in clinical trials.
(16) The person participating in a trial must consent to the
scrutiny of personal information during inspection by
competent authorities and properly authorised persons,
provided that such personal information is treated as
strictly confidential and is not made publicly available.
(17) This Directive is to apply without prejudice to Directive
95/46/EEC of the European Parliament and of the
Council of 24 October 1995 on the protection of indi-
viduals with regard to the processing of personal data
and on the free movement of such data (2).
(18) It is also necessary to make provision for the monitoring
of adverse reactions occurring in clinical trials using
Community surveillance (pharmacovigilance) procedures
in order to ensure the immediate cessation of any clin-
ical trial in which there is an unacceptable level of risk.
(1) OJ L 214, 24.8.1993, p. 1. Regulation as amended by Commission
Regulation (EC) No 649/98 (OJ L 88, 24.3.1998, p. 7) (2) OJ L 281, 23.11.1995, p. 31.
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(19) The measures necessary for the implementation of this
Directive should be adopted in accordance with Council
Decision 1999/468/EC of 28 June 1999 laying down
the procedures for the exercise of implementing powers
conferred on the Commission (1),
HAVE ADOPTED THIS DIRECTIVE:
Article 1
Scope
1. This Directive establishes specific provisions regarding the
conduct of clinical trials, including multi-centre trials, on
human subjects involving medicinal products as defined in
Article 1 of Directive 65/65/EEC, in particular relating to the
implementation of good clinical practice. This Directive does
not apply to non-interventional trials.
2. Good clinical practice is a set of internationally recog-
nised ethical and scientific quality requirements which must be
observed for designing, conducting, recording and reporting
clinical trials that involve the participation of human subjects.
Compliance with this good practice provides assurance that the
rights, safety and well-being of trial subjects are protected, and
that the results of the clinical trials are credible.
3. The principles of good clinical practice and detailed
guidelines in line with those principles shall be adopted and, if
necessary, revised to take account of technical and scientific
progress in accordance with the procedure referred to in Article
21(2).
These detailed guidelines shall be published by the Commis-
sion.
4. All clinical trials, including bioavailability and bioequiva-
lence studies, shall be designed, conducted and reported in
accordance with the principles of good clinical practice.
Article 2
Definitions
For the purposes of this Directive the following definitions
shall apply:
(a) ‘clinical trial’: any investigation in human subjects intended
to discover or verify the clinical, pharmacological and/or
other pharmacodynamic effects of one or more investiga-
tional medicinal product(s), and/or to identify any adverse
reactions to one or more investigational medicinal
product(s) and/or to study absorption, distribution, metab-
olism and excretion of one or more investigational medi-
cinal product(s) with the object of ascertaining its (their)
safety and/or efficacy;
This includes clinical trials carried out in either one site or
multiple sites, whether in one or more than one Member
State;
(b) ‘multi-centre clinical trial’: a clinical trial conducted
according to a single protocol but at more than one site,
and therefore by more than one investigator, in which the
trial sites may be located in a single Member State, in a
number of Member States and/or in Member States and
third countries;
(c) ‘non-interventional trial’: a study where the medicinal
product(s) is (are) prescribed in the usual manner in
accordance with the terms of the marketing authorisation.
The assignment of the patient to a particular therapeutic
strategy is not decided in advance by a trial protocol but
falls within current practice and the prescription of the
medicine is clearly separated from the decision to include
the patient in the study. No additional diagnostic or
monitoring procedures shall be applied to the patients and
epidemiological methods shall be used for the analysis of
collected data;
(d) ‘investigational medicinal product’: a pharmaceutical form
of an active substance or placebo being tested or used as a
reference in a clinical trial, including products already with
a marketing authorisation but used or assembled (formu-
lated or packaged) in a way different from the authorised
form, or when used for an unauthorised indication, or
when used to gain further information about the author-
ised form;
(e) ‘sponsor’: an individual, company, institution or organ-
isation which takes responsibility for the initiation,
management and/or financing of a clinical trial;
(f) ‘investigator’: a doctor or a person following a profession
agreed in the Member State for investigations because of
the scientific background and the experience in patient
care it requires. The investigator is responsible for the
conduct of a clinical trial at a trial site. If a trial is
conducted by a team of individuals at a trial site, the
investigator is the leader responsible for the team and may
be called the principal investigator;
(g) ‘investigator's brochure’: a compilation of the clinical and
non-clinical data on the investigational medicinal product
or products which are relevant to the study of the product
or products in human subjects;
(h) ‘protocol’: a document that describes the objective(s),
design, methodology, statistical considerations and organ-
isation of a trial. The term protocol refers to the protocol,
successive versions of the protocol and protocol amend-
ments;
(i) ‘subject’: an individual who participates in a clinical trial as
either a recipient of the investigational medicinal product
or a control;(1) OJ L 184, 17.7.1999, p. 23.
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(j) ‘informed consent’: decision, which must be written, dated
and signed, to take part in a clinical trial, taken freely after
being duly informed of its nature, significance, implica-
tions and risks and appropriately documented, by any
person capable of giving consent or, where the person is
not capable of giving consent, by his or her legal repres-
entative; if the person concerned is unable to write, oral
consent in the presence of at least one witness may be
given in exceptional cases, as provided for in national
legislation.
(k) ‘ethics committee’: an independent body in a Member
State, consisting of healthcare professionals and non-
medical members, whose responsibility it is to protect the
rights, safety and wellbeing of human subjects involved in
a trial and to provide public assurance of that protection,
by, among other things, expressing an opinion on the trial
protocol, the suitability of the investigators and the
adequacy of facilities, and on the methods and documents
to be used to inform trial subjects and obtain their
informed consent;
(l) ‘inspection’: the act by a competent authority of
conducting an official review of documents, facilities,
records, quality assurance arrangements, and any other
resources that are deemed by the competent authority to
be related to the clinical trial and that may be located at
the site of the trial, at the sponsor's and/or contract
research organisation's facilities, or at other establishments
which the competent authority sees fit to inspect;
(m) ‘adverse event’: any untoward medical occurrence in a
patient or clinical trial subject administered a medicinal
product and which does not necessarily have a causal
relationship with this treatment;
(n) ‘adverse reaction’: all untoward and unintended responses
to an investigational medicinal product related to any dose
administered;
(o) ‘serious adverse event or serious adverse reaction’: any
untoward medical occurrence or effect that at any dose
results in death, is life-threatening, requires hospitalisation
or prolongation of existing hospitalisation, results in
persistent or significant disability or incapacity, or is a
congenital anomaly or birth defect;
(p) ‘unexpected adverse reaction’: an adverse reaction, the
nature or severity of which is not consistent with the
applicable product information (e.g. investigator's
brochure for an unauthorised investigational product or
summary of product characteristics for an authorised
product).
Article 3
Protection of clinical trial subjects
1. This Directive shall apply without prejudice to the
national provisions on the protection of clinical trial subjects if
they are more comprehensive than the provisions of this
Directive and consistent with the procedures and time-scales
specified therein. Member States shall, insofar as they have not
already done so, adopt detailed rules to protect from abuse
individuals who are incapable of giving their informed consent.
2. A clinical trial may be undertaken only if, in particular:
(a) the foreseeable risks and inconveniences have been weighed
against the anticipated benefit for the individual trial
subject and other present and future patients. A clinical
trial may be initiated only if the Ethics Committee and/or
the competent authority comes to the conclusion that the
anticipated therapeutic and public health benefits justify the
risks and may be continued only if compliance with this
requirement is permanently monitored;
(b) the trial subject or, when the person is not able to give
informed consent, his legal representative has had the
opportunity, in a prior interview with the investigator or a
member of the investigating team, to understand the objec-
tives, risks and inconveniences of the trial, and the condi-
tions under which it is to be conducted and has also been
informed of his right to withdraw from the trial at any
time;
(c) the rights of the subject to physical and mental integrity, to
privacy and to the protection of the data concerning him in
accordance with Directive 95/46/EC are safeguarded;
(d) the trial subject or, when the person is not able to give
informed consent, his legal representative has given his
written consent after being informed of the nature, signifi-
cance, implications and risks of the clinical trial; if the
individual is unable to write, oral consent in the presence
of at least one witness may be given in exceptional cases, as
provided for in national legislation;
(e) the subject may without any resulting detriment withdraw
from the clinical trial at any time by revoking his informed
consent;
(f) provision has been made for insurance or indemnity to
cover the liability of the investigator and sponsor.
3. The medical care given to, and medical decisions made
on behalf of, subjects shall be the responsibility of an appro-
priately qualified doctor or, where appropriate, of a qualified
dentist.
4. The subject shall be provided with a contact point where
he may obtain further information.
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Article 4
Clinical trials on minors
In addition to any other relevant restriction, a clinical trial on
minors may be undertaken only if:
(a) the informed consent of the parents or legal representative
has been obtained; consent must represent the minor's
presumed will and may be revoked at any time, without
detriment to the minor;
(b) the minor has received information according to its
capacity of understanding, from staff with experience with
minors, regarding the trial, the risks and the benefits;
(c) the explicit wish of a minor who is capable of forming an
opinion and assessing this information to refuse participa-
tion or to be withdrawn from the clinical trial at any time
is considered by the investigator or where appropriate the
principal investigator;
(d) no incentives or financial inducements are given except
compensation;
(e) some direct benefit for the group of patients is obtained
from the clinical trial and only where such research is
essential to validate data obtained in clinical trials on
persons able to give informed consent or by other research
methods; additionally, such research should either relate
directly to a clinical condition from which the minor
concerned suffers or be of such a nature that it can only be
carried out on minors;
(f) the corresponding scientific guidelines of the Agency have
been followed;
(g) clinical trials have been designed to minimise pain, discom-
fort, fear and any other foreseeable risk in relation to the
disease and developmental stage; both the risk threshold
and the degree of distress have to be specially defined and
constantly monitored;
(h) the Ethics Committee, with paediatric expertise or after
taking advice in clinical, ethical and psychosocial problems
in the field of paediatrics, has endorsed the protocol; and
(i) the interests of the patient always prevail over those of
science and society.
Article 5
Clinical trials on incapacitated adults not able to give
informed legal consent
In the case of other persons incapable of giving informed legal
consent, all relevant requirements listed for persons capable of
giving such consent shall apply. In addition to these require-
ments, inclusion in clinical trials of incapacitated adults who
have not given or not refused informed consent before the
onset of their incapacity shall be allowed only if:
(a) the informed consent of the legal representative has been
obtained; consent must represent the subject's presumed
will and may be revoked at any time, without detriment to
the subject;
(b) the person not able to give informed legal consent has
received information according to his/her capacity of
understanding regarding the trial, the risks and the benefits;
(c) the explicit wish of a subject who is capable of forming an
opinion and assessing this information to refuse participa-
tion in, or to be withdrawn from, the clinical trial at any
time is considered by the investigator or where appropriate
the principal investigator;
(d) no incentives or financial inducements are given except
compensation;
(e) such research is essential to validate data obtained in clin-
ical trials on persons able to give informed consent or by
other research methods and relates directly to a life-threat-
ening or debilitating clinical condition from which the
incapacitated adult concerned suffers;
(f) clinical trials have been designed to minimise pain, discom-
fort, fear and any other foreseeable risk in relation to the
disease and developmental stage; both the risk threshold
and the degree of distress shall be specially defined and
constantly monitored;
(g) the Ethics Committee, with expertise in the relevant disease
and the patient population concerned or after taking advice
in clinical, ethical and psychosocial questions in the field of
the relevant disease and patient population concerned, has
endorsed the protocol;
(h) the interests of the patient always prevail over those of
science and society; and
(i) there are grounds for expecting that administering the
medicinal product to be tested will produce a benefit to the
patient outweighing the risks or produce no risk at all.
Article 6
Ethics Committee
1. For the purposes of implementation of the clinical trials,
Member States shall take the measures necessary for establish-
ment and operation of Ethics Committees.
2. The Ethics Committee shall give its opinion, before a
clinical trial commences, on any issue requested.
3. In preparing its opinion, the Ethics Committee shall
consider, in particular:
(a) the relevance of the clinical trial and the trial design;
(b) whether the evaluation of the anticipated benefits and risks
as required under Article 3(2)(a) is satisfactory and whether
the conclusions are justified;
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(c) the protocol;
(d) the suitability of the investigator and supporting staff;
(e) the investigator's brochure;
(f) the quality of the facilities;
(g) the adequacy and completeness of the written information
to be given and the procedure to be followed for the
purpose of obtaining informed consent and the justification
for the research on persons incapable of giving informed
consent as regards the specific restrictions laid down in
Article 3;
(h) provision for indemnity or compensation in the event of
injury or death attributable to a clinical trial;
(i) any insurance or indemnity to cover the liability of the
investigator and sponsor;
(j) the amounts and, where appropriate, the arrangements for
rewarding or compensating investigators and trial subjects
and the relevant aspects of any agreement between the
sponsor and the site;
(k) the arrangements for the recruitment of subjects.
4. Notwithstanding the provisions of this Article, a Member
State may decide that the competent authority it has designated
for the purpose of Article 9 shall be responsible for the consid-
eration of, and the giving of an opinion on, the matters
referred to in paragraph 3(h), (i) and (j) of this Article.
When a Member State avails itself of this provision, it shall
notify the Commission, the other Member States and the
Agency.
5. The Ethics Committee shall have a maximum of 60 days
from the date of receipt of a valid application to give its
reasoned opinion to the applicant and the competent authority
in the Member State concerned.
6. Within the period of examination of the application for
an opinion, the Ethics Committee may send a single request for
information supplementary to that already supplied by the
applicant. The period laid down in paragraph 5 shall be
suspended until receipt of the supplementary information.
7. No extension to the 60-day period referred to in para-
graph 5 shall be permissible except in the case of trials
involving medicinal products for gene therapy or somatic cell
therapy or medicinal products containing genetically modified
organisms. In this case, an extension of a maximum of 30 days
shall be permitted. For these products, this 90-day period may
be extended by a further 90 days in the event of consultation
of a group or a committee in accordance with the regulations
and procedures of the Member States concerned. In the case of




For multi-centre clinical trials limited to the territory of a single
Member State, Member States shall establish a procedure
providing, notwithstanding the number of Ethics Committees,
for the adoption of a single opinion for that Member State.
In the case of multi-centre clinical trials carried out in more
than one Member State simultaneously, a single opinion shall
be given for each Member State concerned by the clinical trial.
Article 8
Detailed guidance
The Commission, in consultation with Member States and
interested parties, shall draw up and publish detailed guidance
on the application format and documentation to be submitted
in an application for an ethics committee opinion, in particular
regarding the information that is given to subjects, and on the
appropriate safeguards for the protection of personal data.
Article 9
Commencement of a clinical trial
1. Member States shall take the measures necessary to
ensure that the procedure described in this Article is followed
for commencement of a clinical trial.
The sponsor may not start a clinical trial until the Ethics
Committee has issued a favourable opinion and inasmuch as
the competent authority of the Member State concerned has
not informed the sponsor of any grounds for non-acceptance.
The procedures to reach these decisions can be run in parallel
or not, depending on the sponsor.
2. Before commencing any clinical trial, the sponsor shall be
required to submit a valid request for authorisation to the
competent authority of the Member State in which the sponsor
plans to conduct the clinical trial.
3. If the competent authority of the Member State notifies
the sponsor of grounds for non-acceptance, the sponsor may,
on one occasion only, amend the content of the request
referred to in paragraph 2 in order to take due account of the
grounds given. If the sponsor fails to amend the request
accordingly, the request shall be considered rejected and the
clinical trial may not commence.
4. Consideration of a valid request for authorisation by the
competent authority as stated in paragraph 2 shall be carried
out as rapidly as possible and may not exceed 60 days. The
Member States may lay down a shorter period than 60 days
within their area of responsibility if that is in compliance with
current practice. The competent authority can nevertheless
notify the sponsor before the end of this period that it has no
grounds for non-acceptance.
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No further extensions to the period referred to in the first
subparagraph shall be permissible except in the case of trials
involving the medicinal products listed in paragraph 6, for
which an extension of a maximum of 30 days shall be
permitted. For these products, this 90-day period may be
extended by a further 90 days in the event of consultation of a
group or a committee in accordance with the regulations and
procedures of the Member States concerned. In the case of
xenogenic cell therapy there shall be no time limit to the
authorisation period.
5. Without prejudice to paragraph 6, written authorisation
may be required before the commencement of clinical trials for
such trials on medicinal products which do not have a
marketing authorisation within the meaning of Directive 65/
65/EEC and are referred to in Part A of the Annex to Regula-
tion (EEC) No 2309/93, and other medicinal products with
special characteristics, such as medicinal products the active
ingredient or active ingredients of which is or are a biological
product or biological products of human or animal origin, or
contains biological components of human or animal origin, or
the manufacturing of which requires such components.
6. Written authorisation shall be required before
commencing clinical trials involving medicinal products for
gene therapy, somatic cell therapy including xenogenic cell
therapy and all medicinal products containing genetically
modified organisms. No gene therapy trials may be carried out
which result in modifications to the subject's germ line genetic
identity.
7. This authorisation shall be issued without prejudice to the
application of Council Directives 90/219/EEC of 23 April 1990
on the contained use of genetically modified micro-organ-
isms (1) and 90/220/EEC of 23 April 1990 on the deliberate
release into the environment of genetically modified organ-
isms (2).
8. In consultation with Member States, the Commission
shall draw up and publish detailed guidance on:
(a) the format and contents of the request referred to in para-
graph 2 as well as the documentation to be submitted to
support that request, on the quality and manufacture of the
investigational medicinal product, any toxicological and
pharmacological tests, the protocol and clinical information
on the investigational medicinal product including the
investigator's brochure;
(b) the presentation and content of the proposed amendment
referred to in point (a) of Article 10 on substantial amend-
ments made to the protocol;
(c) the declaration of the end of the clinical trial.
Article 10
Conduct of a clinical trial
Amendments may be made to the conduct of a clinical trial
following the procedure described hereinafter:
(a) after the commencement of the clinical trial, the sponsor
may make amendments to the protocol. If those amend-
ments are substantial and are likely to have an impact on
the safety of the trial subjects or to change the inter-
pretation of the scientific documents in support of the
conduct of the trial, or if they are otherwise significant, the
sponsor shall notify the competent authorities of the
Member State or Member States concerned of the reasons
for, and content of, these amendments and shall inform the
ethics committee or committees concerned in accordance
with Articles 6 and 9.
On the basis of the details referred to in Article 6(3) and in
accordance with Article 7, the Ethics Committee shall give
an opinion within a maximum of 35 days of the date of
receipt of the proposed amendment in good and due form.
If this opinion is unfavourable, the sponsor may not imple-
ment the amendment to the protocol.
If the opinion of the Ethics Committee is favourable and
the competent authorities of the Member States have raised
no grounds for non-acceptance of the abovementioned
substantial amendments, the sponsor shall proceed to
conduct the clinical trial following the amended protocol.
Should this not be the case, the sponsor shall either take
account of the grounds for non-acceptance and adapt the
proposed amendment to the protocol accordingly or with-
draw the proposed amendment;
(b) without prejudice to point (a), in the light of the circum-
stances, notably the occurrence of any new event relating
to the conduct of the trial or the development of the
investigational medicinal product where that new event is
likely to affect the safety of the subjects, the sponsor and
the investigator shall take appropriate urgent safety meas-
ures to protect the subjects against any immediate hazard.
The sponsor shall forthwith inform the competent authori-
ties of those new events and the measures taken and shall
ensure that the Ethics Committee is notified at the same
time;
(c) within 90 days of the end of a clinical trial the sponsor
shall notify the competent authorities of the Member State
or Member States concerned and the Ethics Committee that
the clinical trial has ended. If the trial has to be terminated




1. Member States in whose territory the clinical trial takes
place shall enter in a European database, accessible only to the
competent authorities of the Member States, the Agency and
the Commission:
(a) extracts from the request for authorisation referred to in
Article 9(2);
(b) any amendments made to the request, as provided for in
Article 9(3);
(1) OJ L 117, 8.5.1990, p. 1. Directive as last amended by Directive
98/81/EC (OJ L 330, 5.12.1998, p. 13).
(2) OJ L 117, 8.5.1990, p. 15. Directive as last amended by Commis-
sion Directive 97/35/EC (OJ L 169, 27.6.1997, p. 72).
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(c) any amendments made to the protocol, as provided for in
point a of Article 10;
(d) the favourable opinion of the Ethics Committee;
(e) the declaration of the end of the clinical trial; and
(f) a reference to the inspections carried out on conformity
with good clinical practice.
2. At the substantiated request of any Member State, the
Agency or the Commission, the competent authority to which
the request for authorisation was submitted shall supply all
further information concerning the clinical trial in question
other than the data already in the European database.
3. In consultation with the Member States, the Commission
shall draw up and publish detailed guidance on the relevant
data to be included in this European database, which it oper-
ates with the assistance of the Agency, as well as the methods
for electronic communication of the data. The detailed
guidance thus drawn up shall ensure that the confidentiality of
the data is strictly observed.
Article 12
Suspension of the trial or infringements
1. Where a Member State has objective grounds for consid-
ering that the conditions in the request for authorisation
referred to in Article 9(2) are no longer met or has information
raising doubts about the safety or scientific validity of the
clinical trial, it may suspend or prohibit the clinical trial and
shall notify the sponsor thereof.
Before the Member State reaches its decision it shall, except
where there is imminent risk, ask the sponsor and/or the
investigator for their opinion, to be delivered within one week.
In this case, the competent authority concerned shall forthwith
inform the other competent authorities, the Ethics Committee
concerned, the Agency and the Commission of its decision to
suspend or prohibit the trial and of the reasons for the
decision.
2. Where a competent authority has objective grounds for
considering that the sponsor or the investigator or any other
person involved in the conduct of the trial no longer meets the
obligations laid down, it shall forthwith inform him thereof,
indicating the course of action which he must take to remedy
this state of affairs. The competent authority concerned shall
forthwith inform the Ethics Committee, the other competent
authorities and the Commission of this course of action.
Article 13
Manufacture and import of investigational medicinal
products
1. Member States shall take all appropriate measures to
ensure that the manufacture or importation of investigational
medicinal products is subject to the holding of authorisation.
In order to obtain the authorisation, the applicant and, subse-
quently, the holder of the authorisation, shall meet at least the
requirements defined in accordance with the procedure referred
to in Article 21(2).
2. Member States shall take all appropriate measures to
ensure that the holder of the authorisation referred to in para-
graph 1 has permanently and continuously at his disposal the
services of at least one qualified person who, in accordance
with the conditions laid down in Article 23 of the second
Council Directive 75/319/EEC of 20 May 1975 on the approx-
imation of provisions laid down by law, regulation or adminis-
trative action relating to proprietary medicinal products (1), is
responsible in particular for carrying out the duties specified in
paragraph 3 of this Article.
3. Member States shall take all appropriate measures to
ensure that the qualified person referred to in Article 21 of
Directive 75/319/EEC, without prejudice to his relationship
with the manufacturer or importer, is responsible, in the
context of the procedures referred to in Article 25 of the said
Directive, for ensuring:
(a) in the case of investigational medicinal products manufac-
tured in the Member State concerned, that each batch of
medicinal products has been manufactured and checked in
compliance with the requirements of Commission Directive
91/356/EEC of 13 June 1991 laying down the principles
and guidelines of good manufacturing practice for medi-
cinal products for human use (2), the product specification
file and the information notified pursuant to Article 9(2) of
this Directive;
(b) in the case of investigational medicinal products manufac-
tured in a third country, that each production batch has
been manufactured and checked in accordance with stan-
dards of good manufacturing practice at least equivalent to
those laid down in Commission Directive 91/356/EEC, in
accordance with the product specification file, and that
each production batch has been checked in accordance
with the information notified pursuant to Article 9(2) of
this Directive;
(c) in the case of an investigational medicinal product which is
a comparator product from a third country, and which has
a marketing authorisation, where the documentation certi-
fying that each production batch has been manufactured in
conditions at least equivalent to the standards of good
manufacturing practice referred to above cannot be
obtained, that each production batch has undergone all
relevant analyses, tests or checks necessary to confirm its
quality in accordance with the information notified
pursuant to Article 9(2) of this Directive.
Detailed guidance on the elements to be taken into account
when evaluating products with the object of releasing batches
within the Community shall be drawn up pursuant to the good
manufacturing practice guidelines, and in particular Annex 13
to the said guidelines. Such guidelines will be adopted in
accordance with the procedure referred to in Article 21(2) of
this Directive and published in accordance with Article 19a of
Directive 75/319/EEC.
(1) OJ L 147, 9.6.1975, p. 13. Directive as last amended by Council
Directive 93/39/EC (OJ L 214, 24.8.1993, p. 22).
(2) OJ L 193, 17.7.1991, p. 30.
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Insofar as the provisions laid down in (a), (b) or (c) are
complied with, investigational medicinal products shall not
have to undergo any further checks if they are imported into
another Member State together with batch release certification
signed by the qualified person.
4. In all cases, the qualified person must certify in a register
or equivalent document that each production batch satisfies the
provisions of this Article. The said register or equivalent docu-
ment shall be kept up to date as operations are carried out and
shall remain at the disposal of the agents of the competent
authority for the period specified in the provisions of the
Member States concerned. This period shall in any event be not
less than five years.
5. Any person engaging in activities as the qualified person
referred to in Article 21 of Directive 75/319/EEC as regards
investigational medicinal products at the time when this
Directive is applied in the Member State where that person is,
but without complying with the conditions laid down in
Articles 23 and 24 of that Directive, shall be authorised to
continue those activities in the Member State concerned.
Article 14
Labelling
The particulars to appear in at least the official language(s) of
the Member State on the outer packaging of investigational
medicinal products or, where there is no outer packaging, on
the immediate packaging, shall be published by the Commis-
sion in the good manufacturing practice guidelines on investi-
gational medicinal products adopted in accordance with Article
19a of Directive 75/319/EEC.
In addition, these guidelines shall lay down adapted provisions
relating to labelling for investigational medicinal products
intended for clinical trials with the following characteristics:
— the planning of the trial does not require particular manu-
facturing or packaging processes;
— the trial is conducted with medicinal products with, in the
Member States concerned by the study, a marketing author-
isation within the meaning of Directive 65/65/EEC, manu-
factured or imported in accordance with the provisions of
Directive 75/319/EEC;
— the patients participating in the trial have the same charac-
teristics as those covered by the indication specified in the
abovementioned authorisation.
Article 15
Verification of compliance of investigational medicinal
products with good clinical and manufacturing practice
1. To verify compliance with the provisions on good clinical
and manufacturing practice, Member States shall appoint
inspectors to inspect the sites concerned by any clinical trial
conducted, particularly the trial site or sites, the manufacturing
site of the investigational medicinal product, any laboratory
used for analyses in the clinical trial and/or the sponsor's
premises.
The inspections shall be conducted by the competent authority
of the Member State concerned, which shall inform the
Agency; they shall be carried out on behalf of the Community
and the results shall be recognised by all the other Member
States. These inspections shall be coordinated by the Agency,
within the framework of its powers as provided for in Regula-
tion (EEC) No 2309/93. A Member State may request assis-
tance from another Member State in this matter.
2. Following inspection, an inspection report shall be
prepared. It must be made available to the sponsor while
safeguarding confidential aspects. It may be made available to
the other Member States, to the Ethics Committee and to the
Agency, at their reasoned request.
3. At the request of the Agency, within the framework of its
powers as provided for in Regulation (EEC) No 2309/93, or of
one of the Member States concerned, and following consulta-
tion with the Member States concerned, the Commission may
request a new inspection should verification of compliance
with this Directive reveal differences between Member States.
4. Subject to any arrangements which may have been
concluded between the Community and third countries, the
Commission, upon receipt of a reasoned request from a
Member State or on its own initiative, or a Member State may
propose that the trial site and/or the sponsor's premises and/or
the manufacturer established in a third country undergo an
inspection. The inspection shall be carried out by duly qualified
Community inspectors.
5. The detailed guidelines on the documentation relating to
the clinical trial, which shall constitute the master file on the
trial, archiving, qualifications of inspectors and inspection
procedures to verify compliance of the clinical trial in question
with this Directive shall be adopted and revised in accordance
with the procedure referred to in Article 21(2).
Article 16
Notification of adverse events
1. The investigator shall report all serious adverse events
immediately to the sponsor except for those that the protocol
or investigator's brochure identifies as not requiring immediate
reporting. The immediate report shall be followed by detailed,
written reports. The immediate and follow-up reports shall
identify subjects by unique code numbers assigned to the latter.
2. Adverse events and/or laboratory abnormalities identified
in the protocol as critical to safety evaluations shall be reported
to the sponsor according to the reporting requirements and
within the time periods specified in the protocol.
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3. For reported deaths of a subject, the investigator shall
supply the sponsor and the Ethics Committee with any addi-
tional information requested.
4. The sponsor shall keep detailed records of all adverse
events which are reported to him by the investigator or investi-
gators. These records shall be submitted to the Member States
in whose territory the clinical trial is being conducted, if they
so request.
Article 17
Notification of serious adverse reactions
1. (a) The sponsor shall ensure that all relevant information
about suspected serious unexpected adverse reactions
that are fatal or life-threatening is recorded and reported
as soon as possible to the competent authorities in all
the Member States concerned, and to the Ethics
Committee, and in any case no later than seven days
after knowledge by the sponsor of such a case, and that
relevant follow-up information is subsequently commu-
nicated within an additional eight days.
(b) All other suspected serious unexpected adverse reac-
tions shall be reported to the competent authorities
concerned and to the Ethics Committee concerned as
soon as possible but within a maximum of fifteen days
of first knowledge by the sponsor.
(c) Each Member State shall ensure that all suspected unex-
pected serious adverse reactions to an investigational
medicinal product which are brought to its attention are
recorded.
(d) The sponsor shall also inform all investigators.
2. Once a year throughout the clinical trial, the sponsor
shall provide the Member States in whose territory the clinical
trial is being conducted and the Ethics Committee with a listing
of all suspected serious adverse reactions which have occurred
over this period and a report of the subjects' safety.
3. (a) Each Member State shall see to it that all suspected
unexpected serious adverse reactions to an investiga-
tional medicinal product which are brought to its atten-
tion are immediately entered in a European database to
which, in accordance with Article 11(1), only the
competent authorities of the Member States, the Agency
and the Commission shall have access.
(b) The Agency shall make the information notified by the




The Commission, in consultation with the Agency, Member
States and interested parties, shall draw up and publish detailed
guidance on the collection, verification and presentation of
adverse event/reaction reports, together with decoding proced-
ures for unexpected serious adverse reactions.
Article 19
General provisions
This Directive is without prejudice to the civil and criminal
liability of the sponsor or the investigator. To this end, the
sponsor or a legal representative of the sponsor must be estab-
lished in the Community.
Unless Member States have established precise conditions for
exceptional circumstances, investigational medicinal products
and, as the case may be, the devices used for their administra-
tion shall be made available free of charge by the sponsor.
The Member States shall inform the Commission of such
conditions.
Article 20
Adaptation to scientific and technical progress
This Directive shall be adapted to take account of scientific and




1. The Commission shall be assisted by the Standing
Committee on Medicinal Products for Human Use, set up by
Article 2b of Directive 75/318/EEC (hereinafter referred to as
the Committee).
2. Where reference is made to this paragraph, Articles 5 and
7 of Decision 1999/468/EC shall apply, having regard to the
provisions of Article 8 thereof.
The period referred to in Article 5(6) of Decision 1999/468/EC
shall be set at three months.
3. The Committee shall adopt its rules of procedure.
Article 22
Application
1. Member States shall adopt and publish before 1 May
2003 the laws, regulations and administrative provisions neces-
sary to comply with this Directive. They shall forthwith inform
the Commission thereof.
They shall apply these provisions at the latest with effect from
1 May 2004.
When Member States adopt these provisions, they shall contain
a reference to this Directive or shall be accompanied by such
reference on the occasion of their official publication. The
methods of making such reference shall be laid down by
Member States.
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2. Member States shall communicate to the Commission the
text of the provisions of national law which they adopt in the
field governed by this Directive.
Article 23
Entry into force
This Directive shall enter into force on the day of its publica-
tion in the Official Journal of the European Communities.
Article 24
Addressees
This Directive is addressed to the Member States.
Done at Luxembourg, 4 April 2001.
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News and updates on pharmaceuticals
EudraLex - Volume 10 Clinical trials guidelines
 Volume 10 of the publications "The rules governing medicinal products in the European Union"
contains guidance documents applying to clinical trials.
 
General information (July 2006)
Chapter I: Application and Application Form
Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for
human use to the competent authorities, notification of substantial amendments and declaration of
the end of the trial  (revision 3 of March 2010) 
Annex 1 revised Pdf version  Word version (revision 4 of November 2009) - EudraCT Version
8.0 uses the Revision 4 dated November 2009 of the Clinical Trials Application Form.  For
more information please refer to the EudraCT website
Substantial Amendment Notification Form :   PDF version - Word version (revision 3 of June
2010)
Declaration of the End of Trial Form : PDF version - Word version (revision 3 of June 2010)
Detailed guidance on the application format and documentation to be submitted in an application
for an Ethics Committee opinion on the clinical trial on medicinal products for human use (revision
1 of February 2006)
Detailed guidance on the European clinical trials database (EUDRACT Database) (revision of April
2004)
 Chapter II: Safety Reporting
Detailed guidance on the collection, verification and presentation of adverse event/reaction
reports arising from clinical trials on medicinal products for human use (‘CT-3’)  (June 2011)
ICH guideline E2F - Note for guidance on development safety update reports (September 2010)
Chapter III: Quality of the Investigational Medicinal Product
Template for the qualified person's declaration equivalence to EU GMP for Investigational
Medicinal Products manufactured in third countries (may 2013)
Good manufacturing practices for manufacture of investigational medicinal products (February
2010)
Community basic format for  manufacturing authorisation / Community basic format for
manufacturers / importers
Guideline on the requirements to the chemical and pharmaceutical quality documentation
concerning investigational medicinal products in clinical trials
Guideline on the requirements for quality documentation concerning biological investigational
medicinal products in clinical trials (May 2012)
Guidance on Investigational Medicinal Products (IMPs) and 'non investigational medicinal products'
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Guidance for the preparation of GCP inspections (June 2008)
Recommendation on inspection procedures for the verification of good clinical practice compliance
(July 2006)
Guidance for the conduct of GCP inspections (June 2008)
Annex I to Guidance for the conduct of GCP inspections - investigator site (June 2008)
Annex II to Guidance for the conduct of GCP inspection - clinical laboratories (June 2008)
Annex III to Guidance for the conduct of GCP inspections - computer systems (June 2008)
Annex IV to Guidance for the conduct of GCP inspections - Sponsor and CRO (June 2008)
Annex V to Guidance for the conduct of GCP inspections - Phase I Units (November 2008)
Annex VI to Guidance for the conduct of GCP inspections - Record keeping and archiving of
documents (March 2010)
Annex VII to Guidance for the conduct of GCP inspections - Bioanalytical part, Pharmacokinetic
and Statistical Analyses of Bioequivalence Trials (November 2008)
Guidance for coordination of GCP inspections and co-operation between GCP inspectors, the
reference and concerned Member States and CMD(h) , in the context of the evaluation of the GCP
compliance of marketing authorization applications for mutual recognition and decentralized
procedures (June 2009)
Guidance for exchange of GCP Inspection Reports according to Article 15(2) of Directive
2001/20/EC (revision 1 - May 2009)
Guidance for the communication on GCP inspections and findings (June 2008)
Procedure for standardisation of GCP inspection entries in EudraCT (November 2008)
Guidance for the preparation of Good Clinical Practice inspection reports (June 2008)
Recommendations on the qualifications of inspectors verifying compliance in clinical trials with the
provisions of Good Clinical Practice (July 2006)
 Chapter V: Additional Information
Guidelines on good clinical practice (ICH E6: Good Clinical Practice: Consolidated guideline,
CPMP/ICH/135/95) (1996)
Detailed guidelines on good clinical practice specific to advanced therapy medicinal products
(December 2009)
Recommendation on the content of the trial master file and archiving (July 2006)
"Questions & Answers" Document - Version 11.0  (May 2013)
Ethical considerations for clinical trials on medicinal products conducted with the paediatric
population (2008)
Guideline 2008/C168/02 on the data fields from the European clinical trials database (EudraCT)
that may be included in the European database on Medicinal Products (July 2008)
List of fields contained in the 'EudraCT' clinical trials database to be made public, in accordance
with Article 57(2) of Regulation (EC) No 726/2004 and its implementing guideline 2008/C168/02
(February 2009)
Guideline 2009/C28/01 on the information concerning paediatric clinical trials to be entered into
the EU Database on Clinical Trials (EudraCT) and on the information to be made public by the
European Medicines Agency (EMEA), in accordance with Article 41 of Regulation (EC) No
1901/2006  (February 2009)
List of fields to be made public from EudraCT for Paediatric Clinical Trials in accordance with
Article 41 of Regulation (EC) No 1901/2006 and its implementing guideline 2009/C28/01 (February
2009)
Guidance on posting and publication of result-related information on clinical trials in relation to the
implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation
(EC) No 1901/2006  (October 2012)
Technical guidance on the format of the data fields of result-related information on clinical trials
submitted in accordance with Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of
Regulation (EC) No 1901/2006 (January 2013)
EudraCT - List of additional fields contained in EudraCT (reasons for negative opinions of the
Ethics Committee) (November 2010)
Chapter VI: Legislation
Directive 2001/20/EC OF the European Parliament and of the Council of 4 April 2001 on the
approximation of the laws, regulations and administrative provisions of the Member States relating
to the implementation of good clinical practice in the conduct of clinical trials on medicinal products
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for human use.
Commission Directive 2005/28/EC of 8 April 2005 laying down principles and detailed guidelines
for good clinical practice as regards investigational medicinal products for human use, as well as
the requirements for authorisation of the manufacturing or importation of such products. 
Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of
good manufacturing practice in respect of medicinal products for human use and investigational
medicinal products for human use (Official Journal L 262, 14/10/2003 p. 22 - 26). 
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EFGCP Annual Conference 2015
How do we improve health without  
betraying confidentiality within current and 
upcoming EU Regulations?
 
27 & 28 January 2015 – Brussels, Belgium
What is the price of maintaining  
confidentiality for patients in health research?
OBJECTIVES 
• A description and report on data protection arrangements in research  
 across the EU through the EFGCP Research Ethics Committee survey
• Debate on and development of a draft statement on secondary use of       
  data in research 
• EFGCP report and recommendations that will be provided to those 
   involved in the legislative process. 
WHO WILL ATTEND
• European and National regulatory authority representatives 
• Health authority representatives
• Pharma, CRO and industry professionals
• Ethics Committees
• Patient organisations
• Clinical Research professionals 
And many others
PROGRAMME COMMITTEE 
Insa Bruns, Central Office of the KKS-Network, 
Germany - Anna Chioti, CRP-Santé, Luxembourg - 
Hugh Davies, Health Research Authority, 
UK - Lode Dewulf, UCB Pharma Belgium - 
Nicky Dodsworth, Premier Research, UK - 
Robert Frost, GSK, UK - Yves Geysels, Quintiles, 
Belgium - Shahid Hanif, ABPI, UK - Sarah Hills, 
Euradia, UK -  Laurence Hugonot-Diener, Broca 
Hospital/ MedForma, France - Heinrich Klech,
Medical University Vienna, Austria - Ingrid 
Klingmann, Pharmaplex, Belgium - Olga 
Kubar, Pasteur Institute/EFGCP, Russia  - Rick 
Lilley, UCB Pharma, Belgium - Marianne Maman, 
Novartis Pharma AG, Switzerland - Anastassia 
Negrouk, EORTC, Belgium - Achenyo Ochuma, 
Toronto, Canada - Mark Taylor, Confidentiality
ABPI, UK - Heather Sampson, Toronto East
General Hospital / University of Toronto, 
ABOUT EFGCP
For twenty one years the European 
Forum for Good Clinical Practice has acted as a 
forum to bring patients, researchers, sponsors, 
competent  authorities and ethics committees 
It will provide an opportunity to hear up to date 
information from experts involved, listen to 
together  and  debate current topics. It is 
one of the most fora for multi stakeholder 
debate. In the 2015 Annual Conference we will 
 debate the tensions between confidentiality and 
transparency in health research. 
differing viewpoints, particularly those of 
patients and patient groups whose voice 
must be central in this debate. It will also 
present opportunity to consider current solutions.
For any query please contact the EFGCP Secretariat  
Tel: +32 2 732 87 83  
Email: conferences@efgcp.eu 
OVERVIEW
Progress in our understanding of the factors underpinning good health is 
leading us towards developing better treatments. Much of this advance is 
founded on the use of personal data, such as our health records. Without 
access to this data, medical progress would be seriously impeded and 
proposed restrictive access to clinical information poses a serious, 
This has been recognised within the discussions around the new 
EU Clinical Trial Regulations but it could be irreparably damaged 
by proposed Data Protection Regulations. While protection of 
privacy must be a central tenet of any legislation, some 
amendments will make vital research unworkable. The use of personal 
health data in research would become impossible in practice. This poses a 
significant risk to our health. Our conference will seek to strike a 
balance in answering the key questions.
immediate threat to research. There is a real danger we will sleepwalk 
  into a position where we undermine health research designed to provide 
health care benefit.  
 
To follow the development of the programme 
visit our website: www.efgcp.eu
Advisory Group, UK - Beth Thompson, 
Wellcome Trust, UK  
 
 
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE 
Individual Membership Form 
 
Please fax, e-mail or mail this form to: 
EFGCP Secretariat, Rue de l’Industrie 4 - 1000 Brussels, Belgium 





Welcome to EFGCP! Joining EFGCP provides you with an opportunity to promote ethics and science in 
European research through the single European organisation devoted to Good Clinical Practice and 
medicinal product development. 
WHO JOINS EFGCP? 
Membership in EFGCP is open to professionals and individuals representing patient groups, ethics 
committees, academic & industry research enterprises, regulatory officials, and those concerned to develop 
the ethics and science of Good Clinical Practice in Europe and globally. 
BENEFITS OF JOINING EFGCP 
EFGCP provides a unique meeting place for decision-making in the fields of ethics and science in Good 
Clinical Practice. Your participation in this forum will contribute to the advancement of research in an 
environment that puts the patient’s interest first. 
As an EFGCP member, you will benefit from: 
• An access to the leading European and international discussions on ethics and science in clinical 
research. 
• An opportunity to contribute to the development of Good Clinical Practice in Europe and globally. 
• A direct access to the foremost developments in European regulatory and ethical discussions on 
GCP and the development of medicinal products. 
• Access to EFGCP Working Parties engaging current ethics and GCP issues in health research 
(Ethics, Audit, Education, Children’s Medicines, EGAN-EFGCP Patients’ Roadmap to Treatment and 
Geriatric Medicines) (subject to the chairs’ approval). 
• A way to build excellence in clinical research within your institution through dialogue with others. 
• Personal login to the members’ area of the EFGCP Website with unlocked access to information and 
members’ general directory. 
• Regular updates through e-mails, conferences, workshops and publications (The biannual ‘EFGCP 
News’, meeting reports and guidelines). 
• Reduced registration fees for all EFGCP events. 
INDIVIDUAL MEMBERSHIP REGISTRATION FEE 
The annual EFGCP membership registration fee is set according to the members’ status. Membership is 
valid one full year independently of the calendar year. 
EFGCP Membership Automatic Renewal: Your membership will renew automatically unless you notify us 
otherwise. This means that at the beginning of the membership year, we will charge you automatically for 
the next membership period to guarantee uninterrupted access to benefits. A reminder email giving you the 
opportunity to update payment or contact information, or cancel your auto-renewal membership will be sent 
at least one month prior to your annual membership renewal date.   
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Individual Membership Form 
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EFGCP Secretariat, Rue de l’Industrie 4 - 1000 Brussels, Belgium 









 Mr.  Ms.   Dr.  Prof. 
Family Name: ........................................................................................... First Name: ......................................................................... 
Position: ................................................................................................... Department: ........................................................................ 
Organisation/Company: ......................................................................................................................................................................... 
Address: ................................................................................................................................................................................................. 
Zip Code: ................................  City: ...................................................... Country: .............................................................................. 
Phone: ..................................................................................................... Fax: .................................................................................... 
Email: ..................................................................................................................................................................................................... 
 
Member’s Profile and Membership Fee 
 
 
 Academic Organisation €70  Insurance Company €140 
 Association €70  Medical Journalist €70 
 Biotech Industry €140  Medical Society €70 
 Care Giver €70  National Regulatory Authority/Agency €70 
 Consultant €140  Non-Governmental Organisation €70 
 CRO Industry €140  Nurse €70 
 Device Manufacturer €140  Nutrition Company €140 
 Ethics Committee €70  Other Contact us 
 EU Project Consortium Member (non commercial / commercial) €70/€140  Patient Organisation/Advocate €70 
 European Regulatory Authority/Agency €70  Pharmaceutical Industry €140 
 Hospital Pharmacist/Lab Staff €70  Retired Member €30 
 HTA commercial stakeholder (non commercial / commercial) €70/€140  Student* €30 
 
All fees are excluding VAT to be added according to your or your organisation VAT status: 
 
21% VAT VAT Registered and not VAT Registered Members from Belgium 
Not VAT registered Members from EU and Rest of the World 
0% VAT VAT Registered Members from EU and Rest of the World 
                                                 
 
* Please provide a certificate issued by your university that states your full-time student status when 
returning this membership form. 
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Individual Membership Form 
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EFGCP Secretariat, Rue de l’Industrie 4 - 1000 Brussels, Belgium 






Billing Information (To be completed for VAT-registered members)  
 
 
Organisation/Company: .......................................................................................................................................................  
VAT #: .................................................................................................................................................................................  
Contact Person: ...................................................................................................................................................................  
Position: ........................................................................................  Department: ...............................................................  
Address: ..............................................................................................................................................................................  
Zip code: ............................. City: ................................................  Country: .....................................................................  
Phone: ...........................................................................................  Fax: ............................................................................  
Email: ............................................................................................  Purchase Order # or other reference: ........................  
 
Way of Payment 
 
 BANK TRANSFER All charges to be borne by principal, to the order of the EFGCP. 
Account Holder: EFGCP Events Bank Name: ING, Brussels, Belgium BIC/Swift BBRUBEBB 
Account #: 310-1960818-49 IBAN: BE97 3101 9608 1849 Communication Invoice # Member’s name 
 
 
 CREDIT CARD:  VISA  American Express  Mastercard 
Cardholder: ................................................................  Amount: ……………………………………+VAT if applicable 
Card #: ........................................ Expiry date: ..................... Security Code (CVC): ...............................
Date: ........................................ Signature: .....................................................................................................
 
A proforma invoice will be provided along with the membership confirmation. The formal invoice will be sent once payment is 
received. 
 
 
 
